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1 lB-hydroxysteroid dehydrogenase efficiently inactivates potent glucocorticoid hormones
(Cortisol and corticosterone), leaving aldosterone unmetabolised. Abundant 11B-HSD activity
in human placenta plays a central role in controlling fetal glucocorticoid exposure, which if
excessive is harmful and may predispose to low birth weight and hypertension in adulthood..
Similar 11B-HSD activity in the distal nephron protects mineralocorticoid receptors from
glucocorticoids and appears important in normal blood pressure control Loss of this protection
results in hypertension : the syndrome of apparent mineralocorticoid excess (SAME). In
previous work an NADP-dependent isoform of 11B-HSD has been purified from rat liver, a
cDNA isolated and the human homologue cloned. For sometime the gene encoding this
isoform (11B-HSD1) was believed to give rise to the 11B-HSD activity responsible for the
crucial 'protective' 11B-HSD activities in placenta and kidney. However, some evidence
suggested there may be tissue-specific 11B-HSD activities that could not be explained by the
'liver-type' isoform. In particular, 'liver-type' 11B-HSD antigen appeai-s absent from renal DCT
and the hepatic enzyme's relatively low affinity for Cortisol and corticosterone suggest a
limited effectiveness in clearing these glucocorticoids.
The work in this thesis began by partially purifying the 11B-HSD activity from human
placenta and comparing it to that from rat liver. The activities differed substantially in all
parameters measured and did not merely reflect species differences as rat placental 11B-HSD
was similar to the human placental isoform. This clearly showed, for the first time that human
tissues contained an 11B-HSD isoform (which we designated 11B-HSD2) distinct from that
encoded by the previously known 'liver-type' isoform (11B-HSD1). Moreover this 11B-HSD2
isoform was an exclusive dehydrogenase and kinetic measurements indicated it had over one
hundred fold higher affinity for glucocorticoids and thus was much better suited to the tissue-
specific eradication of glucocorticoids attributed to the crucial 'protective' 11B-HSD activities
in placenta and kidney.
Purification of human placental 11B-HSD2 16000-fold, to homogeneity, was achieved by
subcellular fractionation, detergent solubilisation, AMP-affinity chromatography and 2-D
electrophoresis. Placental 11B-HSD2 is ~40 kDa protein, with a basic pi and is N-terminally
blocked. Over 100 residues of internal amino acid sequence was obtained by digestion of tire
homogeneous protein and sequencing of several of the resulting tryptic peptides. Purification
was assisted by a novel technique allowing highly specific (single spot on 2-dimensional
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electrophoresis) photoaffinity labelling of active 11B-HSD2 in crude tissue extracts by its
glucocorticoid substrates. This work reveals 11B-HSD2 is a novel member of the short chain
alcohol dehydrogenase superfamily (apparent monomer Mr 40000). It is a very basic
(apparent pi = 9.1) intrinsic membrane protein requiring, as yet undefined, membrane
constituents for full stability. Affinity chromatography and affinity labelling studies suggest
11B-HSD2 has a compulsory ordered mechanism, with NAD binding first, followed by
conformational change allowing glucocorticoid binding with high affinity.
Amino acid sequence from homogeneous human placental 11B-HSD2 was used to isolate an
1897bp cDNA encoding this enzyme (predictedMr 44126, predicted pi 9.9). Transfection into
mammalian (CHO) cells produces 11B-HSD2 activity which is NAD-dependent, without
reductase activity, avidly metabolises glucocorticoids (Kms for corticosterone, Cortisol and
dexamethasone of 12.4 1.5, 43.9 8.5 and 119 15nM respectively) and is inhibited by
glycyrrhetinic acid and carbenoxolone (IC50 10-20nM). Rabbit antiserum recognising 11B-
HSD2 has been raised to an [11B-HSD2 residues 370-383]-carrier conjugate. Recombinant
11B-HSD2, like native human placental 11B-HSD2, is detectable with affinity labelling and
11B-HSD2 antiserum, and appears to require little post-translational processing for activity.
11B-HSD2 mRNA ( 1.9kb transcript) is expressed in placenta, aldosterone target tissues
(kidney, parotid, colon and skin) and pancreas. In situ hybridisation and
immunohistochemistry localise abundant 11B-HSD2 expression to distal nephron in human
adult kidney and to trophoblast in placenta. 11B-HSD2 transcripts are expressed in fetal kidney
(but not lung, liver or brain at 21-26weeks), suggesting an 11B-HSD2 distribution resembling
that in adult is established by this stage in human development.
Thus the work presented in this thesis describes the identification of a new 11B-HSD isofoim
(11B-HSD2), methods for its highly specific photoaffinity labelling and purification to
homogeneity followed by the isolation and sequencing of tryptic peptides and a full-length
cDNA and raising of a specific antibody. Tissue localisation of the 11B-HSD2 activity,
enzyme protein and mRNA all confirm it to be the isoform responsible for the crucial
protective 11B-HSD activities in placenta and kidney. Moreover several researchers have now
shown that mutations in 11B-HSD2 are indeed the cause of hypertension in SAME and now
11B-HSD2 is regarded by many as a candidate gene contributing to the causation of essential
hypertension.
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NAD(II) nicotinamide adenine dinucleotide (reduced form)
NADP(H) nicotinamide adenine dinucleotide phosphate (reduced form)
NEPHGE non-equilibrium pH gradient gel electrophoresis
PBS phosphate-buffered saline
PVDF polyvinylidene difluoride
PVP-40 polyvinylpyrrolidone (average mol. wt. 40000).
RNA ribonucleic acid
SAME syndrome ofapparentmineralocorticoid excess
SCAD short chain alcohol dehydrogenase
(SDS)-PAGE (sodium dodecyl sulphate) polyacrylamide gel electrophoresis
TBS Tris-bufifered saline
TEMED N,N,N' ,N' -tetramethylethyldiamine
TFA trifluoroacetic acid
TLC thin layer chromatography
UV ultraviolet
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Chapter 1: Introduction
1.1 Glucocorticoids, mineralocorticoids and their receptors
Glucocorticoids and mineralocorticoids are synthesised in the adrenal cortex and are
collectively known as corticosteroids. Glucocorticoids are very potent (normal, unstressed,
human plasma Cortisol ranging 50-600nM) and have a very large number of diverse effects
throughout the body, being of particular importance at times of stress and in modulating the
body's fuel metabolism and immune and inflammatory responses[149]. Aldosterone is the
principal mineralocorticoid inmost species, including humans and rodents. Aldosterone is also
a very potent hormone, circulating levels being in the high picomolar range (100-1000 fold
lower than levels of total glucocorticoid), but its actions are largely restricted to homeostasis of
fluid and electrolyte balance and to the control of blood pressure, and are exerted through its
actions on a limited number of 'target tissues' (notably the distal nephron ofthe kidney).
In the late 1960s and early 1970s the receptors for corticosteroids were identified by binding
studies[21,140,142]. The type II corticosteroid receptor bound glucocorticoids with high
affinity, was a poorer binder of aldosterone[23] and was almost ubiquitously distributed
amongst tissues. This fitted very well with the actions of glucocorticoids and the receptor
became known as the glucocorticoid receptor or GR. In contrast, the type I corticosteroid
receptor bound aldosterone with very high affinity and so could be expected to be responsive*-
to the relatively low levels at which this hormone circulates[21,150]. Moreover, the type I
receptor had a much more restricted tissue distribution, which included the target tissues of
aldosterone[20,150]. These findings fitted very well with the actions of aldosterone and tire
type I corticosteroid receptor also became known as the mineralocorticoid receptor or MR. A
type III corticosteroid receptor was also described originally and seemed to bind corticosterone
with highest affinity (corticosterone > Cortisol > progesterone > aldosterone > dexamethasone)
[22] and was particularly abundant in the kidney. The exact nature of this 'type III binder' has
not been completely resolved, but the evidence points to it not being a receptor through which
the actions of corticosteroid hormones are mediated[98], unlike GR andMR which are widely
accepted as the mediators of the vast majority of the genomic actions of corticosteroid
honnones[149].
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Although, it had been known that glucocorticoids could bind MR and that aldosterone had
some binding to GR[21,23], the overall picture that mineralocorticoids acted through MR and
glucocorticoids through GR was sufficiently compelling that relatively little attention was paid
to this incongruous binding. In 1983 however, a careful study of binding came to the
conclusion that MR bound aldosterone and Cortisol with approximately the same affinity[8],
This paradox came into sharp focus in 1987 when the cDNA for MR was cloned and the
recombinantly expressed receptor protein did indeed bind Cortisol and aldosterone with equal
affinity and moreover bound the glucocorticoid corticosterone with the highest affinity of
all [18]. Another study showed that in vivo, despite circulating at much lower levels,
aldosterone was nonetheless gaining access to MR in preference to glucocorticoids in
aldosterone 'target tissues' (e.g. distal nephron), though not in other MR containing tissues
such as the hippocampus[34]. Thus, there seemed to be an unexpected tissue-specific
regulation ofaccess to MR. Initially, this was proposed to be due to a form of intracellular
glucocorticoid binding protein[29]. However, the real mechanism turned out to be due to local
inactivation of glucocorticoids by an enzyme 1 lB-hydroxysteroid dehydrogenase (11B-HSD),
which is the subject ofthis thesis.
1.2 llB-Hydroxysteroid dehydrogenase.
11B-HSD catalyses the conversion of physiological glucocorticoids (Cortisol and
corticosterone) into their inactive 11-dehydro products (cortisone and 11-
dehydrocorticosterone, respectively). 11B-HSD enzyme activity had been known about since
the 1950s [151,152] and has been reported present in many organs in the adult, placenta and
fetus in humans and in a large range of animal tissues investigated [52], Its distribution
included kidney, but was certainly not restricted to aldosterone target tissues. It was also
evident that the reverse, 1 lB-reductase, reaction was present in some tissues, notably liver, but
the tissue distribution of this activity was less clear and 1 lB-reductase was known to be a
relatively labile enzyme activity [31]. It was unclear how this 1 lB-reductase related to the 11B-
HSD dehydrogenase activity.
Although the existence of 11B-HSD activity was well documented, its physiological relevance
was obscure. It had been reported to be deficient in association with a rare disorder known as
the syndrome of apparent mineralocorticoid excess (SAME) in which there is severe
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hypertension, sodium retention and hypokalemia [75]. In 1985 the investigation of a unique
adult patient showed that the disorder was due to novel renal mineralocorticoid actions of
Cortisol [99]. Thus, the apparent renal mineralocorticoid excess and hypertension could be
reversed by suppressing endogenous Cortisol with dexamethasone, and recreated by concurrent
infusion of physiological doses of Cortisol. This work and imaginative studies with liquorice
[33], which was shown to inhibit 11B-HSD, led to the suggestion that normally 11B-HSD in
the distal nephron inactivated Cortisol and that if this enzyme was deficient (either congenitally
as in SAME or acquired as in liquorice ingestion) then Cortisol gained access to MR in the
distal nephron and caused mineralocorticoid hypertension. Thus, it was proposed that 11B-
HSD was the tissue-specific regulator of access toMR [16,17].
In 1988,11B-HSD was purified from rat liver [35] and specific antisera were raised [35,38], an
encoding cDNA cloned [36] and the human homologue isolated [41]. Over expression of the
11B-HSD cDNA in mammalian cells finally proved this one enzyme was capable ofNADPH-
dependent 1 lB-reductase activity as well as NADP-dependent llB-dehydrogenase activity
[40], As 11B-HSD was proposed to have such an important role in the distal nephron, efforts
were made to localise the 11B-HSD protein and mRNA in kidney, frnmunohistochemistry
showed 11B-HSD in kidney, but in proximal not distal nephron [14,17], Activity staining of rat
kidney appeared to reveal 11B-HSD activity in the distal nephron utilising the cofactor NAD
rather than NADP, but only with an unusual substrate (11-hydroxyandrostenedione), rather
than the expected substrates corticosterone or Cortisol [50],
Thus by 1991, the time when the work in this thesis commenced, there was good evidence to
suggest 11B-HSD activity was important in determining MR specificity although it was not
definitively proven. It was however, very unclear whether the 11B-HSD isolated from liver
was responsible and this lead to much speculation about other 11B-HSD variants or even a
second NAD-dependent isoform [47,50,52], 11B-HSD activity had been documented in many
other tissues not regarded as aldosterone 'target tissues', including placenta where the enzyme
was clearly able to affect the glucocorticoid exposure of the developing fetus. Interest in
placental 11B-HSD began to grow rapidly following the rapidly accumulating evidence for a
link between the in utero environment, reduced birthweight and adult disease especially
hypertension.
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1.3 Placental 11B-HSD and the link between the in utero environment, birth weight and
adult disease especially hypertension.
11B-HSD activity was first reported to be present in placenta in 1960[153] and placental 1113-
HSD has since been described in several species[19,27,51,52,138,144,153]. The majority of
reports are clear that the net activity in placenta is 1 lB-dehydrogenase i.e. inactivating
glucocorticoids. Although some in vivo work in baboons suggests that the predominant
activity atmid-gestation is 1 lB-reductase, by term it is clearly 1 lB-dehydrogenase and all work
in humans supports placental 11B-HSD being predominantly llB-dehydrogenase, not just at
term but throughout gestation. Thus work, based on:- in vitro enzyme assays, ex vivo perfusion
studies and results of both of the in vivo radioactive tracer studies carried out during human
pregnancy[24,139], all support the net activity in human placenta being 1 lB-dehydrogenase. A
very high level of 11B-HSD activity has been reported in placenta from several species and in
human placenta in particular. It has been calculated that the glucocorticoid-inactivating activity
of human placental 11B-HSD is sufficient to account for the much lower glucocorticoid levels
in the fetal circulation[32]. Although other mechanisms may assist in the partitioning of active
glucocorticoid at much lower concentrations in the fetal compartment (e.g. maternal-fetal
gradients of glucocorticoid binding proteins, CBG[25] and albumin[143]) the evidence for
these is conflicting and it is widely accepted that placental 11B-HSD activity seems the major
factor in human placenta close to term.
In human and inmany animal species studied, fetal glucocorticoid levels are much lower (3-10
fold lower in human pregnancy) than maternal levels. Thus there seems a need, conserved in
evolution, to limit fetal glucocorticoid exposure during at least part ofgestation. This led to the
idea that glucocorticoid exposure of fetal tissues is of importance in normal development and
that placental 11B-HSD plays a key role in regulating these levels and thus in promoting
normal development. Certainly it is clear that excess fetal glucocorticoid exposure is harmful.
Many studies have shown high dose glucocorticoids during pregnancy can be teratogenic in
animals[4,5,7,124-126,128,131]. In humans this seems less certain, but with high dose
maternal glucocorticoid treatment there are reports of teratogenesis[l]. In human pregnancy a
clearer risk of glucocorticoid treatment is fetal intra-uterine growth retardation (IUGR)*
resulting in reduced birth weight for gestation[3]. Glucocorticoids are involved in many
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processes during development. For example, glucocorticoids are essential for the normal
structural development of organs such as the adrenal medulla and lung[6]. Glucocorticoid
levels have a powerful influence on the maturation of many important fetal and neonatal
homeostatic systems such as:- the handling of carbohydrate fuels by the liver[120-
123,127,130]; the level oferythropoetin in the kidney[134]; the feedback responsiveness of the
hypothalamic-pituitary-adrenal axis[135,136,141]; many aspects of the development of the
sympathetic nervous system from early migration of neural crest and determination of neural
crest cell fate[6,129,132,137] to transmitter phenotype[154,155] and tissue responsiveness at
the receptor[79] and post-receptor levels[78,l 18,119]. Many of these glucocorticoid influences
on fetal tissue maturation seem likely to give rise to permanent consequences if deranged. It is
well established in work on rats that disordered steroid hormone action during development
can lead to life-long consequences. For example, briefneonatal exposure to sex steroids lead to
permanent neuroanatomical, neurochemical and behavioural changes which persist throughout
adult life[156]. Similarly, a single neonatal testosterone injection has been shown to
irreversibly programme the level of several enzymes (especially 5a and 513-reductases) [157].
Some effects of in utero steroid action may programme aspects of physiology in a fashion
which gives the offspring an increased vulnerability to certain diseases much later in life. An
example in humans being diethylstilboestrol exposure of the developing female fetus and
greatly increased risk ofvaginal cancer many years later in these daughters[158]. Thus there is
good evidence that the level of fetal glucocorticoid exposure affects not only the rate of fetal-
growth and birth weight but also the structural development of organs and the maturation of
homeostatic systems. Such developmental effects of steroid hormones are likely to have
permanent consequences on the offspring's physiology (fetal programming) and may affect
their lifetime vulnerability to certain diseases. There was thus considerable interest in the work
of Professor David Barker, who in 1990[159] reported an association from human
epidemiology in the UK (since verified by many studies[165]), showing a strong link between
low birth weight and the risk ofhypertension in adulthood.
The first clues ofa link between early life events and major common 'Western diseases' (such
as ischaemic heart disease, stroke and chronic bronchitis) came from studies showing an
association between the maternal, perinatal and infant mortality rates in a region and the
incidence of such common 'Western diseases' in adults originally from that region, whether or
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not they migrated away from their birthplace[160,161], These clues led to Barker's remarkable
retrospective cohort follow-up studies on populations bom in Preston and Hereford[81,165]. In
these centres, excellent records of obstetric and perinatal morphological measurements were
found and over 15000 people who were referred to in such birth records were traced, then all
being in middle age or older. Correlations were then possible between characteristics at birth
and subsequent risk of common adult diseases. Many striking findings emerged from these
studies and it was clear that birth weight and body shape at birth were strongly linked to, and
so predictive of, the individual's risk of hypertension[165]. The smaller the birth weight: the
higher the risk of adult hypertension[159]. This strong relationship persisted when common
confounding factors such as prematurity and social class had been controlled for. Moreover,
the relationship held not just for extremes of birthweight but was continuous throughout the
normal ranges ofbirth weight and blood pressure. Two types of low birth weight baby seemed
predisposed to hypertension[163]. Firstly, a long thin baby, with a reduced head circumference
and low ponderal index (weight/[length]); such babies tended to have small placentas and
were predisposed to hypertension in association with syndromeX (dyslipidaemia, insulin
resistance and non-insulin dependent diabetes mellitus) [163,164], Secondly, babies that were
disproportionately short for their head size; such babies tended to have large placentas and
were predisposed to hypertension in association with elevated plasma
fibrinogen[162,163,165]. These striking findings strongly implicated in utero events resulting
in low birth weight for gestation in the causation of human hypertension. Two studies which-
began around the time of commencement of this thesis clearly implicate glucocorticoid action
in utero in this link. Firstly, Benediktsson et. al.. showed placental 11B-HSD in rats correlated
with birth weight[59,133]. Two other studies, in humans, have reached the same
conclusion.[71,166] Secondly, Lindsay et. al.. showed that administration of dexamethasone
to pregnant rats throughout pregnancy resulted in offspring with significantly reduced
birthweight (using a dose of dexamethasone causing no significant change in maternal weight
gain during pregnancy compared to untreated normal controls) [80,166], Moreover, the
offspring then developed hypertension in adulthood. These studies support the hypothesis [58]
that fetal glucocorticoid exposure in utero programmes fetal physiology in a manner that
reduces birthweight and predisposes to adult hypertension.
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Since placental 11B-HSD is a major determinant of fetal glucocorticoid exposure this enzyme
was clearly important and merited much closer study. Moreover, almost immediately on
beginning the work of this thesis it became apparent that placenta contained 11B-HSD activity
with many differences from the NADP-dependent 11B-HSD isoform cloned from liver. Early
findings(see Chapter 4) suggested the placental 11B-HSD activity was due to a second isofomi
with properties consistent with it being similar to the activity expected in the distal nephron of
Hie kidney; in other words the sought after tissue-specific protector ofMR thought deficient in
die human hypertensive condition SAME [17]. This added a second very compelling reason
for close study of the 11B-HSD enzyme activity in human placenta in the expectation it would
help in understanding the pathophysiology ofhuman hypertension.
1.4 Aims.
The work in this thesis had the following aims in studying human placental 11B-HSD:-
1) To characterise and isolate the major 11B-HSD activity from human placenta.
2) To purify human placental 11B-HSD to homogeneity and obtain amino acid sequence.
3) To clone a cDNA encoding the enzyme responsible for the 11B-HSD activity in human
placenta.
4) To raise a specific antibody against human placental 11B-HSD.
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Chapter 2 : Materials and Methods.
2.1 Materials
[1,2,6,7 ^H] corticosterone, Cortisol, aldosterone and [1,2,4,6,7 ^H] dexamethasone (specific
35
activity 78, 73, 80, and 84 Ci/mmol respectively), S-methionine (specific activity >1000
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Ci/mmol), S- and P-labelled nucleotides, Hybond N and Hybond ECL membranes,
Hyperfilm Bmax, Sequenase v2 and the ECL Western blotting systems were purchased
from Amersham International (Little Chalfont, U.K.). Autodigestion resistant modified
trypsin and S.Aureus V8 protease were obtained from Promega (Southampton, UK) and
hydrogenated Triton X100 (RTX-100, protein grade) from Calbiochem (Nottingham, UK).
Glycerol and protein standards for SDS-PAGE (#44264L), electrophoresis grade SDS and
urea were purchased from BDH Laboratory Supplies (Poole, Dorset UK). Coomassie blue dye
concentrate, standardised bovine serum albumin and 2-D electrophoresis protein standards
(#1610320) were purchased from Bio-Rad (Hemel Hempstead, UK). HPLC grade methanol
and water were purchased from Rathburn Chemicals (Walkerburn, UK) and Quickszint 302
HPLC scintillant from Zinsser Analytic (Maidenhead, UK). Entensify fluoroautoradiography
solutions were obtained from Du Pont/NEN (Stevenage, UK). PVDF (Problott) membranes
were obtained from Applied Biosystems (Warrington, UK). AscI was obtained from New
England Biolabs (Hitchin, U.K.). PGEM-llzf( ) plasmids, micrococcal nuclease-treated
canine pancreatic microsomes (#Y4041), and other restriction enzymes were obtained
from Promega (Southampton, U.K.). Synthetic oligonucleotides were synthesised by
Oswel DNA Service (Edinburgh, U.K.). lkb ladder DNA size markers, Lipofectin, media
and reagents for tissue culture were purchased from Gibco/BRL (Paisley, U.K.).
Vectastain Elite ABC and DAB reagent system for immunohistochemistry was
purchased from Vector Laboratories (Peterborough U.K.). Affinity chromatography
matrices, Pharmalytes, detergents and other chemicals (both reagent and molecular biology
grade) were obtained from Sigma Chemical Co. (Poole, Dorset, UK).
2.2 Buffers.
Tissue processing and chromatography buffer systems used were as follows:- Buffer A; 20%
glycerol, 5mM potassium phosphate pH7.0, ImM EDTA, ImM dithiothreitol. Buffer B; 10%
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glycerol, 300mM sodium chloride, 4mM CHAPS (3-[(3-cholamidopropyl)
dimethylammonio]-l- propanesulphonate), ImM EDTA, 0.02mM Tris-HCl pH 7.7 ( buffer
B2; sodium chloride omitted ). Buffer C; 10% glycerol, 300mM sodium chloride, 1 mM
EDTA, 0.02 mM Tris-HCl pH 7.7. Where pH was varied buffers included 10% glycerol,
ImM EDTA, 300mM sodium chloride and 0.1M buffer:- pH 5-6, potassium acetate; pH 6.5-
7.5, potassium phosphate; pH 7.5-9, Tris-HCl; pH 9.5-10, potassium carbonate and pH 10.5-
11, glycine-NaOH. Buffers were pH adjusted at the temperature of use. Where the buffer
varies from that above, the variation is appended in [brackets].
2.3 Tissues and tissue processing.
Human term placentae (400-600g, normal vaginal delivery), were rapidly placed on ice and
tissue processed within 2h. Adherent membranes, umbilical cord and large vessels were
removed. Placental tissues were rapidly minced with scissors, washed in ice cold 0.9% saline,
blotted dry, suspended in approximately 3 times their weight of buffer A and homogenised
with a commercial blender. Homogenate was filtered through 2 layers of muslin and the
filtrate fractionated rapidly by differential centrifugation:- (i) 10 min x 750g, (ii) 40 min x 25
OOOg and (iii) 60 min x 110 OOOg. The supernatant from each centrifugation was subjected to
the next centrifugation finally leaving cytosolic supernatant. Rat (fasted Wistar adult animals
killed by decapitation) and other human tissues were handled and fractionated similarly
though because the amount of tissue was usually much smaller than for human placenta
homogenisation was with Dounce or Ystral homogenisers (Scientific Instrument Centre, UK)
and to aid fractionation, the homogenate was then diluted twofold (with buffer A), rather than
being filtered so as to minimise losses from the small tissue quantities. Fractions resulting
from tissue processing were frozen at -80°C, or used immediately. When 11B-HSD activity
was labile (e.g. rat placenta) 1113-HSD assays were always performed immediately.
2.4 Assays of 11B-HSD activity.
C-l 1 dehydrogenase activity was determined by measuring the rate of conversion of 1.12x10"
^M [U4]-steroid substrate (corticosterone or Cortisol) to product (11-dehydrocorticosterone or
cortisone respectively) in the presence of 400pM NAD or NADP (unless otherwise stated),
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and calculating the percentage conversion during the assay. The 250pl assay consisted of:-
lOpl containing tritiated steroid, 50pl containing cofactor and 190pl enzyme in 0.1M
potassium phosphate pH 7.5, 300mM sodium chloride buffer (buffer only in blank controls).
Reactions were incubated at 37°C for 10 min and terminated by adding 2ml ice-cold ethyl
acetate and mixing. The organic layer was separated, evaporated and the steroid resuspended
in 0.6ml 50% methanol:50% water. 0.2ml of this was injected into a Berthold HPLC system
fitted with a Waters Associates pBondpack CI8 column, which was eluted with 50%
methanol:50% water v/v (at 1.8 ml/min for corticosterone substrate reactions). Eluted steroids
were monitored by aUV absorbence detector and a Berthold LP506 CI scintillation counter to
detect tritiated steroids. The latter was flushed with Quickszint 302 scintillant (at twice the
column elution rate) and output calibrated against known authentic steroid standards. The
percentage conversion of steroid substrate to product was calculated as an index of enzyme
activity. Cofactor concentrations and buffer pH were varied in experiments specifically
examining these effects. The assay pH was verified by measuring the pH ofa parallel mixture
containing unlabelled steroid.
Protein was estimated by the method of Bradford [82] using Bio-Rad protein dye and
calibration against standards of bovine serum albumin. Preliminary work identified optimum
assay conditions for each tissue so that the amount ofprotein added (i) was in the linear region
of the curve ofprotein concentration versus percentage substrate converted with 400pM of the
more active cofactor (NAD orNADP) and (ii) resulted in a percentage conversion of 10-40%
in 10 min. All experiments had blank (no protein) assays run in parallel to establish the
background level of steroid product. 1 lB-reductase activity was measured using the same
reaction conditions except that 400pM NADH, or NADPH, and [^Hj-l 1-
dehydrocorticosterone were used as substrates. The latter was prepared from PH]-
corticosterone by a variation of the method of Lakshmi and Monder[35] using human
placental enzyme with NAD at pH 7.5. Kinetic parameters were calculated from the initial
velocity determinations in assays giving less than 30% conversion.
2.5 Detergent solubilisation of 11B-HSD activity.
All solubilisation was carried out at 0-2°C. Tissue fractions, resuspended in buffer C to 6mg
protein/ml, were mixed with an equal volume of solubilisation buffer (in buffer C with
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detergent at twice final concentration). After 30 min, the mixture was centrifuged at 110 OOOg
for 1 h. Supernatant containing soluble enzyme was carefully removed.
A screen was performed using 13 detergents of diverse classes[90], at concentrations of twice
and half their critical micelle concentrations (CMC), see Chapter3 for details. Following this
screen, conditions were refined for solubilising human placental 11B-HSD in the most
promising detergent (CHAPS). When comparison was made with rat liver 11B-HSD, 0.06%
Triton XI00 (final detergent/protein ratio of 0.2) was used as this was found optimal for
solubilising microsomal rat liver 11BHSD (in agreement with Lakshmi et. al. [30]).
2.6 Affinity Chromatography.
Affinity chromatography matrices were hydrated, loaded into simple columns and equilibrated^
in buffer B. Affinity matricies were screened for useful purification ofNAD dependent 11B-
HSD using 1 ml bed-volume columns. The CHAPS-solubilised tissue fraction containing 11B-
HSD activity was loaded onto the column which was then washed with buffer B. 11B-HSD
was eluted with nucleotide cofactor in buffer B as indicated in the text. 1.5ml fractions from
the column were collected, placed on ice and rapidly assayed for 11B-HSD enzyme activity. In
some experiments larger columns (5ml affinity matrix) were used and a 0-3000pM elution
gradient of NAD, AMP or NADP in buffer B2 was applied across a total of 10 column
volumes (50ml) After completion of the gradient the column was washed with buffer B and
any remaining 11B-HSD eluted with buffer B[3mM NAD], This protocol was designed to
determine thresholds ofelutionwith different cofactors allowing their affinity for the active site
of the enzyme to be compared [84,178]. Having identified the most useful affinity matrix
preparative and analytical protocols were developed which maximised yield and purity
respectively.
For the preparative 5'AMP-agarose chromatography, six 5ml columns were run in parallel,"
having a common outflow and collecting 5ml fractions. CHAPS-solubilised placental 25000g
pellet fraction (180ml) was loaded (2.4mftmin) onto the columns, then washed with 205ml
buffer B and 45ml buffer B[0.25M NaCl], and 11B-HSD eluted with 170ml buffer B[0.2M
NaCl + ImM NAD], all at 3.5 ml/min. Fractions were placed on ice and rapidly assayed for
11B-HSD enzyme activity. Fractions with abundant 11B-HSD2 were pooled and concentrated
(Amicon stirred cells, Centricon 10 concentrators, acetone precipitation).
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Analytical work used 1ml columns run manually (collecting 1-1.5 ml fractions). For highest
purity ofeluting 11B-HSD an N6-5'AMP-agarose column was washed with Buffer B (15ml)5>
Buffer B[0.02M NaCl + 0.4mM NADH](10ml), Buffer B (15ml) then eluted with Buffer
B[0.125M NaCl + ImMNAD], The flow rate was 420pl/min, reducing to 200-3OOpl/min on
elution. The increased purity was at the cost of lower yield and reproducibility than the
preparative protocol (above).
2.7 Removal ofNAD from affinity purified 11B-HSD.
NAD was removed from partially purified 11B-HSD enzyme (eluted as above) by 3
successive filtration/dilution cycles in a Centricon-10 concentrator (Amicon). Following
filtration by centrifugation at 4600g for 90 min, samples were diluted in buffer B and the cycle
repeated. Removal ofNAD was verified by measuring Apgf). During this process samples
were assayed for 11B-HSD activity to determine dependence on added cofactor.
2.8 Statistical Analysis ofEnzymeActivity Results.
Results ofenzyme activity are shown as mean ± standard error. Series ofpaired samples were
compared by one-way analysis of variance (ANOVA) of their difference. Kinetic parameters
were estimated by Lineweaver-Burke and Eadie-Hofstee analysis facilitated by computer
generated linear regression.
2.9 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE).
This was by the method of Laemmli [83] with 12.5% resolving gels (3.3% cross-linker).
Fractions with low protein levels were concentrated by acetone precipitation. Gels were silver
stained by the method of Wray[86] with variations of NH4+/Na+ ratio to minimise the
chances ofprotein being undetected.
2.10 UV Photoaffinity Labelling and Fluoroautoradiography.
Tissue fractions with high 11B-HSD activity were diluted in buffer C to 0.05-0.25mg
3
protein/ml (see text) and H-steroid, 5mM NAD and 250mM DTT added to give final
3
concentrations of 400pM NAD, 25mM DTT and 50nM H-steroid. Unless otherwise stated
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reactions were carried out in the wells of a 24-well plate (diameter 1.5cm) with the lid off and
using a final reaction volume of 600pl. In the work leading to the purification of 11B-HSD2 it
was important to minimise UV damage to protein and reactions were at 37°C for a limited
period (see Chapter 3 for details). For detecting 11B-HSD2 protein in transfected mammalian
cells the procedure was adjusted in this context to maximise labelling as minor damage to
protein was less of a concern and accordingly labelling was carried out with 254nm UV
light on supernatants cooled to 1-2°C and using at 0.25mg protein/ml. Transfected cells to
be affinity labelled were homogenised, briefly centrifiiged (lOOOrpm x 15s spin; to pellet
lumpy debris) and the supernatant removed for labelling. Labelling reactions of placental
25000g pellet (at 0.15mg protein/ml) were run in parallel.
Labelled samples were acetone precipitated and resolved by SDS-PAGE[83], or 2-D
electrophoresis. Finished gels, stained with Coomassie Blue to allow detection of major
proteins and molecular weight standards, were processed for fluoroautoradiography in
'Entensify' solutions and vacuum dried before exposure to film.
2.11 2-D Electrophoresis.
2-D electrophoresis work involved running duplicate gels in parallel; usually one was silver
stained (to visualise all the proteins) the other stained with Coomassie blue (to allow alignment
between gels and to visualise SDS-PAGE protein standards) and processed for
autoradiography. A set of 2-D electrophoresis protein standards was run under identical
conditions on a third gel when new running parameters were used.
Conventional 2-D PAGE, i.e. isoelectric focusing (IEF) + SDS PAGE, used a variation of the
method of 0'Farrell[87]. NEPHGE 2-D electrophoresis (non-equilibrium pH gradient gel
electrophoresis) conditions were based on the methods of 0'Farrell[88] and Witzmann[89]
with variations of sample buffer and rod gel composition. Rod-gels (17cm x 2.5mm: length x
internal diameter) were cast from: 9M urea, 2% NP40, 4% acrylamide:bis (19:1), 3%
pharmalytes (1.2% pH 6-8 + 1.8% pH 3-10), polymerised with 32pl 10% ammonium
persulphate and 27pi TEMED per 20ml of rod gel mixture. Optimal results (higher yield,
better resolution), especially for basic hydrophobic proteins, were obtained with a dodecyl
maltoside based NEPHGE sample buffer:- 5.7lg urea, 154mg dithiothreitol, 4ml 10% dodecyl
maltoside, 750pl Pharmalytes (300pl pH 6-8,450pl pH 3-10) 2.25 ml HPLC water adjusting
pH to 4.2 (adding 90pl 5M HC1 and 160pl HPLC water). This buffer, which was a great
improvement, is close to solidifying at room temperature and is melted, warming to 30°C, to-
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adjust pH on preparation and on using. NEPHGE gels were run at 500V for 2250V.hours.
AfterNEPHGE, rods were extruded into 10ml equilibration buffer for 7 min and either frozen
or loaded directly onto second dimension SDS-PAGE gels. 150ml equilibration buffer
consisted of 15ml 2-B-mercaptoethanol, 9g SDS, 90ml HPLC water, 5.6ml 0.075%
bromophenol blue and 37.5ml 4x Laemmli stacking buffer ( 0.4% SDS, 0.5M Tris-HCl pH
6.8). For both IEF and NEPHGE the second dimension was run according to the resolving gel
system of Laemmli[83] using 12.5% gels (3.3% cross-linker). Silver staining was by the
method ofWray[86].
Concentrated protein from preparative AMP affinity chromatography runs was divided among
several 1,5mm thick preparative 2-D gels. Precautions were taken to reduce protein N-terminal
modifications; the second dimension gel was pre-run in a Laemmli running buffer containing
1 part in 200 of freshly made lOOmM glutathione and then changed to running buffer with 1
part in 1000 lOOmM sodium thioglycholate[92]. These precautions were successful in
allowing N-terminal sequence to be obtained from other proteins in our laboratory.
2.12 Protein Blotting for Sequencing.
This was based on the CAPS (3[cyclohexylamino]-l-propanesulphonic acid) buffer method of
Matsudera[93] and was performed from SDS-PAGE or second dimension gels on to PVDF
(Problott) membranes using a Bio-Rad Mini Trans-Blot apparatus. Sections of gels to be
blotted were washed for exactly 30 sec in CAPS transfer buffer (to allow shrinkage and
removal of excess surface SDS). Electroblotting was for 75 min at 250 mA (90-110V). After
transfer, the PVDF sheets were stained (amido black), destained (water), air dried and desired,
bands/spots cut out and stored at -70°C.
2.13 Proteolytic Digests ofPVDF Blotted Protein.
This was based on the method of Fernandez[94], Membranes were cut into small pieces,
blocked (0.2% PVP-40 in methanol for 45 min) and extensively washed in deionised EfPLC
water. Auto-digestion resistant trypsin was added in AHT buffer (20% acetonitrile, 1%
hydrogenated Triton XI00 in lOOmM Tris pH8) to a concentration of 1:20 (trypsin : blotted
protein) and digestion continued for 24 h at 37°C. Fragments were eluted using vigorous
sonication and washes (AHT buffer, then 0.1% TFA)[94], Eluted peptides were concentrated.
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removing acetonitrile, and loaded as a lOOgl sample onto an Applied Biosystems microbore
HPLC system fitted with a C8 RP300 column (1x250mm, 7pm particle size) equilibrated in
solvent A (0.1% TFA/water). This was developed with a linear gradient of 0-100% solvent B
(0.08% TFA in 80% acetonitrile/water) over 45min at 200pl/min. The spectrophotometric
absorbence at 220nm (A220) °f eluate allowed collection of peptide peaks. Control digests
(trypsin with PVP-40 blocked blank PVDF slices) were run in parallel to ensure identification
ofall peaks not due to the blotted protein substrate. A large peptide peak yielding no sequence
which was thought to be the blocked N-terminal peptide was sub-digested in solution (50mM
sodium phosphate pH7.8) with Staph. Aureus V8 protease at an estimated ratio of 20:1
(peptide/protease). Products were resolved on FIPLC, as were those from a control (protease
only) digest.
2.14 Amino Acid Sequencing.
Peptide peaks selected for sequencing were pyridyl-ethylated[101], to allow detection of
cysteine residues, and loaded into an Applied Biosystems 477A automated amino acid
microsequencer.
2.15 Degenerate PrimerPCR and Cloning of 11B-HSD2 cDNA Fragment.
Tissue was snap frozen and RNA extracted, as described[85]. RNA was treated with
DNAse I, re-extracted to remove any contaminating genomic DNA and reverse
transcribed using Promega Reverse Transcription system (#A3500) according to the
manufacturer's instructions. Inosine-containing degenerate primers were designed based
on the amino acid sequence of 5 11B-FISD2 tryptic peptides; A, B, B2, C and D (t = top
strand, b = bottom strand)(see Chapter 6). The primers from peptides B and C, generated
the most useful results and had the following sequences (I = inosine):-
Bt = 5' -CA(A/G)GA(C/T)GCIGCICA(A/G)GA(T/C)CCIAA-3',
Bb = 5'-A(A/G)(A/G)TTIGG(A/G)TC(C/T)TGIGCIGC(A/G)TC-3',
Ct = 5'-(A/T)(C/G)ICCIGCIGGI(A/G)(A/C)IATGCCITA-3',
Cb = 5 '-AGCICCIA(A/G)IIIIGG(A/G)TAIGGCAT-3'.
Initial screening, used the following protocol. 5pi of human placental cDNA, was heated,
under mineral oil, at 96°C for 10 min and placed on ice. The reaction mixture was then
added in a volume of 45pl to give a final reaction mix containing 70pmol of each
degenerate primer, 50pmol dNTP, 2U TAQ polymerase in lxPCR buffer. Reactions were
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placed into a thermal cycler (HB-TR1 :Hybaid, Teddington, U.K.) with the block held at
90°C and the programme commenced: 5 cycles of [60s x 95°C, 45 s x 43°C, (43
55°C) x l°C/3s, 90 s x 72°C] followed by 35 cycles of [60s x 95°C, 60 s x 50°C, 90 s x
72°C] and finally 10 min x 72°C. Subsequently, a specific DNA product (of 531bp) was
efficiently amplified using the CtBb primer pair and the following programme: 5 cycles
of [60s x 95°C, 60s x 47°C, (47 50°C) x l°C/5s, (50 55°C) x l°C/2s, 150 s x
72°C] followed by 40 cycles of [60s x 95°C, 60s x 50°C, (50 55°C) x 1 °C/s, 150 s x
72°C] and finally 10 min x 72°C. This allowed the 531bp product to be directly cloned
into pCRII (TA Cloning system v2, Invitrogen, San Diego, CA: #K2000-01) to yield
clone pCRIICtBb.
2.16 PCR Screening of a pcDNAl Human Placental cDNA Libraiy.
Specific PCR primers nested within this 531 bp fragment were designed (top primer, SCt,
= 5'-ATCCGTGCTTGGGGGCCTATGGAACCT-3'; bottom primer, SBb = 5'-
CTGCAGTGCTCGAGGCAGACAGTGACT-3'). These produced a strong band of the
expected size (455bp) as the only product amplified by RT-PCR of human placental
RNA. A human placental cDNA library in pcDNAl (Invitrogen #A900-11) was then
screened by increasing dilutions using this 455bp product to detect positive pools ard
adapting a PCR screening method[103] for use with plasmid libraries. Other specific
primers were used to cross-check positives. PCR with one primer to the pcDNAl vector
arm and the other to the insert was used to estimate clone insert size. A partial 11B-HSD2
clone was isolated (1177bp insert). On re-screening no clones long enough to be full
length (>1.7kb: coding region (40k protein) + 3'UTR 1.7kb) were found that produced
11B-HSD activity on expression in CHO cells.
2.17 Screening ofa DR2 cDNA Library.
A DR2 human placental cDNA library (Clontech, Palo Alto CA: #HL1144x), with a
higher proportion of longer cDNA inserts, was screened by conventional means[171],
using the incomplete 11B-HSD2 sequence isolated from the pcDNAl library. Briefly,
700000 plaques were plated, duplicate filter lifts made, denatured, fixed, rinsed, dried and
UV cross-linked before hybridisation in SSC/formamide buffer (6xSSC, 50% formamide,
5x Denhardt's solution, 0.5% SDS, lOOpg/ml salmon sperm DNA) with random primed^
32p-dCTP labelled probe from the incomplete 11B-HSD2 sequence. Washes were
SSC/SDS based, finishing with one 15 min wash at 65°C in 0.2 x SSC/0.1%SDS.
Positives from the primary screen were purified by a secondary screen at low density.
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Secondary positives were converted from phage ( DR2) to plasmid (pDR2) clones by
means of the endogenous CRE/LOX recombinase of the host bacterial strain (E.coli
AMI)[112] and were tested for 11B-HSD2 enzyme activity by transfection into CHO
cells, as described below. Nucleotide sequences were determined following sequencing of
both strands by the dideoxy termination method using Sequenase v2 (Amersham/USB).
2.18 Nucleic Acid and Protein Sequence Analysis.
The 11B-HSD2 cDNA sequence and predicted 11B-HSD2 protein sequence were'
analysed using the computing facilities at the HGMP resource centre (Cambridge, U.K.
[104]), specifically PredictProtein[105] and the GCG package[106]. Protein secondary
structure was predicted by three methods, according to:- Chou-Fasman as amended for
overall structure probability[74,107], Garnier-Osguthorpe-Robson[108], and Rost-
Sander[105]. The features described are for regions where there was no disagreement in
predictions ( fig.7.2(b) also extends illustration to areas (grey regions in fig.7.2(b)) with a
complete concordance between two predictions and where the third 'dissenting'
prediction is not in complete agreement). Assessment of hydrophobicity was based on the
Kyte-Doolittle index[109] while prediction of flexible and exposed/buried regions was
according to the methods of Karplus-Schulz[73] and Emini[110], respectively. Estimates
of percent identity in nucleic acid and protein alignments used the GAP algorithm[106]
with standard settings of gap weight = 3, length weight = 0.1 for protein alignment.
2.19/« Vitro Translation.
The 11B-HSD2 cDNA was subcloned into pGEM-1 lzf oriented so that the 5' end of the
cDNA was adjacent to the vector T7 promoter. In vitro translation was performed with a
T7 polymerase driven, rabbit reticulocyte based, coupled transcription/translation system
(K)
(TNT lysates: Promega #L4610), to which a methionine deficient amino acid mixture
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and S-methionine were added. In a standard volume of 25pl, 0.5pg of subcloned 11B-
HSD2 plasmid DNA was added. Microsomal co-translational processing was examined
by including 0-4.5pi ofmicrococcal nuclease-treated canine pancreatic microsomes in the
standard 25pi incubation at 30°C for 90min. Control reactions to verify signal peptide
cleavage (0.1 pg E.coli B-lactamase mRNA) and glycosylation (0.1 pg S.cerevisiae -
factor mRNA) activities of the microsomes were carried out in parallel. For
autoradiography, 0.05-5pl of each reaction was run per lane on SDS-PAGE, stained with
Coomassie blue, processed in Entensify fluoroautoradiography solutions (NEN/DuPont,
Stevenage, U.K.) dried and exposed to Kodak X-OMAT AR film.
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2.20 CHO cell Transfection.
CHO cells were maintained in Dulbecco's modified Eagle Medium, supplemented with
15% fetal calf serum, 100 IU/ml penicillin, lOOpg/ml streptomycin and 200mM
glutamine. 24h prior to transfection cells were seeded onto dishes at a density of 2xl06
cells/10cm plates. For transfection 5pg DNA (in 800pl Optimem) was mixed with 42pl
Lipofectin (in 800pl Optimem) and incubated for 15 min at room temperature. Optimem
was added to 10ml and the mixture was gently overlaid onto cells which had been washed
in Optimem. After 24h the Optimem/DNA mix was removed and replaced with normal
medium. Cells were harvested 24h later. The human placental 11B-HSD2 cDNA was
transfected into cells using the clone (in pDR2) isolated from library screening and there-
were appropriate controls for transfection efficiency. Assays of 11B-HSD activity were
. 3
either with intact cells ( H-steroid added to the medium within the last 24h, as
described[69]) or using homogenates of scraped cells (as below).
2.21 Kinetic and Inhibitor Studies on Transfected Mammalian Cells.
CHO cells were scraped, homogenised (2x106 cells/0.5 ml Buffer C: 0.02M Tris pH 7.7,
10% glycerol, ImM EDTA, 300mM NaCl) centrifuged briefly (lOOOrpm x 15s,
Eppendorf centrifuge; to pellet heavy debris), and the supernatant assayed for protein
concentration and 11B-HSD2 activity (as described in Chapter 2). 11B-HSD2 assays
contained 400pM NAD, unless otherwise stated, and were analysed by HPLC when the
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H-steroid concentration was >2.5nM, TLC based analysis was also used at H-steroid
concentrations <5nM. Reaction products were identified (HPLC and TLC) by
comparison with steroid standards run in parallel. Incubations were for 60min (120min
for dexamethasone). Kinetic parameters were calculated from the initial velocity-
determinations, obtained with experiments performed with a wide range of substrate
concentrations (0.3, 0.4, 0.8, 1.5, 2, 3, 4, 8, 15, 20, 40, 80, and 150nM 3H-steroid, with 80
and 150nM omitted for corticosterone). Enzyme concentrations giving less than 30%
conversion were used. Control ('vector-only' transfected cells) and blank assays were
carried out in parallel.
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2.22 Northern Hybridisation.
Adult human tissue samples were obtained at surgery, frozen within 10 min, and stored at -
80°C. Most samples were normal tissue removed adjacent to a tumour on resection, this was
the case for:- kidney (with adjacent adrenal), parotid, colon (splenic flexure), breast (with
adjacent skin and dermis), stomach (with distal oesophagus). Normal ovary (pre¬
menopausal) was obtained at hysterectomy. Pancreas was an unaffected area in a pancreatic
tail resected for chronic pancreatitis. Liver was from a partial hepatectomy in a young
woman to remove a hepatic cyst (benign). Placenta was from a normal delivery. Regions of
a normal human post-mortem (36h) brain were also dissected. RNA was extracted as
described[85], separated on denaturing agarose/formaldehyde gels[171] ( lOpg/lane) and
blotted onto HybondN membrane (Amersham). A human multiple tissue northern blot was
purchased from Clontech (#7756-1). 2jig of highly purified poly A RNA from fetal tissues
(brain, lung, liver(female) and kidney) recovered following spontaneous abortions (at least 2
specimens pooled for each organ) had been run in each lane and blotted. The exact age
ranges were:- fetal brain 21-26weeks, fetal lung 22-23 weeks, fetal liver 22-26weeks and
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fetal kidney 19-23weeks. Blots were hybridised with random primed P-labelled pi 1132
Ascl-Dral fragment (bases 217-1737 fig.7.2.) at 55°C overnight in hybridisation buffer
(0.2M sodium dihydrogen phosphate, 0.6M disodium hydrogen phosphate, 5mm EDTA,
6% SDS and lOOpg/ml denatured herring testis DNA). Washes were SDS/SSC based
finishing with O.lxSSC, 0.1%SDS at 65°C followed by autoradiography (-70°C, 3-8 days). -
2.23 In Situ Hybridisation.
Cryostat sections (lOpM) were cut from frozen samples of human kidney (normal tissue
from the opposite pole to a discrete renal cell carcinoma) obtained at surgery and normal
placenta. Sections were mounted onto gelatin, and poly-L-lysine, coated slides, and stored at
-80°C. Slides were postfixed in 4% paraformaldehyde, washed in 2xSSC and incubated
with pre-hybridisation buffer for 3h at 50°C, as previously described[10], before
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hybridisation with SP6 transcribed S-UTP labelled antisense cRNA probes from Xbal
linearized pCRIICtBb (531 bp of pi 1132, bases 654-1184 : dashed box in fig.7.2). Sense
controls used T7 transcribed cRNA primed from Hindlll linearized pCRIICtBb. RNA
probes were denatured, added at a final concentration of 10x10 cpm/ml in hybridisation
buffer, applied to slides, as described[10] and incubated overnight at 50°C. Following
hybridisation, sections were rinsed twice in 2xSSC, treated with RNase A (30 pg/ml,
60min, 37°C), and washed to a maximum stringency ofO.lxSSC at 60°C for 60min. After
dehydration in increasing concentrations ofethanol, slides were exposed to autoradiographic
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film (Hyperfilm Bmax). Slides were dipped in photographic emulsion (NTB-2, Kodak,
U.K.), exposed in a light-tight box for 5 weeks, before being developed (D19; Ilford U.K.)
and counterstained with 1% pyronin.
2.24 Raising Antisera andWestern blotting.
Solid phase synthesis of an 11B-HSD2 peptide HCLPRALQPGQPGT (residues 370-383,
fig.7.2) with high predicted antigenicity was carried out. The peptide was N-terminally
coupled to keyhole limpet haemocyanin and rabbits were inoculated with the conjugate and
Freund's adjuvant, boosting monthly. Antiserum highly specific for 11B-HSD2 and reacting
to the peptide 370-383 were obtained after the fourth boost in one rabbit. Western blots were
performed with the 11B-HSD2 antiserum, at 1/10000 dilution (as primary antibody), using
the Amersham ECL system and methods recommended in the manufacturers' protocols
accompanying the ECL system reagents.
2.25 Immunohistochemistry.
Sections of human tissue, stored at -80°C, were thawed into neutral formalin fixative (for 8
h), paraffin processed and 4pm sections cut. After drying, sections were dewaxed, hydrated,
and treated in 3% H2O2 (20 min) and blocked with 20% sheep serum in TBS (Tris buffered
saline pfi 7.6 with 1% bovine serum albumin and 0.1% sodium azide). This diluent was-
also used for primary and secondary antibodies. Immunostaining, using an avidin-biotin
complex (ABC) method at room temperature, was as follows:- primary antibody (1/2000),
30min; TBS wash; secondary antibody (1/400 biotinylated sheep anti-rabbit F(Ab)2
fragments, Boehringer Mannheim, Lewes, U.K.), 30min; TBS wash; Vectastain ABC
Elite reagent, 30min; DAB substrate/chromagen reagent, 5 min. Sections were
counterstained in Mayer's Haematoxylin, dehydrated, cleared and mounted. Primary
antibody preparations used were (a)llB-HSD2 antiserum, (b) pre-immune serum from the
same rabbit and (c)llB-HSD2 antiserum pre-absorbed for 16h with peptide 370-383 at
50pg perml ofdiluted antibody. Both (b) and (c) were used as controls for (a).
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Chapter 3 : Solubilisation and Partial Purification of Human
Placental llfi-HSD.
3.1 Introduction.
Placental 11B-HSD was clearly of great interest and seemed to have characteristics distinct
from the 'liver-type' 11B-HSD activity (see Chapter 4). In particular placental 11B-HSD
appeared to be NAD-dependent. In order to clarify whether it represented a different isoform
and to allow study in detail it was essential to obtain tools (purified enzyme, specific antibody,
encoding cDNA etc.) allowing its specific detection. To begin to pursue these goals it was'
essential to isolate the enzyme responsible for this 11B-HSD activity in placenta as far as
possible. There are cytosolic as well as membrane bound steroid dehydrogenases/reductases
and the majority of successful purifications have been for the enzymes in the soluble
group[188-190]. Although quite a number of the membrane bound enzymes have remained
intractable to extensive purification, often despite extensive efforts (e.g. 5a-reductase where
only 8-40 fold purifications have been reported [186,187]) a number have been purified to
homogeneity, notably 'liver-type' 11B-HSD[35]. One of the main reasons for this difference is
that membrane-bound enzymes may require membrane components for full activity whilst
even those which can be fully solubilised may be prone to aggregation and precipitation out of
solution if they are brought into close proximity with chromatography matrices. Accordingly,
whilst soluble enzymes are often successfully purified in active form by a procedure with
several chromatography stages, this is very rare for membrane proteins. If membrane bouiN
enzymes are successfully purified, this is often by using a very high resolution technique
(typically affinity or immunoaffinity chromatography) in a short, one or two stage, purification
procedure. This was the case for 'liver-type' 11B-HSD where purification to homogeneity was
achieved withNADP-agarose[35].
Thus, in the purification of human placental 11B-HSD the strategy was to use subcellular
fractionation and, whether the enzyme was cytosolic or membrane bound, to screen for an
affinity chromatography matrix providing useful purification. As the placental enzyme
metabolised glucocorticoids, and appeared to prefer NAD as co-substrate, affinity matrices
withNAD or glucocorticoids as ligands were to be tried.
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3.2 Results.
3.2.1 Followingplacental llfi-HSD activity.
In initial experiments on human placenta it soon was clear that [3H]-corticosterone and [-%!]-
cortisol produced qualitatively similar results, but [^HJ-corticosterone was clearly a better
substrate for placental 11B-HSD than [3H]-Cortisol (see Chapter 4). Moreover, separation of
substrate and product on HPLC was better in assays with [^HJ-corticosterone. 11B-
dehydrogenase activity was the activity to be purified in these studies because 1 IB-reductase in
the human placental tissue studied (full term placentae) was only a very minor activity (less
than 5% of 1 IB- dehydrogenase at pH 7.5). Thus the fractionation and purification of the
3
enzyme was to be followed by assaying its activity to metabolise H-corticosterone to 11-.
dehydrocorticosterone.
3.2.2 Subcellular Fractionation.
Human placental 11B-HSD activity was well preserved during subcellular fractionation.
Placental 11B-HSD was clearly a membrane-associated protein (as >95% activity remained in
the membrane bound fraction, pelleting by 1 lOOOOg) and was most abundant in the 25 OOOg
pellet, which contained over two-thirds of the total enzyme activity in under one sixth of the
total protein; five-fold higher than in the microsomal 110 OOOg pellet, (fig.3.1). Moreover, the
25 OOOg pellet had as high a specific activity as the 110 OOOg microsomal pellet, and its
activity was stable and more rapidly prepared. Differential centrifugation of the 25 OOOg pellet
did not produce any useful refinement. This fraction was used for further purification, and has
been found to be very stable on storage at -70°C, with no decline in activity in over 2 years..
11B-HSD assays of this human placental 25OOOg fraction were at protein concentrations of 2-
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3.2.3 Solubilisation.
3.2.3.I Increasing Ionic Strength
The criteria for designating 11B-HSD activity "soluble" is that it remains in the supernatant
after centrifugation at 110 OOOg for 1 h. Increasing salt concentration is sufficient to solubilise a
proportion of membrane proteins which are only associated with the membrane by surface
contacts that dissociate with increased ionic strength[91]. Such solubilisation was attempted
with placental 11B-HSD (from resuspended 25 OOOg pellet) using a sodium chloride
concentration ranging from 0 to 2.4M. The ionic strength clearly affected 11B-HSD activity
before centrifugation as shown below in Table 3.1.
Table 3.1 Effect of ionic strength on placental 1115-HSD activity.
BUFFER IONIC STRENGTH (M) RELATIVE 11B-HSD ACTIVITY






0.3 M NaCl produced the maximum increase (doubling) of soluble 11B-HSD activity
compared to no NaCl. However, this was from only 0.9% to 1.8% of 11B-HSD activity and
when corrected for the increased activity before centrifugation was only a 1.1-1.2%
solubilisation. As 99% remained insoluble it was clear placental 11B-HSD was an integral
membrane protein rather than merely membrane surface associated and that detergent would
be required for its solubilisation.
3.2.3.2 DetergentSolubilisation.
A screen was performed using 11 detergents of diverse classes[90], at concentrations of twice
and half their critical micelle concentrations (CMC). Where the CMC was quoted as a range,
half the lower limit and twice the mid-range were used. Following this preliminaiy screen,.
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conditions were refined for the most promising detergent (CHAPS), the related detergent
Bigchap, and the detergent used to solubilise 11B-HSD1 for purification (Triton DF18)[35],
The total of 13 detergents tested are given below in Table 3.2. along with their CMC and the
concentrations used (mM).
Table 3.2-Detergents screened in solubilising human placental 111J-HSD.
DETERGENT CMC(mM) CONCENTRATIONS USED(mM).
CHAPS 6-10 3 and 16,1.5,4,5,6,7.5,10
taurodeoxycholic acid 1-4 0.5 and 5
Polyoxyetylene-10-lauryl
ether
0.20 0.1 and 0.4
digitonin 3.2-4 1.6 and 7.2
n-octylglucoside 20-25 10 and 45
Tween2 0.05-0.06 0.025 and 0.11
Tween 80 10-12,5 5 and 22
sodium dodecyl sulphate 7-10 3.5 and 17
n-lauryl sarcosine 13.7 6.8 and 27
Triton X100 0.2-0.30 0.1 and 0.5






0.16%, 0.24% and 0.4%
* The molecularweight ofthis detergentwas not available so concentration is expressed as%(v/v).
All solubilisation was carried out at 0-2°C. After 30 min, the mixture was centrifuged at 110
OOOg for 1 h. Supernatant containing soluble enzyme was carefully removed and the
percentage of the pre-solubilisation 11B-HSD activity remaining in this detergent solubilised
fraction is shown for the detergents screened in fig,3.2. Placental 11B-HSD activity was
inactivated by concentrations of detergents required fully to transform membrane proteins into








Fig 3.3 Refinement of human placental 11B-HSD solubilisation with
CHAPS. A range of concentrations of CHAPS (the most promising
detergent) were screened revealing 4mmol/l was optimal for placental 11B
HSD solubilisation. (mean±SE, n=4).
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was achieved with gentle conditions (detergent concentration < CMC), being best with
zwitterionic detergents with bile acid or steroid-like head groups (such as CHAPS, Bigchap
and taurodeoxycholic acid).
Following this preliminary screen, conditions were refined for the most promising detergent
(CHAPS) as shown in fig.3.3, the related detergent Bigchap, and the detergent used to
solubilise 11B-HSD1 for purification (Triton DF-18) [35], The best solubilisation achieved
with Bigchap and Triton DF18 are shown in fig.3.2.4mM CHAPS in combination with buffer
C (which contains 0.3M NaCl) was found optimal, solubilising 40-45% of the 25000g pellet
protein and 9.5% of its llfi-HSD activity (CHAPS (9.5%) > Bigchap (7.1%) >
taurodeoxycholic acid (6.3%) >Zwittergent3-10 >rest). This represented approximately a 7-8
fold increase over no detergent. Moreover on repeated re-extraction of the initially insoluble
protein with 4mM CHAPS, 13-20% ofthe original 11B-HSD activity could be solubilised.
3.2.4Affinity Chromatography.
Since, 11B-HSD uses NAD and glucocorticoids as substrates, columns with ligands
mimicking these were screened. It was found that one matrix, N6-linked 5'-AMP-agarose
(Sigma # A3019) bound substantial 11B-HSD activity that could be eluted with cofactor
(NAD>NADH>5'AMP»NADP). Two other kinds of 5'-AMP-agarose (ribose hydroxyl
(Sigma # A8895) and C8-linked (Sigma # A1271)) and two types of NAD-agarose were
ineffective with a small percentage (2%) binding to the third type ofNAD-agarose available
(linked at C8, Sigma # N1008), eluting specifically withNAD. 11B-HSD activity did not bind
to NADP-agarose, cAMP-agarose or to dexamethasone-agarose (Sigma # D4657, 0.5-
1 pmol/ml dexamethasone immobilised at CI7).
Preliminary studies with this N6-linked 5'AMP-agarose revealed it to be very useful for 11B-
HSD2 purification. Loading human placental CHAPS solubilised extracts (containing
solubilised 11B-HSD) onto this matrix, washing and using sequential elution with ImMNAD,
NADP and AMP, a large proportion of the human placental 11B-HSD activity eluted
specifically withNAD (fig.3.4(a)). Human placental 11B-HSD fractions which eluted from the
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elute with 11B-HSD activity (fig.3.4(b)). In multiple fractions over many chromatography
experiments (under a variety of conditions) the 40K protein band, and no other, was seen to
repeatedly segregate with 11B-HSD activity (as shown in figs.3.4(b) and 3.4(c)). This contrasts
with the rat liver 11B-HSD isoform which has aMr of 34 000 [35]. The quantity ofprotein in
tire fractions with 11B-HSD activity was estimated by comparison with known quantities of
protein standards run in parallel. The purification achieved was in excess of 1000-fold
(fig.3.4(c)).
3.3 Discussion.
Thus, placental 11B-HSD2 appears to be an integral membrane protein that requires factor(s)
present in membrane subtractions ofplacenta which are not satisfactorily substituted by a wide
range of detergents. Nonetheless a method allowing 13-20% of activity to be solubilised
rapidly had been defined and this was sufficient to permit the purification to proceed further. It-
was obvious therefore that purification of this enzyme to homogeneity was going to be very
difficult. Indeed, it was known that several groups, especially one in Chile collaborating with
the late Dr Carl Monder (who had purified 11B-HSD from rat liver) [191] had made extensive
attempts to purify 11B-HSD from human placenta but the difficulties in its solubilisation
prevented any useful purifications. The group in Chile had found tire best detergent screened to
be Triton DF-18, but the solubilisation was poor and the purification was eventually
abandoned. Several years later Lakshmi el al.. (who had purified rat liver 11B-HSD with
Monder) reported a partial solubilisation of 11B-HSD from human placenta with Triton
TX100 but it appears this did not permit an extensive purification. In fact, a purification -10-
fold is the only report this group made ofthis work [63], Similarly, a group from Australia had
attempted to purify NAD-dependent 11B-HSD activity from rat or pig kidney and had been
unable to solubilise it effectively and so the attempt at purification was abandoned[l 81].
As the work above defined a method allowing a modest solubilisation and purification of
>1000-fold leading to identification of the likely protein responsible this represented a
considerable advance on previous efforts. Other findings during this work and characterisation
of the partially purified placental 11B-HSD activity led to substantial evidence this isoform
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was distinct from the 'liver-type' 11J3-HSD activity (see Chapter 4) and also gave insights into
the likely kinetic mechanism ofthe placental 11B-HSD enzyme (see Chapter 11).
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Chapter 4 : Characterisation of Placental 11B-HSD Clearly
Identifies it as a New Isoform : 1115-HSD Type 2.
4.1 Introduction.
As outlined in the Chapter 1, 11B-HSD was purified from rat liver in 1988 [35] and an
encoding cDNA cloned in 1989. However, within several tissues, particularly the distal
nephron, there are striking discrepancies between the presence of 11B-HSD enzyme activity,
and the absence of the 'liver- type' protein (by immunohistochemistry) [15,17] or 'liver-type'
(1.7 kb) mRNA[39,49], This, and other evidence suggesting the presence of variant tissue-
specific forms of 11B-HSD[38,39,45,46,48], led to speculation about a second 11B-HSD
enzyme[167]. Work on renal DCT, particularly supported this view with an apparent NAD-
dependent 11B-HSD isoform detectable by histochemical activity staining[50,168].
As the methods developed in Chapter 3 had allowed production of substantially purified 11B-
HSD from human placenta it was possible to characterise this enzyme activity and compare
and contrast it to the 'liver-type' 11B-HSD from rat liver microsomes. To determine if
differences observed were solely due to differences between species parallel investigations in
the rat placenta were made when possible. Human placental 11B-HSD was found to be most
abundant in the 25 OOOg pellet (see Chapter 3). The same fraction was used for rat placenta.
For rat liver, microsomes (110 OOOg pellet) were used as these were the source of the purified
enzyme[35] for which the encoding gene has been cloned[36,46]. Finally, some comparison is
made in the discussion with what was known of the 11B-HSD activity derived from rabbit
cortical collecting duct cells[64] which was published after completion of the work in this
Chapter.
4.2 Results.
4.2.1 Tissue activities compared.
For all 3 tissues [^HJ-corticosterone and [^FQ-cortisol produced qualitatively similar results,
but [3]T|-corticosterone was clearly a better substrate for 11B-HSD than pH]-cortisol (as
illustrated for human placenta in fig.4.1(a)). Moreover, separation of substrate and product on
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HPLC was better in assays with [3H]-corticosterone. Thus, corticosterone was mainly used in
the studies presented below.
1 lB-dehydrogenase activity was concentrated upon in these studies as 1 lB-reductase in human
and rat placental tissue (tull term placentae) was only a very minor activity (0-5% of 1 1B-
dehydrogenase at pH 7.5). Moreover, placental llB-reductase was unstable and its activity
underwent a progressive decline at 37°C. This attenuation ofactivity was detectable even at 10
minutes. All studies compared llB-dehydrogenase in the 25 OOOg pellet of placental tissues
with rat liver microsomal 11B-HSD. Comparing the three tissues, rat placental 11B-HSD was
found to be the least abundant, most labile and was the only activity markedly attenuated by
freezing and thawing. Accordingly rat placental fractions were freshly prepared and used
rapidly.
4.2.2 llJi-HSD CofactorDependence.
To define and compare the cofactor preference of 11B-HSD in the three tissues the activity of
1 IB- HSD was determined when the concentration ofNAD, orNADP, varied across the range
O-lOOOpM (fig.4.1). Both human and rat placental 11B-HSD preferred NAD (ANOVA:
pO.OOl for both tissues), whilst the rat liver enzyme preferred NADP (pO.OOl). The activity
with lOO-lOOOpM cofactor was comparable in the three tissues (largely 30-45% conversion),
whereas, with no cofactor, the activity was 22% conversion for rat liver and only 2% and 5%
for human and rat placenta respectively. Although there appeared to be no NAD-dependent
11B-HSD activity in liver microsomes, the high activity without addition of exogenous
cofactor (which has been noted before in liver[169]) made this difficult to assess. Minor
NADP-associated 11B-HSD activity was seen in human and rat placental fractions. Eadie--
Hofstee analysis of the data for human placental 11B-HSD show rectilinear plots with NAD
(apparent Km for NAD = 13pM, Vmax = 180 pmol/mg protein/min), but curved plots with
NADP, suggesting the possibility that two distinct enzymes (with low and high Km for
NADP) contribute to the minor NADP-associated activity.
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Fig.4.1 Cofactor dependence of 11B-HSD activity. 11G-HSD activity
(mean±SE) in (A) human placenta, (B) rat liver and (C) rat placenta with
corticosterone as substrate in the presence of 0-1000pM cofactor (NAD
or NADP). Protein concentrations used in assays were:- human placenta,
2pg/ml; rat liver, 50pg/ml; rat placenta 500pg/ml. Human placental 116-
HSD activity with Cortisol and NAD shown too (with Cortisol and
NADP conversion remains <2%). Rat placenta n=4, otherwise n=5.
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4.2.3pH-dependence ofllfi-HSD activity.
The variation of 11B-HSD activity in the 3 tissues over pH range 5-11 is shown in fig.4.2. The
similarity between human and rat placental 11B-HSD activity with either NAD or NADP is,
striking, as is their difference from 11B-HSD activity in rat liver microsomes. Placental 11B-
HSD has a broad pH optimum of 7-8.5 with NAD (peak 7.5-8 in human placenta). With
NADP as cofactor the optimum is more alkaline (pH 8-9). Above pH 9 placental 11B-HSD
activity falls off sharply (especially NAD-associated activity). In contrast, pH 9-10 is the
optimum for rat liver 11B-HSD. The activity of liver 11B-HSD is largely or wholly
independent of added NAD (fig.4.1(b)). The liver 1 IB- HSD activity with added NAD may
be due to a relatively high level of endogenous cofactor[170]. Reductase activities for all 3
tissues were optimal at more acidic pH: pH5 for rat liver 1 lB-reductase with NADPH and pH
5-6 for human placental reductase. Solubilised 11B-HSD pH profiles are discussed below.
4.2.4Solubilisation ofllfi-HSDActivities.
Detergents were used to solubilise 11B-HSD, which was membrane associated in all 3 tissues.-
4mM CHAPS was found to be optimal for solubilising human placental 11B-HSD (see
Chapter 3). This is a lower concentration than used in other studies on 11B-HSD[35,37], Triton
XI00 has been shown to be a good detergent for solubilisation of rat liver[30] 11B-HSD.
0.06% Triton XI00 was optimal for solubilising rat liver microsomal 11B-HSD activity. This
corresponds to a detergent/protein ratio of 0.2 - the optimum found by Monder and
Lakshmi[30],
To compare detergent solubility, all 3 tissues were treated with (i)0.06% Triton XI00, (ii)4mM
CHAPS or (iii) buffer only. For each detergent the proportion of total protein solubilised was
similar for all 3 tissues (around 65% with Triton XI00, 45% with CHAPS). 11B-HSD assays
were performed on samples taken (i) before centrifiigation and from the detergent-solubilised
fraction (110 OOOg supernatant) at (ii)l hour and (iii)24hours after centrifugation. Results of (i)
and (ii) are shown in fig.4.3. Solubilisation of rat liver 11B-HSD was very efficient compared
to placental 1 IB- HSD. Addition of either Triton X100 or CHAPS increased rat liver 11B-
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Fig.4.2 pH dependence of llfi-HSD activity. 11B-HSD activity
(mean±SE) in (A) human placenta, (B) rat liver and (C) rat placenta
with corticosterone and 400pM NAD, or NADP, across pH range 5-11.
Protein concentrations used in assays were:- human placenta, 2pg/ml;
rat liver, 20pg/ml; rat placenta, lOOpg/ml. Dotted line shows pH profile
of solubilised enzyme (with 0.06% Triton XI00 or 4mM CHAPS for rat
liver and 4mM CHAPS for human placenta). These are superimposed (to
allow comparison of shape) to intersect corresponding graph without
detergent at its pH optimum (human placenta NAD pH 7.7,NADP pH
8.5; rat liver NADP pH 10). Rat placenta n=4, otherwize n=5.
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Fig.4.3 Behaviour in detergent of 11B-HSD activity. Activity of 11B-
HSD (mean±SE) in (A) human placenta, (B) rat liver or (C)rat placenta
with corticosterone and 400pM NAD or NADP. All tissues were
suspended at 3mg/ml in:- buffer C only (Nil); buffer C + 0.06% Triton
XI00 (TX100) or buffer C + 4mM CHAPS and assayed firstly, before
centrifugation and secondly in supernatant after centrifugation at 110
OOOg for 60 min. Results are expressed as percentage of activity with
preferred cofactor, without detergent and before centrifugation, with
protein concentration as follows:- human placental, 2pg/ml; rat liver,
20pg/ml and rat placenta 300pg/ml. Rat placenta n=4, otherwise n=10.
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centrifiigation a large proportion of the activity was soluble: between 90 and 100% of that
before detergent (compared to <2% when no detergent was added).
In contrast, human placental 11B-HSD showed minimal latency and was sparingly soluble
(9%) in CHAPS, whereas, the use of Triton X100 did not significantly increase 11B-HSD
activity solubilised (1±0.08% compared to 0.84±0.02% without detergent). Rat placental 11B-
HSD behaved similarly to human placental 11B-HSD (compare fig.4.3(a) with 4.3(c)),
however, analysis of rat placental 11B-HSD was hindered by the lability of the enzyme. The
soluble 11B-HSD activities in both human placenta and rat liver extracts were stable with
>80% remaining after 24 hours at 0-2°C. Solubilisation changed the pH profile of rat liver
11B-HSD, whereas veiy little change occurred when the human placental enzyme was
solubilised. The altered liver 11B-HSD pH profile remained very different from those of the
placental enzymes in the pH 8.5-10 range (fig.4.2).
Thus, using the same detergent and protein concentrations, the liver and placental 11B-HSD
enzyme activities behaved veiy differently.
4.2.5 ComparativeAffinity Chromatography.
Human placental and rat liver CHAPS solubilised extracts (containing solubilised 11B-HSD)
were subjected to affinity chromatography using columns of the N6 AMP-agarose matrix
identified in Chapter 3 as achieving 1000-fold purification of placental 11B-HSD. Sequential
elution was with ImM NAD, NADP and AMP (for human placenta:figs.3.4(a) and 4.4(a))
with NADPH following this for rat liver. A large proportion of the human placental 11B-HSD
activity eluted specifically withNAD. By contrast, liver 1 IB- HSD had no affinity for the same
column and no 11B-HSD activity eluted with any of the pyridine nucleotides (fig.4.4(b)).
When the human placental 11B-HSD fractions which eluted from the column were analysed
by SDS-PAGE a protein ofMr 40 000 was seen to co-elute with 11B-HSD activity (Chapter 3,
fig.3.4). This contrasts with the rat liver 11B-HSD isoform which has a Mr of 34 000
determined by SDS-PAGE[35]. This suggested that the placental isoform was NAD
dependent and distinct from the known isoform cloned from rat liver.
Samples of rat kidney were processed and run, in a similar fashion, on affinity chromatography


















Fig.4.4 Comparative Affinity Chromatography for 11B-HSD. AMP
affinity chromatography of CHAPS solubilised 25000g fractions from
(A) human placenta and (C) rat kidney; assaying fractions for NAD-
dependent 116-HSD activity. Both clearly show specific binding of 116-
HSD2-like activity. In contrast, panel (B) shows chromatography of
CHAPS solubilised rat liver microsomes revealing that the 116-HSD
activity in this tissue (which is NADP-dependent) has no affinity for the
same AMP affinity matrix. For all three tissues the solubilised tissue
extract was loaded on to the columns which were then: washed
(fractions 1-8), eluted with ImM NAD(fractions 9-12), washed (fraction
13) and finally eluted with ImM NADP (beginning during fraction 14).
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supposed to be present in distal nephron. As with human placenta and unlike rat liver, a
significant quantity of 1 lfi-HSD activity bound specifically to the column and eluted with
NAD(fig.4.4(c)). This provided evidence that an isoform similar to placental 1 lfi-HSD was
indeed present in kidney[l 80],
4.2.6 Assessment of substrate and cofactor preferences of partially purified human
placental llfi-HSD.
CHAPS produced competitive inhibition of human placental 1 lfi-HSD, reaching 50% (Kj) at
0.37mM. Estimates of kinetic parameters for the partially purified enzyme eluted both with
and without CHAPS were in good agreement when corrected for this competitive inhibition.
Thus, the Km of the partially purified human placental 1 lfi-HSD was 14±1 nM (mean ± SE)
for corticosterone and 54±14 nM for Cortisol, with a Vmax of approximately 25nM[mg
protein, min]"l with either steroid. The cofactor preference of placental llfi-HSD was
examined by removal ofNAD by repeated filtration in a Centricon-10 apparatus (see Chapter
2). At a residual NAD concentration of below 2pM, addition of 400pM NADP promoted an
increase in llfi-HSD activity. When residual NAD was above 2pM, addition of 400pM
NADP was without effect. Thus a >200-fold excess ofNADP over NAD was required to
demonstrate an effect on the enzyme.
When gradients of nucleotide cofactors were used to elute bound human placental 1 lfi-HSD
from the AMP affinity column the 1 lfi-HSD activity began to elute at thresholds of 30pM
NAD and 300pM AlMP but did not elute at all during a 0-3000pM NADP gradient (fig.4.5).
After the AMP gradient a small amount of enzyme eluted with 3mM NAD. After the NADP
gradient a large amount of 1 lfi-HSD activity eluted with NAD (fig.4.5). This again clearly
demonstrated the NAD-dependent nature ofhuman placental 1 lfi-HSD enzyme which was in










































Fig.4.5 Gradient elution off AMP matrix with cofactor. CHAPS
solubilised human placental fractions were loaded onto the AMP affinity
column and the relative efficiency of elution by NADP, NAD and
5'AMP was determined gradient elution. Findings with NADP gradient
illustrated. Fractions: 1-5, flow through/wash; 6-15, wash; 16-48,
increasing NADP gradient 0-3000pM; 48-50, wash; 51-60, 3mM NAD
elution. In the equivalent scheme for NAD and AMP gradients 11B-HSD
eluted beginning at fraction 29 (30pM) and 38 (300pM) respectively
(not shown).
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HSD(dehydrogenase activity), which is in contrast with the abundant rat liver 1113-
HSD(reductase activity)[28,40]. Secondly, the subcellular localisation of the 1113-HSD appears
different. Rat liver 1113-HSD is localised to microsomal and 'nuclear' ffactions[28]. By
contrast, our preliminary work suggests a different and more widespread subcellular
localisation of placental 1113-HSD (see Chapter 3) with activity abundant in the microsomal-
(llOOOOg pellet) and mitochondrial/ heavy microsomal (25000g pellet) fractions. Further
differential centrifiigation of the human placental 25000g fraction produced "mitochondria
enriched" and "microsome enriched" sub-fractions with similar 1113-HSD activity. Thirdly, rat
liver microsomes were found to have substantial 1113-HSD activity in absence of added
cofactor, being increased less than two-fold by 400pM NADP. In contrast, placental 25 OOOg
membrane pellets had little 1113-HSD activity in the absence of added cofactor, but this was
increased ten-fold by 400pM NAD. The cause of this difference is unclear, though the higher
pyridine nucleotide cofactor concentrations in liver[170] and the relatively low Km of liver
1113-HSD forNADP (0.196pM) [35] would cause any NADP sequestered in the microsomes
to have a potent influence. The apparent Km of human placental 1113-HSD for NAD is
considerably higher (13pM) making the enzyme less sensitive to trace amounts ofendogenous
cofactors and causing it to show a clearer cofactor preference. In intact cells NAD is more
abundant thanNADP[170] hence both enzymes are suited to respond to physiological cofactor
levels. Fourthly, our preliminary data suggest that their immuno-reactivity to anti-'liver-type'
anti-sera is very different. In conditions that cause minor immuno-neutralisation and major
immuno- precipitation of solubilised liver microsomal 1113-HSD, the solubilised placental
1113-HSD showed absolutely no immuno-neutralisation or immuno-precipitation of the 1113-
HSD activity with either 56-125 or 56-126 anti-sera[38](gift ofDr Carl Monder, Population
Council,New York).
4.3 Discussion.
The existence of a second enzyme (1113-HSD2) has been the subject of much
speculation^67], largely based on evidence of the presence of 1113-HSD activity in the
absence of liver type 1113-HSD protein or mRNA. In addition, variant mRNAs which
hybridise to rat liver 1113-HSD cDNA have been identified in kidney[39] and colon[46,54].
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Further experimentation, however, has shown these renal mRNA variants to be derived from
differential promoter usage of the characterised liver 11B-HSD gene[46] and may encode
proteins with no demonstrable 11B-HSD activity[57,61]. This has implications for in situ
hybridisation results on renal cortex[13,44] as hybridisation to 'liver type' 11B-HSD probes in
kidney may be detecting variant mRNA species without the potential for translation to active
11B-HSD enzyme. Antibodies to 'liver-type' 11B-HSD also detect what appear to be
additional tissue-specific proteins (e.g. 26K in brain, 40K in kidney and 47K in testis) with
strong antigenic similarities to 'liver-type' 11B-HSD[38], Indeed, when attempts have been
made to separate such proteins (26K species) from the 34K liver-type 11B-HSD protein the.
variant protein had no demonstrable activity[45]. Thus the evidence suggests 11B-HSD2 is the
product ofa separate gene and is not, therefore, readily detectable by antibodies or nucleic acid
probes specific for 'liver-type' 11B-HSD. From the evidence presented here it seems clear the
placental isoform represents an 11B-HSD enzyme distinct from the 'liver-type' 11B-HSD. It
seemed more than coincidence that both placental 11B-F1SD and the isoform that had been
reported in renal distal nephron (rabbit cortical collecting duct):- (i) are NAD-dependent; (ii)
have a Km for physiological glucocorticoids two orders ofmagnitude lower than liver 11B-
HSD (14) and (iii) appear not to be immuno-reactive to 'liver-type' anti-sera[15]. The fact that
kidney 11B-HSD activity bound specifically to the same 5'AMP affinity column as placental
11B-HSD strongly supported the conclusion that these tissues contained very similar or
identical 11B-HSD isoform(s) [180].
In summary we find strong evidence for anNAD-dependent 11B-HSD isoform in both human
and rat placental tissue which is distinct from the previously characterised enzyme in rat liver
and may be encoded by a separate gene. Henceforth, in this thesis, this isoform in placenta is
referred to as 11B-HSD type 2 or 11B-HSD2.
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Chapter 5 : Development of a Novel Method Allowing Highly
Specific Affinity Labelling of 11B-HSD2.
5.1 Introduction.
The kinetic studies of 11B-HSD2 purified by AMP-agarose chromatography from human
placenta revealed a very low Km for corticosterone (14 1 nM) (see Chapter 4). This is an
uncommonly low figure for the Km ofan enzyme for amajor substrate and is getting down to
the range of the Kds of receptors for their ligands. As purification ofplacental 11B-HSD2 was
revealing that when the enzyme was purified significantly beyond 1000-fold, its activity was
labile and prone to inactivation on further purification procedures (see Chapter 6), it was clear
that it would be a major advantage to be able to track the enzyme even if inactive. Receptors
can often be affinity labelled by ligands (or their homologues) which bind them with high-
affinity; having a in the low nM range. Thus, because of the receptor-like Km of human
placental 11B-HSD2 for corticosterone, affinity labelling with this steroid was successfully
attempted using the following method.
5.2 Results.
5.2.1 Method developed for UV Photoaffinity Labelling and its analysis by
Fluoroautoradiography.
The standard method developed used a reaction volume of 600pl irradiated by intense UV
light in the wells of a 24 well plate (diameter 1.5 cm) with the lid off. 467pi of tissue sample
diluted in buffer C was added to wells of 24 well plates (diameter 1.5cm) and maintained at
37°C for 3 min. Addition of60pl of250mM dithiothreitol, 48pl of5mMNAD (both in buffer
C) and finally ^H-steroid (in 25pi of 10% ethanol: buffer C) completed the reaction giving a*
final concentration of 50nM ^H-steroid in 600pl, unless otherwise stated. In the experiments
presented in this Chapter (to minimise UV damage to protein), reactions were placed in UV
light (312nm transilluminator at distance of 5cm above plate; lid off) for 15 min at 37°C. The
procedure was easily scaled up. Similar labelling occurs at 254nm and is even stronger at 0°C
or with longer UV exposure. However, all three of these variations also induce formation of
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(a) Liver Purified Cytosol 25000g Nuclear (b)
PS F B Dx
I I I I
Fig.5.1 Native photoaffinity labelling of 11B-HSD2. The bottom panels are
autoradiographs of labelled protein samples run on the 12.5% SDS-PAGE gels
shown in the top panels (stained with Coomassie blue). Apparent Mr (xlOOO)
ofprotein standards (PS) indicated to left side of gels. (A) Triplicate samples of
rat liver microsomes, AMP chromatography purifiecTFiuman placental 1113-
HSD (similar to fraction 6 in fig 3.4(b)) and three human placental subcellular
fractions. All samples were photoaffinity labelled simultaneously with H
corticosterone in the presence of 400pM NAD (d at top of lane), 400pm
NADP (p), both cofactors at 400pM (dp) or both cofactors and 50pM
carbenoxolone (cx). A single protein band at 40k is labelled in an NAD-
dependent, carbenoxolone-blockable fashion. (B) Samples of human placental
25000g pellet (mitochondria + heavy microsomes) p^iotoaffinity labeled
simultaneously in the nresence of 400pM NAD and H-cortisol (F), H-
corticosterone (B) or H-dexamethasone (Dx). Protein loading <0.5pg for
"purified" lanes, otherwise 30pg/lane in studies (A) and (B).
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minor bands below 40k and protein damage with prolonged 254nm UV exposure will be
more extensive.
During analytical work leading to identification of the 11B-HSD2 protein, duplicate labelled
samples were acetone precipitated and resolved by SDS-PAGE[83], or 2-D
electrophoresis[87,88] (see Methods: Chapter 2). One of the finished gels was stained with
Coomassie Blue to allow detection ofmajor proteins and molecular weight standards and was
processed for fluoroautoradiography in 'Entensify' solutions and vacuum dried before exposure
to film. The other was silver stained allowing identification of all the proteins (major and
minor) to assess the extent to which the labelled 11B-HSD2 protein had been fully resolved-
from contaminants (see Chapter 6)
5.2.2 Characteristics ofthephotoaffinity labelledprotein identify it as 11JI-HSD2.
As fig.5.1 shows, a protein with all the expected characteristics of 11B-HSD was uniquely
photoaffinity labelled. This protein was 40k in size, present in the subcellular fractions with
11B-E1SD activity (25000g pellet> 750g pellet (nuclear/debris) llOOOOg pellet (light
microsomes, not shown)), but absent in cytosol. The labelling was NAD-dependent,
independent of NADP and blocked by carbenoxolone. Labelling of fractions after AMP-
agarose chromatography showed the labelled protein exactly followed 11B-HSD activity,
being present when 11B-HSD eluted with NAD (e.g. fig.6.1(b). fractions 87-120), and in the
flow-through (fractions 1-30), but absent in the inactive wash fractions. Moreover, the same
protein could be affinity labelled with Cortisol and dexamethasone
(corticosterone»cortisol»dexamethasone: fig.5.1(b)), but there was no labelling with'
aldosterone. This novel technique appears to result in completely selective labelling of
placental 11B-HSD by glucocorticoids, with a potency which parallels their affinities as
substrates for the enzyme. Using this technique it was possible to track the 11B-HSD2 protein
after activity had been lost, so allowing final purification by 2-D electrophoresis.
5.3 Discussion.
The affinity labelling technique developed here is unusually straightforward and specific for
11B-HSD2. Photoaffinity labelling is more commonly described for receptors and binding
proteins and a few such procedures report labelling by unmodified steroid compounds acting
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as ligand (e.g. GR by dexamethasone) but even in such cases these 'common' ligands lack the
desired specificity and are replaced by compounds developed to allow greater specificity (e.g.
RU26988 and RU28362 for exchange assays/photoaffinity labelling specific for GR[9,100]).
Affinity labelling of enzymes is much less commonly by photoactivation and more often
achieved using a specifically designed activatable compound containing a reactive functional
group (usually electrophilic e.g. bromoacetate) which is attacked by an activating substituent
(usually a nucleophilic side chain of an amino acid) in the enzyme's active site (e.g. 3-
14
methoxyestriol 16(bromo[2- C] acetate) labelling homogeneous placental 17B-HSD type 1 at
two histidines in its active site[96]). Less commonly, enzymes can bephotoaffmiXy labelled by
precisely chosen synthetic compounds which, when photoactivated, develop short-lived highly
reactive substituents which label the target enzyme if a suitable amino acid residue is nearby
(e.g. UV induced labelling by 19 nortestosterone acetate ofpurified 5-3 ketosteroid isomerase
from Pseudomonas testosteroni[\77]). What makes the labelling technique described here
particularly unusual is that it can use a physiological substrate, in a crude tissue extract,
containing thousands ofdifferent proteins (in contrast to the two examples, given above, using
pure enzyme), and label the enzyme for that substrate with great specificity (analysis in
Chapter 6 reveals only a single labelled spot on 2-D electrophoresis). To our knowledge, the
only other study describing photoaffinity labelling of a steroid metabolising enzyme by what
may be a natural substrate is the labelling of Pseudomonal 5-3 ketosteroid isomerase, with
testosterone. This, however is a less avid label than synthetic 19-nortestosterone acetate.
Though the parallels are intriguing, that study[l 76,177] utilised pure enzyme and 500-fold
higher steroid concentrations than employed here for 11B-HSD2 labelling.
Several findings suggest the affinity labelling procedure, described above, occurs within the
steroid binding pocket of the active site. Firstly, the affinity labelling is NAD-dependent as is
11B-HSD2 activity. There are a few reports of cofactor-dependent affinity labelling of other
dehydrogenases. NAD-dependent lactate dehydrogenase is affinity labelled, in the presence of
NAD, by bromopyruvate on the major catalytic residue (histidine 195)[175,179], Secondly;
carbenoxolone, an 11B-HSD2 inhibitor, blocks labelling, as does a 1000-fold excess of cold
corticosterone. Thirdly, the rank order of potency for glucocorticoid labelling correlates with
the substrate affinities ofhuman placental 11B-HSD2.
Finally, the glucocorticoid groups most likely to participate in covalent photoaffinity labelling
of 11B-HSD2 are the carbonyl group at C3 and the CI 1 position itself. Labelling via the C20
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carbonyl appears less likely as it is expected to be less photoexcitable and as covalent
attachment of the C20-C21 grouping (following the common C17-C20 cleavage) would not
attach any radioactivity, as the steroids are tritiated at CI,2,6 and 7 only. The C3 carbonyl
would be highly photoactivated to produce both alkoxy radicles and reactive ketenes, both
would react relatively indiscriminately[2], potentially with almost any closely approximated"
amino acid, but especially with reactive cysteine, lysine, histidine or tyrosine residues. The
photoreactive state ofCll is harder to anticipate but likely to be greatly heightened in the
active site where it will make the transition to a CI 1 carbonyl, a photoexcitable group in its
own right.
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Chapter 6 : Purification to Homogeneity and Determination of
Amino Acid Sequence of 11B-HSD2.
6.1 Introduction.
Having identified a means of solubilising human placental 11B-HSD2 and an affinity
chromatography matrix allowing 1000-fold purification, the aim was now to obtain amino
acid sequence from the 11B-HSD2 protein. Thus further purification was required to allow
isolation ofhomogeneous protein.
6.2 Results.
6.2.1 Refining the AMP Affinity Chromatography Procedure.
Firstly, the N6 5'AMP affinity chromatography procedure was optimised. Throughout this
optimisation the 40kDa band originally observed (Chapter 3) continued to be the only one
consistently segregating with 11B-HSD2 activity. It was found that a purification of several
thousand-fold could be achieved in this one step using a small (1ml) column of this 5'AMP-
agarose and resulted in small volumes ofeluate where the 40k protein was the only significant
protein detected. However, by this degree of purification the 11B-HSD2 activity was very
labile and easily inactivated. Chromatography for highest purity (e.g. lanes A1 + A2,
fig.6.1(a)), used the 'analytical' method detailed in Chapter 2 (Methods: Affinity
chromatography) but suffered from reduced reproducibility and low yield of active 1 lB-HSD.^
It was clear these losses were unacceptably high when the procedure was tried at preparative
scale using a 30ml AMP-agarose column. Accordingly a second set of optimisations were
carried out for preparative scale purification. This revealed higher yield and higher purification
was possible with 6 x 5ml columns run in parallel rather than a single 30ml column. The
optimised 'preparative' procedure is as outlined in Chapter 2. This preparative scale method
would reliably yield 80-100ml of eluate having high 11B-HSD2 activity (50pl giving >90%
3
conversion in 10 mins of 12nM H-corticosterone during a standard 11B-HSD2 assay).
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6.2.2Purification BeyondAMPAffinity Chromatography.
These large scale preparative conditions (see Chapter 2 and fig.6.1(b)) reproducibly gave 20-
fold higher yield («35%) at somewhat reduced, though still 1000-fold, purification (fig6.1(a)
fractions PI and P2). Note the 40k band (starred) is the most prominent but contamination
persists at a range ofmolecular weights, notably several narrow bands very close to (especially
above) 40k. These closely flanking bands indicated contaminating proteins that were likely to
defeat further purification steps based solely on resolution by size (e.g. gel filtration).
Accordingly separation by charge was attempted using ion exchange chromatography.
Conditions using DEAE-Sepharose were determined allowing >90% yield and 5-8 fold
purification of CHAPS-solubilised placental 25000g pellet 11B-HSD2 activity. However,
when this was tried, either before or after the preparative affinity chromatography the yield of
active enzyme fell to <2%. This loss ofactivity was intractable to alteration ofconditions and if
was clear the solubilised, highly purified placental 11B-HSD2 enzyme eluting off AMP
affinity chromatography was too labile to withstand significant further purification procedures.
At this stage efforts were made to find amethod of tracking the enzyme when inactive and the
highly successful affinity labelling procedure was rapidly developed (see Chapter 5). This
allowed the enzyme to be tracked after activity had been lost in a fashion which withstood
harsh denaturing conditions. Thus it was decided to further purify the placental 11B-HSD2 by
separating by both size and charge using 2D electrophoresis having affinity labelled a portion
of the enzyme between AMP affinity chromatography and 2D-electrophoresis.
6.2.3 2-D Electrophoresis.
3
Fractions containing enzyme eluted from AMP-agarose were affinity labelled with H-
corticosterone and then subjected to conventional 2-D electrophoresis (IEF + SDS-PAGE).
After prolonged exposure gel autoradiography remained negative. Accordingly, NEPHGE-
gels were run. A strong signal, indicating the presence of a single affinity labelled protein spot
of basic pi (pi 9.1) and apparent molecular weight of 40k, was seen on autoradiography
(fig.6.2(a+b)). It was notable that this was accompanied by other proteins close to 40k which
were not affinity labelled. NEPHGE conditions were optimised (fig.6.2) to allow preparative
scale gels with substantially increased yield and reduced smearing of the affinity labelled










































Fig.6.3 Microbore HPLC profile of 11B-HSD2 tryptic digest. Solid line
indicates elution of peptide peaks (detected by A22O, highest peaks
corresponding to 500pmol). The elution position of trypsin and peaks from
which peptide sequence was obtained (G by V8 sub-digest) are indicated. The
digest was loaded onto the HPLC RP300 column equilibrated in solvent A
(0.1% TFA, water) and developed with a linear gradient {dashed line) of 0-
100% solvent B (0.08% TFA, 80% acetonitrile/water) over 45 min at
200pl/min.
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CYCLE. SEQUENCED PEPTIDES [ Res i d u es, Y i e 1 d (p m oDi.
A A2 B B2 B3 c D E F G
1 N 445 L 190 A 180 412 L 315 V 126 1 55 V 411 ? 1 7 ? V 45
2 V 435 P 163 L 96 405 L 330 s 119 V 36 L 364 L 406 L 16 N 29
3 G 383 V 182 Q 83 351 Q 318 I 117 T 16 E 231 L 307 D 9 F 27
4 Q 311 A 180 P 76 339 M 316 I 117 V 19 F 333 Q 238 S 75 F 15
5 w =60 T 112 G 66 281 D 170 Q 85 G 15 T 74 L 214 ML ? G 10
6 E 195 R 31 Q 57 271 L 243 P 46 SI ? K 37 L 221 G 5 A 9
7 K 97 P 71 20 T 134 G 40 P 15 R 21 F 6 L 7.5
8 G 62 197 K 135 C 40 A 16 TD ? E 2.5
9 T 39 135 P TO F 41 G 14 V 8
10 T 40 116 G 175 K 8 D 12 L 53
11 P 40 121 D TO M 13 A 3.8
12 P 33 92 1 167 P 11 T 3
13 Q 30 82 S 60 Y 10 VP ?
14 D 18 43 R 28 P 10
15 A 23 62 - 0
16 A 25 71 L 8.4
17 Q 15 43 G 7.4
18 D 11 16 A 8.1
19 P 10 21 V 3.5
20 N 10 17 G 2.5
21 L 13 T 1.8
22 S 6 S 2
23 P 9 K 1.5




Table.6.1 11B-HSD2 Peptide Sequence. The amino acid and yield (in
pmol) obtained on sequencing 11B-HSD2 peptides A-G are given by
cycle number. Peptide B was sequenced twice (using a second sample
also from tryptic digestion of purified 11B-HSD2). Cycle C(15)
produced no residue signal. Cycles F(5), F(8), F(13) and C(6) produced
two residues at similar yield making assignment difficult. Cycle A(5) is
definitely W but the yield is imprecise. Note boxed sequence in the C
peptide is a classical short chain alcohol dehydrogenase motif indicating
the likely active site.
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of over 40(-ig of homogeneous 11B-HSD2 protein which was blotted onto PVDF (Problott)
membranes.
6.2.4AminoAcidSequence.
PVDF blots were stained with amido black and the 40k target protein accurately excised.
Sequencing of PVDF pieces revealed homogeneous 11B-HSD2 was N-terminally blocked.
This is unlikely to be an artifact ofthe purification as, on sequencing, an amino acid signal was
completely absent (rather than just low), and we have obtained high yield N-terminal sequence*
from other proteins blotted from gels in the same fashion. In situ tryptic digestion of
approximately 30pg of 11B-HSD2 protein produced multiple peptides and several were
sequenced, yielding in total, over 100 residues of amino acid sequence (fig.6.3 + Table 6.1).
Peptide G was blocked. This was sub-digested with Staph. Aureus V8 protease yielding a
sequencable daughter peptide.
6.2.5 The OverallPurification Procedure.
Table 6.2 summarise the steps in the purification procedure we have described that allowed
isolation of homogeneous 11B-HSD2 protein from human placenta (>16000 fold purification
), and direct determination ofover 100 residues of its internal amino acid sequence. In Chapter
7 it is described how the amino acid sequence derived was used to clone a full length 11B-
HSD2 cDNA from a human placental library which, on transfection into mammalian cells,
expresses 11B-HSD2 activity and a 40k protein which can be affinity labelled (see Chapter 8)
by the method described above in Chapter 5.
6.3.Discussion.
Several findings suggest the 11B-HSD2 membrane environment has polar aspects. Thus,
moderate ionic strength stimulates activity (Table 3.1), the most hydrophobic lipid-like
detergents (e.g. Tween 20) are not the most useful for preserving 11B-HSD2 activity and the
11B-HSD2 protein has a very high pi (pl>9). The very basic pi (pi =9.1) is surprising. Proteins
this basic are unusual, often being ribosomal or associated with nucleic acid (chromatin or
RNA). Rarely are they intrinsic membrane proteins and this combination suggests interactions
of 11B-HSD2 beyond NAD and steroids, perhaps with other membrane proteins or charged








































































Table.6.2SummaryOfPurification11B-HSD2.Purifications g0placen asy eldi43gof16000-foldpuri i1B-HSD2 Affinitylabellingoftraceramou ts11B-HSD2a terAMP- garosechromatographyll w dmeanoassessingyieldbe ondthi stage.11B-HSD2peptidrecovery(followinginsi utrypticdig st,e utionoffPVDFandmicr boreHPLC)wasg rallylo th increasingpeptidehydrophobicity(seefig.6.3).
are involved in stabilising the enzyme, as occurs with the related NAD-dependent, short-chain
alcohol dehydrogenase (SCAD) enzyme, 3-hydroxybutyrate dehydrogenase[95], We have not
investigated this further as development of the affinity labelling technique allowed purification
of 11B-HSD2 to homogeneity, when activity was notmaintained.
All peptide sequence obtained was unique, confirming 11B-HSD2 as a novel protein. This is
the first directly determined 11B-HSD2 peptide sequence from any source. Direct amino acid
sequence allows information about amino acid order and post-translational modification and
avoids some pitfalls of cDNA-predicted amino acid sequence, such as use of rare codons (e.g.
selenocysteine). There is one potential N-linked glycosylation site (NLS: peptide B) which in
the native protein appears to be largely free of glycosylation, at least in human placenta, as the
amino acid sequence yield did not drop across theN residue (asparagine). Peptide C contains a
classical short chain alcohol dehydrogenase (SCAD) motif (boxed in Table 6.1, peptide C)
indicating 11B-HSD2 belongs to this enzyme superfamily. There was one clear 'blank' cycle
in the middle of peptide C (cycle 15); it is possible a modified amino acid naturally occurs
here. Further analysis ofthe 11B-HSD2 sequence is presented in Chapter 7.
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Chapter 7 : Cloning of Human Placental 1115-HSD2 cDNA and
Analysis of the Predicted Structure of the Encoded Enzyme.
7.1 Introduction.
Having obtained extensive amino acid sequence from homogeneous 11B-HSD2, two
objectives then fell within reach:- firstly to raise a specific anti-11B-HSD2 antibody, which
is dealt with in Chapter 9 and secondly to clone the cDNA encoding 11B-HSD2 in placenta
so also allowing prediction of the entire amino acid sequence of the enzyme, which is dealt
with in this Chapter.
7.2 Results and Discussion.
7.2.1 Cloning of11J1-HSD2fromHuman Placenta.
As amino acid sequence had been obtained from several distinct peptides it was decided to
follow a PCR strategy whereby primers corresponding to the peptide sequences would be
used in pairs to amplify the fragments of the 11B-HSD2 cDNA spanning the peptide pair.
Extensive searches of the protein databases were made with the peptide sequences but were
unhelpful in giving definite information about the NH2 to COOH order they occupied in the
11B-HSD2 protein. Thus the five peptides about which there was most certainty in the
amino acid sequence (peptides A, B, C, D and B2) were chosen and the region giving the
least degenerate primers were selected and the corresponding degenerate primers for both
top and bottom DNA strands were synthesised. Where there was a four-fold degeneracy an
inosine was put in the primer sequence. Placental RNA was prepared, extensively DNAse
treated and reverse transcribed to make the placental cDNA on which the degenerate PCR
amplification was carried out.
The degenerate primers were used in all top-bottom pairwise combinations in an initial PCR
screen carried out on human placental cDNA Combinations involving primer Bb resulted
in the amplification of several particularly prominent DNA products, the majority of which
appeared to be independent of the top primer used (fig.7.1 lanes1-4), and indeed PCR with
Bb alone reproduced many ofthese bands. A clear exception was the PCR product arrowed
in fig.7.1 (lane 2), this was specific to the CtBb primer pair and became the major product
(fig.7.1 lane 5) using more stringent PCR conditions. This CtBb fragment was directly
cloned and sequenced revealing a single open reading frame spanning its length (53 lbp) and
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Fig.7.1 PCR to amplify 11B-HSD2 sequences. Ethidium bromide
stained agarose gel showing analysis of PCR amplifications. Lanes 1-5
RT-PCR on human placental mRNA using degenerate primers based on
118-HSD2 peptide sequences A-D. Primers used (Xt = top, Xb =
bottom, X = peptide) indicated above corresponding lane. Lanes 1-4
initial PCR conditions used, lane 5 using more stringent amplification
yielding only the CtBb specific product (531bp) identified initially
{arrowed, lane 2). Lanes 6 + 7 PCR (using vector- specific primers
flanking the cloning sites) of 11B-HSD2 inserts of 1179bp partial
pcDNAl library clone (1157bp + 22bp polyA: lane7) and the 1919bp
(1897 + 22bp polyA) pDR2 clone containing the full coding region (lane
6). Lane L = lkb ladder (Gibco-BRL.)
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with a predicted amino acid sequence encompassing 4 11B-HSD2 peptides (C, B, A and,
B3) including a short chain alcohol dehydrogenase (SCAD) motif (YXXXK, see below).
This CtBb fragment was used (a) to design a synthetic peptide to raise an anti-11B-HSD2
antibody (see Chapter 9) and (b) to isolate a complete 11B-HSD2 cDNA.
A human placental cDNA library in pcDNAl was initially screened by a PCR based
approach and a 1177bp partial clone isolated (lane7, fig.7.1) which contained the CtBb
fragment, 45bp further 5' and 603bp further 3' (reaching to the 3'end of the cDNA with a
22bp polyA tail). Conventional screening of700 000 plaques from a human placental DR2
library (Clontech), using the incomplete 11B-HSD2 sequence as a probe, allowed isolation
of a single clone which, when converted to pDR2 plasmid form (see Methods, Chapter 2),
produced very abundant, NAD-dependent, 11B-HSD2 activity in transfected CHO cells.
This clone was designated pi 1B2.
7.2.2 Characteristics ofthe cDNA clone andPredicted 11JI-HSD2 Protein Sequence.
7.2.2.a Generalfeatures ofthe 1 If-HSD2 cDNA clone.
This active 11B-HSD2 clone, pllB2, contained a 1897bp cDNA with 22bp polyA tail
(1919 bp total), and has a G+C rich composition (63.25%). The 5' end of the cDNA (first
385 bases) is extremely G+C-rich (79.2%) and contains a 'CpG island'[111] with 56
occurrences (in 385 bases) of this usually scarce dinucleotide. G+C and CpG content fall
abruptly beyond the region (to 55% G+C, while CpG frequency falls 4-fold). These
features, which extend to the start of the 11B-HSD2 cDNA, are suggestive of a 5'
transcription regulatory region. The best candidate for initiation of translation is the ATG
codon beginning 134 bases from the 5' end of the cDNA (set to +1 in fig.7.2), this is in a
good context for initiation of translation, with 9/10 matches to the putative ideal ribosome
binding site (GCCGCCATGG)[174], and is within the longest open reading frame (-63
+1215:fig.7.2) defining a predicted coding region of 1215bp (+1 1215), flanked by a 5'
untranslated region (5'UTR) of 133bp (-133 -1) and long 3'UTR of 549bp (1216
1764). The predicted coding region encodes a 405 amino acid protein (calculated mol. wt.
44126) encompassing all the 11B-HSD2 peptide sequence derived from digests of the.
purified protein (boxed in fig.7.2). The most abundant amino acids are leucine (68 in 11B-
HSD2), alanine(46), glycine(32), which are all highly represented in proteins in general,
followed by proline(32) and arginine(30). The high arginine content seems responsible
for the very basic nature of the 11B-HSD2 protein, so clear during purification, as basic
residues (R=30, K=12, H=7) markedly outnumber acidic ones (D=15, E=15), giving a
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ShortC ainAlcoholDehydr genaseMotif ITGCDSGFG-(X)78-LVNNAG- 69-YGTSKAA ITGCDSGFG-(X)78-LVNNAG- 69-YGTSKAA VTGGDCGLG-(X)78-VINNAG- 69-YGSSKAA ITGCDSGFG-(X)76-LVNNAG- 68-YCVSKFG VTGCDSGFG-(X)82-LVNNAG- 6 -YCITKFG VTGASKGIG-(X)78-LILNHI- 69-YSASKFA ITGCSSGIG-(X)78-LVCNAG- 69-YCASKFA VTSATRGIG-(X)72-LVNNFG- 67-YGVSKSG ITGGARGLG-(X)74-LVNNAG- 69-YGASKWG VTGAGKGIG-(X)69-LVNNAA- 70-YSSTKGA VTGAGGGLG-(X)83-WNNAG 69-YSAAKLG ITGAGDGIG-(X)7?-LVNNVG- 71-YSASKAF VTGAGGLLG-(X)92-NVNVKG- 57-YPYSKKL
predicted net positive charge (+19) and very basic predicted isoelectric point of 9.92 for
the 11B-HSD2 polypeptide. Nine cysteine residues are present, one ofwhich occupies the
position at which a 'blank cycle' resulted on sequencing of an 11B-HSD2 peptide (cycle
15, peptide C, see Chapter 6) suggesting this residue may be particularly reactive or
modified in the native protein.
7.2.2. b Detailed analysis ofthepredictedstructure ofthe 11J3-HSD2protein.
Analysis of the primary (fig.7.2(a)) and predicted secondary structure(fig7.2(b)) of the
11B-HSD2 protein suggest four distinct regions. The most N-terminal region (region I)
begins with an exposed loop (Metl-Gly9) followed by a very leucine-alanine rich area
(60% of residues 11-73). This has some incomplete repeats (AALALLAAL, residues 36-
44, close variants beginning at residues 16 and 56) and appears likely to have secondary
structure broken by helix-breaking residues (Gly31 + Pro33, Pro53-Pro54-Pro55) into 3
buried, predicted -helical, segments centring on residues 16-22, 35-41 and 63-69
respectively. The region has imperfect heptad symmetry, and in such a secondary
structure is likely to form a particularly hydrophobic face along which leucines align,
there being 2 such potential axes:- (1) L14-L21-L28-L35-A42, stretching around to the
nearby helical face L13-L20-D27-L34-L41 and (2) reaching further C-terminal in the
region L23-L30-A37-L44-L51-L58-G65-L72. On the helical aspect opposite to these
axes all 7 positively charged residues in the area line-up: R18-R25-R32 R74 and R29-
-R50--R71. Such a structure is suggestive of a domain with a leucine zipper-like tendency
to form protein-protein interactions (often dimerisation) along the hydrophobic axes.
The second region (region II), which unlike the rest of the protein has predicted secondary
structure rich in B-sheets, contains 3 motifs characteristic of members of the SCAD
superfamily. Firstly, the putative cofactor binding site motif (WI)TGXXXGXG, is
present (ITGCDSGFG, residues 87-95) in an area with secondary structure predicted to
incorporate buried B-sheet(84-88), buried loop(89-92) and an exposed helix(96-102).
Secondly a "substrate positioning" motif, noted in previous alignments of SCAD
enzymes [42], which is of the form [LFVM] [VI] [NL] [N] [AVH(F)] [GI] is present
(LVNNAG, residues 164-169). The major predicted features of this substrate positioning
area are an exposed loop (156-160)/buried B-sheet(161-166+) being preceded by an -
helix (centred on residues 145-152) and exposed flexible region likely to loop around
Prol42-Glyl43. Thirdly, the putative catalytic motif YXXXKX[SAG] is present
(YGTSKAA, residues 232-238). This motif, which is predicted to form a small loop
around Gly233, is in the centre of a stretch predicted to have flanking areas consisting of
loop buried B-sheet loop structures (at 211-223 and 252-264). A long hydrophobic -
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helix (residues 236-250) bridges the motif-loop/sheet/loop stretch to the C-terminal side,
however the secondary structure is unclear for the region bridging (residues 224-231)
between the motif and the loop/sheet/loop on the N terminal side. The equivalent of this
'upstream bridging region' in the related SCAD enzyme 3 20B-HSD was shown to be
part of the steroid substrate (cortisone) binding pocket in Xray crystallographies
studies[55].
Region III, residues 275-370, has three positively charged segments, EKRKQ,
ARPRRRY, and LRRRF (residues 277-281, 332-338 and 358-362 respectively). Such
segments may form charge interactions with negatively charged molecules or exert
electrostatic influence on a substrate. In the context of a membrane protein, interactions
with phospholipids helping to stabilise or anchor the protein are particularly likely and
often occur adjacent to helical transmembrane domains (e.g. glycophorin[173]). Indeed
most of the region between the charged segments has predicted helical secondary
structure, especially residues 274-294,298-312 and 324-331).
Finally, region IV, the C-terminal region, is proline/glycine rich (36% of residues 373-
405) and is predicted to form a flexible area with several exposed loops. It contains the
only potential N-glycosylation site in 11B-HSD2. The potential for glycosylation at this
motif is weakened as it is flanked by prolines. Moreover amino acid sequencing yields
across the B-peptide (fig.7.2) suggested Asn394 was largely unglycosylated in the native
protein from human placenta (see Chapter 6).
Although much of the secondary structure can be predicted with some certainty there are
important aspects of the higher order structure of 11B-HSD2 that are unclear. As 11B-
HSD2 is an intrinsic membrane protein from a family of enzymes (SCADs) thought
usually to be tetrameric in the native form, it probably contains both transmembrane
segments and dimerisation interfaces. The N-terminal leucine-alanine rich region
(residues 11-73) may potentially fulfil either role while the helical/charge cluster region
(residues 275-370) contains predicted hydrophobic helical segments which are good
candidates as possible transmembrane regions. Dimerising elements outside the N-
terminal region seem likely, as a number of other SCADs which lack such a region have
been demonstrated to form tetramers. Fig.7.2(b) also illustrates the secondary structure of
the related SCAD enzyme 3 20B-HSD as determined from x-ray crystallography studies.
There is a very striking similarity within region II (the SCAD region) with almost all the
major structural features from BA-BF of 3 20B-HSD being represented clearly in the
predicted 11B-HSD2 structure (the only exception being that BB corresponds to a
segment of 11B-HSD2 (residues 104-109) with uncertain secondary structure). Studies on-
3 20B-HSD have identified areas involved in steroid and cofactor binding and in
dimerisation; some of the corresponding regions in 11B-HSD2 may have similar
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functions The dimerisation interfaces of 3 20B-HSD include the region between the
LVNNAG and YXXXK SCAD motifs ( E-BE- F) and the most C-terminal B-sheet
element (BG) [55],
7.2.2. c Sequence Similarities to Human Placental 11J5-HSD2.
A search of sequence databases shows the most clearly related proteins are SCAD
members (fig.7.2(c)), the closest being microsomal NAD-dependent human 17B-HSD
type2[62] (38.9% amino acid identity), retinal pigment epithelium NAD-dependent
bovine 11-cis retinol dehydrogenase (35.5% identity) and the mitochondrial human
NAD-dependent enzyme 3-hydroxybutyrate dehydrogenase[56] (32.6% identity). There
is 28.3% identity to human 11B-HSD typel[41] (microsomal, NADP-dependent).
Similarity of the four 11B-HSD2 regions (I-IV) are shown in fig.7.2(c) for these enzymes
and others with some functional similarity that are related to 11B-HSD2. The three SCAD
motifs referred to above are highly conserved although the middle motif is atypical in
11B-HSD1 and shifted in relative position or absent in 3B-HSD2 (fig.7.2(c)). This latter
enzyme appears to have the other 2 SCAD motifs in the same orientation and with
spacing typical of SCADs. This highlights the fact that the bi-functional 3B-HSD family
(which share high sequence identity and also have ketosteroid isomerase activity) fit
somewhat uncomfortably into the SCAD superfamily and it is unclear whether they
should be considered as SCADs or as a separate family. Very recently NAD-dependent
llfi-HSD enzymes have been expression cloned from kidney in sheep[68] and
human[70]. The sheep kidney 11B-HSD2 has 78.5% identity at the protein level (82.6%
at nucleic acid level). Similarity is non-uniform across regions I-IV at both
protein(fig.7.2(c)) and nucleic acid levels; thus sheep 11B-HSD2 has 94.2%, 88%, 80%
and 65% identity to human 11B-HSD2 at the cDNA level in regions I-IV respectively.
The 5'UTR and most of the 3'UTR have 70% identity, however this rises sharply again
between bases 1536-1624, fig.7.2(a). (91% identity, reason unclear) and for sequences
adjacent to the polyadenylation motif aaataa (92%: bases 1731-1764: fig.7.2). The human
renal clone is similar, but not identical, to the cDNA from placenta reported here. The
renal clone lacks the first 25 bases (-133 -109), has 2 deletions in the 3'UTR (bases
1270 and 1495: fig.7.2) and a base substitution at 442 resulting in a change in the
predicted amino acid sequence, 148Val Leu. At the points of difference, the sequence
reported above has been confirmed in cDNA we have sequenced derived from a second
placenta, and the Vail48 residue is clearly present in human placental 11B-HSD2 as it is
the first amino acid of the D peptide sequence derived from purified 11B-HSD2 tryptic
digests (Table 6.1). Although it is most likely these differences arise from
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polymorphisms, there may be isoform microheterogeneity similar to that observed with
other steroid metabolising enzymes notably 3 -HSD (98.8% identity) [43,114] and 3B-
HSD (rat 3B-HSD2 being 99.2% and >93% identical to 3B-HSD2 male liver variant[53]
and 3B-HSD1[115] respectively). The finding of polymorphisms that affect the 11B-
HSD2 protein sequence is clearly of considerable interest, especially if a difference in
steroid metabolism is associated. Placental 11B-HSD2 has a Km for corticosterone (see
Table 8.1) virtually identical to that of the 1000-fold purified native 11B-HSD2 from
placenta (see Chapter 4). The Km reported for the renal clone is 3-fold lower ( 4.4nM)
and it could be that amino acid substitutions at residue 148 cause subtle alterations in
steroid metabolising activity by affecting the predicted -helical region ofwhich it is part.
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Chapter 8 : Expression of Recombinant 11B-HSD2 in Cell Free
Lysates and Mammalian Cells.
8.1 Introduction.
Analysis of the predicted amino acid sequence of the pi 1B2 clone revealed that it encoded
for an enzyme of the SCAD superfamily which incorporated all the 11B-HSD2 tryptic
peptide sequences (see Fig.7.2). However to finally prove that expression of the mRNA
corresponding to the pi 1B2 cDNA was necessary and sufficient to produce both the 11B-
HSD2 activity characterised in human placenta (see Chapter 4) and the «40kDa protein
which could be affinity labelled (see Chapter 5), it was necessary to demonstrate that
these properties were conferred upon mammalian cells when transfected with the pi 1B2
cDNA. Other members of the SCAD superfamily have extensive post-translational
modifications, for example 17B-HSD type 4[116]. Some indication of the extent of post-
translational modification could be obtained by examining the protein products of
expression of the 11B-HSD2 cDNA in coupled in vitro transcription/translation systems.
8.2 Results.
8.2.1 Expression Studies with Human Placental 11J1-HSD2 cDNA.
8.2.1a Expression of11J5-HSD2protein.
Expression of pi 1B2 in CHO cells did indeed produce abundant 11B-HSD2 enzyme
activity (see below), accompanied by the expression of a 40k protein which could be
affinity labelled with corticosterone (fig.8.2, lanes 2 cf. 1 and 10 cf. 11), in a similar
manner to affinity labelling of 11B-HSD2 from crude placental sub-cellular fractions
(fig.8.2 lanes 3 and 9). Coupled in vitro transcription-translation of 11B-HSD2 in rabbit
reticulocyte lysates (without microsomal processing) also produced a protein (fig.8.2,
lanes 4 and 8) of similar size to 11B-HSD2 in placenta or expressed in CHO cells. Thus
activity in these tissues appears not to require major cleavages or large covalent
attachments. Addition of canine pancreatic microsomes resulted in a small size increase
and broadening of the protein band, suggesting co-translational processing, possibly-
involving glycosylation, was occurring (fig.8.2 lanes 4-8). Addition of increasing
amounts of microsomes also resulted in a reduced efficiency of translation (a standard
finding with TNT lysates) and accordingly more sample was loaded (to facilitate size
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comparison), and a minor band at 31k became visible. It is unclear if this is a different,
minor, translation product or the result of 11B-HSD2 proteolytic cleavage (from
processing or degradation) occurring at low level in the presence of these microsomes.
Clearly a range of processed states of 11B-HSD2 is demonstrated and may indicate the
possibility of tissue specific co-translational processing depending on the activities within
host tissue microsomes. If cleavage to a 31k form occurs, this is likely to affect enzyme
structure/function and possibly its subcellular localisation. Finally although native
placental 11B-HSD2 is most likely to be located in microsomes this is not confirmed by*
the presence of a classical C-terminal microsomal retention motif[l 17,172], in contrast to
the closely related human 17B-HSD2[62],
8.2.1b Characteristics ofExpressedEnzyme Activity.
Expression of the 11B-HSD2 cDNA in CHO cells produced, high affinity 11B-HSD
activity which had the expected characteristics of 11B-HSD2 activity in placenta. This
was exclusively NAD-dependent in cell homogenates (12nM corticosterone and 0.15mg
protein/ml), showing 49% conversion with 400pM NAD, whilst 400pM NADP
produced no increase over assay with no added cofactor (1.8%), see fig.8.1 (lanes 1-3).
No llB-reductase activity was detected in homogenates of 1 lB-HSD2-transfected CHO
3
cells, or in the medium of the intact cells (which metabolised 99% of 25nM H-
corticosterone in 24 h: fig.8.1, lane 4). 11-dehydro products were the only metabolites
3
detected by HPLC. Thus after 1 h incubation of H-steroid (12nM) with recombinant
11B-HSD2 (0.5mg homogenate protein/ml), >95% of corticosterone, 63% of Cortisol and*
17% of dexamethasone were metabolised, whilst aldosterone was unaltered (Fig.8.1,
lanes 6-9). There was no evidence of 5 or 5B reductase activity encoded by pi 1B2.
Recombinant human placental 11B-HSD2 has a high affinity for glucocorticoid
substrates, especially corticosterone (Table 8.1). At corticosterone concentrations higher
than 80nM there appeared to be a degree of product/substrate inhibition. Examination of
11B-HSD2 inhibition by a range of steroids showed potent inhibition (=IC50) by
glycyrrhetinic acid (1 InM) and carbenoxolone (18nM), with significant inhibition by 11-
dehydro corticosterone (45nM), progesterone (0.8pM) and cortisone (1 pM), whilst there
was little effect (>30pM) with DFIEAS, DHEA, testosterone and estradiol (fig.8.3).
Affinity labelling studies on transfected CHO cells, as with similar studies on unpurified
11B-HSD2 in placental fractions (Chapter 5: fig.5.1), revealed the same rank order of
potency in labelling (corticosterone » Cortisol» dexamethasone, aldosterone = nil) as
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Fig. 8.1 Enzyme activity produced by transient transfection of 1113-
HSD2 cDNA in CHO cells. CHO cells transfected with 11G-HSD2
cDNA (pi 1132 clone, lanes 1-4, 6-9) were homogenised and assayed
[mean ± SE (n=3) 1113-dehydrogenase] at the protein concentrations
and for the assay durations indicated below the columns. The results
indicate the enzyme activity encoded by the 11G-HSD2 cDNA is NAD-
dependent (lanes 1-3), metabolises glucocorticoids [(corticosterone(B)
> cortisol(F) > dexamethasone(Dex), lanes 6-8] but not aldosterone
(lane 9) and is overwhelmingly dehydrogenase, going to completion
(>99%, lane 4) in contrast to the reversible 11B-HSD1 activity from
homogenates of CHO cells transfected with the rat 11B-HSD1 cDNA
(lane 5, ~ 20% dehydrogenase conversion).
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Fig.8.2 Labelling native, expressed and in vitro translated 11B-HSD2
protein. Lanes 1-3 + 9-11. Affinity labelling with H-corticosterone of
(PM) native human placental 116-HSD2 from placental membrane
fractions (lanes 3 and 9): 20 and 80pg protein loaded respectively, from
25000g pellet (heavy microsomal and mitochondrial fraction)) and (CHO)
homogenates of CHO cells (160mg protein/lane) transfected with 1113-
HSD2 cDNA (lanes 2 and 10) and with vector only (lanes 1 and 11).
Lanes 4-8, products of coupled in vitro transcription-translation of 1115-
HSD2 cDNA (sub-cloned into pGEMl lzf) in rabbit reticulocyte lysates
labelled with S-methionine in the presence of varying amounts of
microsomes (indicated above lane: 0, + = 1.5pi, ++ = 3pi, +++ = 4.5pl
(excess)). Lysate volume loaded in lanes 4-8 was 0.5pl, lpl, lpl, lpl and
0.1 pi respectively. The volume loaded was varied to facilitate size
comparison of the translated products and was needed to counter the
reduction of translation in presence of higher microsome concentrations.
Position ofprotein standards (Mr x 1000) is indicated.
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Glucocorticoid. Km (nM) Vmax. (pmol/[h,mg protein])
Corticosterone 12.4+1.5 8.0 ± 0.7
Cortisol 43.9±8.5 4.8 ± 0.7
Dexamethasone 119+15 3.7 ± 0.5
Aldosterone not metabolised
Table.8.1 Kinetic parameters of 11B-HSD2 activity in cells
transfected with 11B-HSD2 cDNA. All estimates based on at least 10
steroid concentrations, n = 5 at each concentration for corticosterone,
n=2 for Cortisol and dexamethasone.
1.1
CONCENTRATION OF INHIBITOR
Fig.8.3 Studies on inhibition of 11B-HSD2. The extent to which a
range ^f compounds reduce recombinant 116-HSD2 conversion of
12nM H-corticosterone is shown. GA = glycyrrhetinic acid, CBX =
carbenoxolone, A = 11-dehydrocorticosterone, P = progesterone, E =
cortisone, E2 = estradiol, DHEA(S) = dehydroepiandrosterone
(sulphate). Reactions in presence of 400pM NAD, using homogenates
(0.15mg protein/ml) of cells transfected with 11B-HSD2 cDNA. N=4,
with standard errors being < 4%.
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as substrate/inhibitor is thus suggested for placental 11B-HSD2 of: glycyrrhetinic acid
carbenoxolone corticosterone > 11-dehydro corticosterone Cortisol > dexamethasone
> progesterone cortisone» DHEAS, testosterone, estradiol, DHEA, aldosterone. This
rank order is very similar to that determined for the type 3 'corticosterone' receptor
sites[22,98] and suggests these 'sites' are related to 11B-HSD2, but whether they are
actually due to the 11B-HSD2 protein remains unclear. In late human gestation
progesterone levels often rise to 0.3-0.5pM in the mother and >lpM in the fetus[113].
Thus the IC50 for 11B-HSD2 of progesterone (0.8pM) may signify a potential influence
ofprogesterone on corticosteroid action during late pregnancy.
8.3 Discussion.
The pi 1B2 clone has all the expected characteristics of the cDNA encoding human placental
11B-HSD2. Thus, expression of the pi 1B2 cDNA in mammalian cells produced 11B-HSD2
enzyme activity and concurrent appearance of a «40kDa protein which could be affinity
labelled by the technique used in the purification ofthe 11B-HSD2 protein.
The pi 1B2 cDNA produced a protein band of «40kDa as the only significant product of in
vitro transcription/translation without co-translational processing. However on addition of
increasing amounts of microsomes, co-translational processing gave rise to a number of
products very close to 40kDa in size. It was clear from the purification of 11B-HSD2 from
placenta that a number of products «40kDa (see fig.6.1) co-purified with the 11B-HSD2
activity across AMP affinity chromatography (implying they may be related, possibly being
processing variants retaining NAD-binding capacity at least), and ran nearby to affinity
labelled 11B-HSD2 on 2-D electrophoresis (see fig.6.2). Thus, there is some evidence to^
suspect 11B-HSD2 processing variants akin to those seen at «40kDa at in vitro translationmay
exist in human placenta. There is no good evidence for a 31kDa band co-purifying from
human placenta, but such a drastic change in structure as loss of lOkDa would be expected to
affect substrate affinity and thus also binding during AMP affinity chromatography. In
Chapter 10 (fig. 10.3), evidence is presented of a «31kDa band in human salivary gland
detected on Western blots using specific antiserum raised to the C-terminus of 11B-HSD2 in
addition to the «40kDa band which is the only band seen in human placenta. This raises the
possibility that a product similar to the one described above on in vitro translation with excess
pancreatic microsomes is produced in a tissue specific manner. The function of such a putative
1 lB-HSD2-related variant is currently unclear.
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Chapter 9 : Generation and Characterisation ofPolyclonal Anti-
11B-HSD2 Antiserum.
9.1 Introduction.
No antisera to the 11B-HSD2 enzyme from any species were available and thus the
determination of human placental 11B-HSD2 amino acid and cDNA sequences brought
the prospect of raising specific anti-11B-HSD2 antiserum for the first time.
9.2 Method.
The 11B-HSD2 peptide sequences and adjoining amino acid sequence from the cDNA
were inspected to choose a suitable region to use in a peptide-carrier conjugate for
generation of antisera. It is known that the C-terminus of a protein is, in general,
disproportionately antigenic and so keeping the chosen region near the C-terminus was an.
advantage. However, minor cleavages and modifications to proteins are commoner in their
terminal portions and a consensus glycosylation sequence (NLS, residues 394-6) was
present in the B-peptide only 8 residues from its C-terminus (12 residues from the 11B-
HSD2 C-terminus). Although this residue seemed unmodified in placenta (see Chapters 6
and 7) it was decided to not cross this site in the chosen peptide. Accordingly, a 14 amino
acid region HCLPRALQPGQPGT which had high predicted flexibility and was slightly
further from the C-terminus (11B-HSD2 residues 370-383, see figs.9.1 and 7.2), was chosen
as the 11B-HSD2 peptide for raising specific antibody and was produced by solid phase
synthesis .
As the 11B-HSD2 peptide was near C-terminal it was expected to be more antigenic if
coupled at the N-terminus, so leaving its C-terminus free. There were two options for such
coupling:- firstly to couple via the near N-terminal cysteine or secondly to couple via the
histidine at the N-terminus. To increase the chances of success both options were used
making two separate conjugates (C- and N-conjugates , respectively) to key-hole limpet
±
haemocyanin at peptide: carrier ratio of 50:1 .
Three rabbits (adult New Zealand White) were immunised with each conjugate, inoculated
initially in Freund's complete adjuvant and boosting monthly in Freund's incomplete
adjuvant.
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Fig.9.1.Positionfimmunogenicpeptidewithistruc uref11B-HSD2 protein.11B-HSD2consistsf405aminoc d ,thefinalCtermi areg (aminoacids365-405)ispredictedtoh veflexiblstructure.A14mino acidpept efromthisregion(aminacids370-383)wasynthesised coupledtkeyhollimpetha mocyaninandrabbitswerinoculateith theconjugateiFreu d'sadjuvant.
9.3 Results and Discussion.
The antisera collected during the immunisation protocol were tested for the ability to detect
11B-HSD2 protein on strips cut from a Western blot of human placental proteins processed
with antisera from rabbits immunised with the 11B-HSD2 conjugates. It can be seen from
fig.9.2 that by the third boost ('C-series' of antisera) rabbit 5 produced a high titre antiserum
recognising a 40kDa protein and that the strength of this specific reaction at 40kDa had risen
dramatically compared to the antiserum from the same rabbit after the previous boost as
shown in lane 5B. The titre of this antibody continued to rise further after the fourth boost
4\
(5D) as the strong band in lane 2 of fig9.3 shows(using 5D at 1/10 ). Fig9.3 also shows the
band has the expected distribution of 11B-HSD2 amongst fractions eluting from AMP
affinity chromatography. Fig.9.4 shows that the «40kDa band appears on transfection of
CHO cells with the 11B-HSD2 (pi 1B2) cDNA and detects a band the same size in kidney.
A minor band at ~70kDa is also sometimes seen in kidney fractions, the significance of this
is currently unknown.
Thus the 5C/D antiserum specifically detect a protein(«40k) with all the following
characteristics expected of the 11B-HSD2 enzyme protein and does so very clearly at up to
1/10000 dilution:-
1) The detected protein appears on transfection of mammalian (CHO) cells with the pi 1B2
cDNA, co-incident with 11B-HSD2 enzyme activity.
2) The protein is «40k, the size of 11B-HSD2 purified from placenta.
3) Like 11B-HSD2 it binds to and is purified by N6-linked 5'AMP-agarose and is absent from
placental subcellular fractions lacking 11B-HSD activity i.e. cytosol (lanes 3 and 7 fig.9.3)
4) It is present in placenta and kidney and as is shown on further tissue localisation work
(Chapter10: fig. 10.3) to be absent from a range oftissues lacking 11B-HSD2 enzyme activity.
Moreover, the antiserum not only has a high titre of anti-11B-HSD2 antibody but the 40kDa
protein is the major (or only significant band) detected in placental or kidney tissue. Thus this
5C/D antibody seems to have the properties required to be very useful in the study of 11B-
HSD2 in human tissues both on western blots and immunohistochemistry. There was also the
unusual advantage, for a polyclonal antibody, that the specificity of positive immunostaining
could be validated not only by pre-immune serum controls but also by pre-absorbing the 5C/D
antiserum with excess 11B-HSD2370.383 peptide so sequestering the anti-11B-HSD2 antibodies.
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Fig.9.2 Raising of 11IJ-HSD2 peptide370-383 antisera. Human
placental western blot analysis of antisera from 6 rabbits after the third
innoculation (lanes 1C-6C) of 11B-HSD2 conjugate. Lane 5B is
comparison from second innoculation of rabbit 5. Position of dye front
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Fig.9.3. Confirmation that antiserum detects band co-segregating
with 11B-HSD2 activity. (Left panel) Western blots (Amersham
ECL) of subcellular fractions of human placenta with high 118-HSD2
activity (25000g pellet, heavy microsomes/ mitochondria) using:
lanel pre-immune antisera (at 1/100 dilution), lane 2 11J3-HSD2
antisera (at 1/104). (Middle panel) Western blot using anti-
peptide370-383 antisera. Lane 3, human placental cytosol (11B-HSD2
activity « nil); lanes 4-6, fractions from 5'AMP affinity
chromatography (purifying 11B-HSD2 > 1000-fold) before (lane 4),
during (lane 5) and after (lane 6) elution of 11B-HSD2 activity
respectively. (Risht panel) Ponceau stain of membrane used in the
middle panel, before detecting with antibody. PST = protein standards







Fig.9.4 Proof the antibody raised detect protein encoded by 1115-
HSD2 cDNA. Western blots using anti-11B-HSD2 antisera on 25000g
pellet fractions (heavy microsomes/ mitochondria) of human placenta
(lane2), human kidney (lane3) and CHO cells transfected with (lane 1)
and without (lane 4) human placental 11B-HSD2 cDNA. Position of
protein molecular weight markers (Mr/1000) indicated on left.
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Solid phase peptide synthesis was carried out by Dr Bala Ramesh, Royal Free Hospital
School ofMedicine, London.
J
Peptide-carrier conjugation was carried out by Dr Brian McGinn, Thistle Peptide Services,
University ofGlasgow.
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Chapter 10 : Tissue Distribution of 110-HSD2.
10.1 Introduction.
11B-HSD2 plays a crucial role in controlling glucocorticoid action and mineralocorticoid
receptor specificity and so its tissue distribution was of great interest. Having cloned the
11B-HSD2 cDNA (Chapter 7) and raised a specific anti-11B-HSD2 antibody (Chapter 9)
it was now possible to determine distribution of 11B-HSD2 gene expression and to look
in detail at the expression in key tissues. This distribution was examined by using
northern blots of human adult and fetal tissues and using in situ hybridisation to look at
the detailed distribution of 11B-HSD2 mRNA in placenta and kidney. Investigation of the
detailed distribution of the 11B-HSD2 enzyme protein in these two key tissues was also
determined using the specific anti-human 11B-HSD2 antibody raised as described in
Chapter 9.
10.2 Results.
10.2.1 Distribution of11J1-HSD2 mRNA in human tissues.
10.2.1aNorthern blot analysis.
Northern analysis revealed a hybridising 1,9kb transcript in placenta, aldosterone target
tissues (kidney, colon, parotid, skin) and pancreas and fetal kidney (fig. 10.1). There was
also hybridisation to mRNA of a larger size ( 4kb) in fetal kidney. Under these
conditions there was no detectable hybridisation to RNA from liver, oesophagus,
stomach, ovary, breast, fetal lung, fetal liver or fetal brain nor to adult human brain sub-
regions (frontal cortex, cerebellum, hippocampus, hypothalamus, pons and medulla: data
not shown).
10.2.1b In situ hybridisation.
In situ hybridisation, with 11B-HSD2 cDNA, on normal human adult kidney (fig. 10.2)
showed abundant 11B-HSD2 mRNA expression restricted to the distal nephron (distal,
convoluted tubule, cortical collecting duct and medullary collecting ducts) with no
specific hybridisation in other regions (glomerulus, proximal tubule etc.). Expression in
distal convoluted tubule extended to loops participating in juxtaglomerular complexes.
There was no hybridisation in sense controls. There was also expression of 11B-HSD2
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10.2.2 Distribution of11J1-HSD2protein in human tissues.
10.2.2a Western blots.
Fig.10.3 shows the distribution of 11B-HSD by western analysis using the anti-11B-
HSD237o.383 antibody (see Chapter 9) on 25000g pellet fractions (mitochondria and heavy
microsomes) of a range of human tissues. Placenta was obtained fresh at delivery, liver and
kidney were obtained fresh at surgery (although 48hrs post-mortem specimens showed
similar findings) Salivary gland(lane 8) obtained at surgery showed a band at 40k, whilst
post-mortem salivary gland specimens often show varying proportions of 40k and 31k
bands. As shown in fig.10.3 lane 10, the 31k band may appear alone. The other tissues were
from post-mortem at 48hrs from organs without major degradation visible macroscopically.
There was no evidence of 11B-HSD2 in liver, spleen, heart, adrenal or lung. A band at ~70k
was visible in liver. Further analysis revealed this was more abundant in liver homogenate
than 25000g fraction and so has a different subcellular localisation to 11B-HSD2.
10.2.2b Immunohistochemistry.
Immunohistochemistry on human placenta reveals dense immunostaining of trophoblast
(fig. 10.4) in the syncytiotrophoblast layer (but not decidua). Very dense immunostaining
in adult human kidney(figl0.5) is seen localised to the distal nephron (distal convoluted
tubule including juxtaglomerular loops, cortical and medullary collecting ducts). In both
tissues the immunostaining was abolished by pre-absorption with the 11B-HSD2(370-
383) peptide. Neither tissue showed any immunostaining using pre-immune serum. The
strength of immunostaining is not uniform across the cells around distal nephron tubules.
Fig. 10.6 shows cortical collecting tubules cut in section which clearly have abundant 11B-
HSD2 expression, however aminority of cells in the tubules, being «10%, have very little





Fig. 10.3 Western blots using anti-lllJ-HSD2 peptide37o_383
antiserum in human tissues. (Left panel) Fractions (25000g pellet)
from a range of human tissues, lanes 1-8 liver, kidney, spleen, heart,
thyroid, lung, placenta and salivary gland. (Right panel) Crude
homogenate salivary gland (lane9) and placental 25000g pellet (lane
10). Note salivary gland specimens show a «40k band (lane 8, 25000g
pellet) or ~31 k band (lane 9, crude homogenate), the latter being a
common finding in crude homogenates of post-mortem specimens of
salivary gland tissue, (lane 8, «40k protein band) was obtained fresh








Fig 10.4 11B-HSD2 immunohistochemistry on human placenta.
Immunohistochemistry on human placenta with haematoxylin
counterstaining (stains nuclei) showing high power view of placental villi
cut cross-sectionally. Lower panel using antisera to human placental 11B-
HSD2 peptide 370-383. Upper panels, control with antisera pre-absorbed
with the 11B-HSD2 peptide 370-383. Fetal blood circulates in fetal
capillaries (marked 'f ') within the villi, maternal blood occupies the
intervillus space (marked 'm'), whilst abundant 11B-HSD2 expression is
localised in the syncytiotrophoblast layer which intervenes between fetal and
maternal circulations and is seen as a dark band at the perimeter of the villi.
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Immunohistochemistry on human adult kidney cortex with haematoxylin
counterstaining (stains nuclei) the section is shown at medium power.
Lower panel using antisera to human placental 11B-HSD2 peptide 370-
383. Upper panel, control with antisera pre-absorbed with the 11B-HSD2
peptide 370-383. The following are labelled: G, glomerulus; D, distal
convoluted tubule; P, area with proximal tubules; C, cortical collecting
duct. Clearly the 11B-HSD2 protein is abundant in distal nephron.
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Fig 10.6 Non-uniform 11B-HSD2 enzyme protein expression across
epithelial cells of distal nephron. Immunohistochemistry on human
adult kidney cortex [with haematoxylin counterstaining; (stains nuclei)]
at high power showing the non-uniform 11B-HSD2 expression around
tubules of the distal nephron. See fig 10.5 for lower power view. Lower
panel using antisera to human placental 11B-HSD2 peptide 370-383.
Upper panel, control with antisera pre-absorbed with the 11B-HSD2
peptide 370-383. Clearly in a minority of distal nephron cells the 11B-
HSD2 enzyme is absent or is expressed at low levels compared to the
majority of epithelial cells in such tubules.
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10.3 Discussion.
11B-HSD2 mRNA ( 1.9kb transcript) is expressed in placenta, aldosterone target tissues
(kidney, parotid, colon and skin) and pancreas. Expression in pancreas was something of a
surprise and is most likely to be in the exocrine gland. As MR are reported to be expressed in
pancreas this raises the possibility that 11B-HSD2 may be controlling MR specificity in this
organ too possibly thereby regulating electrolyte aspects ofpancreatic fluid composition..
11B-HSD2 transcripts are expressed in fetal kidney (but not lung, liver or brain at 21-%
26weeks), suggesting an 11B-HSD2 distribution resembling that in adult is established by this
stage in human development. Two studies, using tissue slices at 10-20 weeks gestation[26]
or adding NAD to tissue homogenates from 16-19weeks[67], have found substantial
levels of 1 lB-dehydrogenase activity in almost all human fetal tissues (including kidney,
lung and brain). Fetal liver was found to have net 1 lB-reductase in the first study and a
NAD-dependent llB-dehydrogenase in the second. We find no 11B-HSD2 hybridisation
in fetal lung, liver or brain. As 11B-HSD1 mRNA is reported absent, at least in the fetal
lung and liver[67], it is possible a third 11B-HSD isoform is expressed in fetus. However,
as our fetal samples were from slightly later in gestation it is possible that 11B-HSD2
expression, while present in early gestation, is switched off in many fetal tissues (kidney
being a clear exception) at mid-gestation (specifically before 22-23weeks in lung, 22-
26weeks in liver and 21-26weeks in brain). Indeed, this interpretation is now supported
by our subsequent work[194] on mouse development (see Chapter 11, s. 11.1). The
mechanism of such developmental control is unknown but interestingly it seems a CpG
island may be associated with 5' regulatory regions of the 11B-HSD2 gene because:- (1)
the CpG island extends to the very start of the 11B-HSD2 clone, (2)from the 11B-HSD2
transcript size on northern blots it appears the pi 1B2 clone must be approximately full
length (although we have not precisely mapped the start site) and (3) CpG islands are
large (typically >lkb) and often include the most 5' exon as well as upstream
sequences[lll]. This is intriguing because CpG islands are often methylated in tissues
where the gene is not expressed. Silencing of the expression of genes with 5' CpG islands
may be associated with methylation of the CpG island. Whether regulatory influence of
this kind occurs in the 11B-HSD2 gene remains to be elucidated. Work on baboon
pregnancy suggests that the 11B-HSD dehydrogenase barrier to maternal glucocorticoids
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only becomes firmly established after mid-gestation[76,113]; it may be therefore that
prior to this fetal tissues may express 11B-HSD2 and "protect themselves" from high
maternal glucocorticoid levels. As the placenta takes over the protective role, fetal tissues
adopt a much more 'adult' 11B-HSD2 expression pattern and fetal adrenal activity may
begin to dictate their glucocorticoid exposure.
The nature of the 4kb 1 lB-HSD2-hybridising transcript in fetal kidney is unclear.
Interestingly, flanking duplications involving the genes encoding human steroid
metabolising enzymes are common (e.g. 17B-HSD typel, the 3B-HSD family, 5 -
reductase type 1, 21-hydroxylase and 17B-HSD type4), and duplicates are often
transcribed, as separate transcripts or, in the case of 17B-HSD4, as a large transcript
traversing the apparent gene duplication.
In situ hybridisation and immunohistochemistry demonstrate abundant 11B-HSD2
mRNA and protein in kidney in the location expected (distal nephron) for 11B-HSD2 to
confer aldosterone selectivity on MR. 11B-HSD2 expression in distal convoluted tubule
extends into loops participating in juxtaglomerular complexes. On closer inspection of the
pattern of immunostaining in the distal nephron it is clear that a minority of the tubular
epithelial cells have little or no 11B-HSD2. This finding is fully reproducible. In such
tubules it is known that there are principal cells, a-intercalated cells and B-intercalated
cells. The rarest of these are the a-intercalated cells which, based on rabbit and some
rodent studies, seem to comprise «10%-20% of outer cortical collecting tubular epithelial
cells[l 82,184,185], These are involved much more with acid excretion/bicarbonate
reabsorption. From the distribution it seems highly likely 11B-HSD2 activity in human
distal nephron is much higher in principal and B-intercalated cell types than a-intercalated
cells. This is in keeping with findings from cell sorting of immunodissected rabbit cortical-
collecting duct[ll] where it was found that both principal cells and B-intercalated cells
expressed NAD dependent 11B-HSD activity (no comment being made about a-
intercalated cells).
In placenta 11B-HSD2 expression was abundant in the syncytiotrophoblast lining the
placental villi; thus being at the very interface between fetal tissue and maternal blood,
which flows in the intervillus spaces. This is exactly the location which would allow 11B-
HSD2 the greatest influence over the passage ofmaternal glucocorticoid to the fetus.
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Studies with western blots revealed 11B-HSD protein in placenta and aldosterone target tissues
(kidney and salivary gland) but not in the other tissues including adrenal and lung. 11B-HSB
assays on these tissues showed NAD-dependent 11B-HSD activity only in the same tissues
which were positive for 11B-HSD2 on western blot. NADP-dependent 11B-HSD activity was
present especially in liver and to a lesser extent in lung and spleen indicating this was likely to
be 11B-HSD1. Thus human adrenal shows no evidence of 11B-HSD2 on northern or western
blot (and is also negative on in situ hybridisation). This is in striking contrast to the abundant
11B-HSD2 expression in adrenal in the sheep [68,183]. The bands at »70k in liver and variably
in kidney are ofuncertain origin. The band in liver seems not to be 11B-HSD2 related as it has
a different subcellular distribution and there is no evidence for 11B-HSD2 mRNA or enzyme
activity(see Chapter 4) in liver. In kidney the origin of the weak ~70k band is less clear. The
finding of a large «4kb transcript in human fetal kidney(fig.lO.l) hybridising to 11B-HSD2
probes on northern blot is intriguing but currently there is no evidence to suggest a definite
relationship between this larger transcript and the 70k protein in kidney. A similar large
transcript hybridising to 11B-HSD2 has also been recently reported in adult kidney in the"
mouse [145].
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Chapter 11: General Discussion.
11.1 Completion OfThe Aims OfThe Thesis.
The original aims of the thesis, which were the purification, cDNA cloning and raising of an
antibody to the isoform of 11B-HSD in placenta and distal nephron(now called 11B-HSD2),
have been completed and in addition a novel method of specifically identifying the human
11B-HSD2 enzyme has been developed. This work has allowed detailed analysis of the 11B-
HSD2 enzyme protein structure and study of the recombinantly expressed 11B-HSD2 protein
and its enzyme activity. The cDNA and specific anti-human 11B-HSD2 antibodies generated
during this work have also allowed study of the tissue distribution of the expression of this key
enzyme at both the mRNA and protein levels. 11B-HSD2 expression is found in
mineralocorticoid target tissues and placenta as was expected. The demonstration of 11B-
HSD2 mRNA in human pancreas was not anticipated. It has been very difficult to obtain
specimens ofnormal human pancreas with optimal preservation. To date we have not yet been
able to demonstrate convincingly the localisation of 11B-HSD2 protein in human pancreas by
immunohistochemistiy nor has there been clear evidence of high 11B-HSD2 activity on assay
of the samples we have obtained. Currently it is unclear whether the 11B-HSD2 enzyme
protein has degraded too quickly to detect (proteolysis of course being a particular problem in
pancreas),or whether the 11B-HSD2 mRNA is largely untranslated in this tissue. In the rat,
another group has reported immunohistochemical localisation of 11B-HSD2 in the exocrine
pancreas [193]. MR expression has also been reported in rat exocrine pancreas[12] and so
these findings suggest the possibility that in the rat 11B-HSD2 may be acting to protectMR in
pancreas as well; possibly regulating the water and electrolyte composition ofpancreatic fluid.
It seems likely this is the case in humans too. However, this is not yet proven and species
differences concerning 11B-HSD2 expression have already been noted for the adrenal gland
(11B-HSD2 being reported absent from the human[102] and mouse[145] adrenal but present
in sheep[68,183] and rat [192]) and so extrapolation between species may not always be
straightforward. 11B-HSD2 gene expression was also present in fetal kidney at 22-26wks and
the 11B-HSD2 expression in term placenta was shown to be in the syncytiotrophoblast, which
is the fetal portion ofplacenta. Interestingly, there was no 11B-HSD2 expression in some other
human fetal tissues at 22-26wks (liver, lung and 'brain') as discussed in Chapter 10, these"
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findings, when compared with findings from enzyme assay of fetal tissues in previous
literature[26][67], suggest that a silencing of 11B-HSD2 gene expression occurs in several
tissues during human development after mid-gestation. We have now carried out extensive in
situ hybridisation studies during mouse development to determine the ontogeny of 11B-HSD2
and find there is indeed a dramatic cessation of 11B-HSD2 gene expression in many tissues
between embryonic day 12.5 (E12.5) and E13.5 (19 days being full gestation in the
mouse) [194], Kidney is a notable exception with 11B-HSD2 expression persisting to full-term
and continuing post-natally into adulthood. These findings strongly support our hypothesis of
a similar silencing of 11B-HSD2 expression in the second half of human gestation in many
fetal tissues with expression persisting in kidney.
11.2 Insights into 11B-HSD2 Enzyme Structure and Function.
112.1 RequirementforMembrane Componentsfor Stability.
Purification of 11B-HSD2 to homogeneity proved to be a formidably difficult task, principally
because tire enzyme activity became labile on attempting solubilisation with all of the wide
range of detergents screened. This suggests the active 11B-HSD2 enzyme protein has an
ordered association within the membranes in which it resides and that detergent disrupts this so
leading to loss of stabilising components and increased exposure of the 11B-HSD2 protein to
inactivating processes. In particular, it seems that 11B-HSD2 requires constituents ofplacental
membrane fractions not adequately substituted by a wide range of detergents. As discussed in
Chapter 7,11B-HSD2 has a highly positively charged structure and these charges are likely to.
cluster or align along faces ofthe protein so making associations with neighbouring negatively
charged molecules likely. Thus stabilisation of 11B-HSD2 by negatively charged moieties of
phospholipids seems particularly likely and such stabilisation has been shown for the two
related SCAD enzymes 3hydroxybutyrate dehydrogenase[95] and human 17B-HSD1 [195].
3hydroxybutyrate dehydrogenase requires negatively charged phospholipid for activity[95],
whilst the crystal structure ofhuman 17B-HSD1 points to the positive charge clusters towards
its C-terminus interacting with phospholipids so stabilising a domain which is otherwise very
unstable and of such flexibility that it cannot be seen on crystal structure determined in the
absence ofmembrane components[195]. Although there are compelling reasons to believe that
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lipids are required to stabilise 11B-HSD2 it is possible that other membrane proteins aro
involved(especially those with negatively charged regions). Indeed, it is clear from the
purification of 11B-HSD2 that several other membrane proteins ofdiffering molecular weights
extensively co-purified with 11B-HSD2 while it remained highly active and when purification
eventually substantially eliminated these co-purifying proteins 11B-HSD2 had high lability or
became inactive (see Fig.6.1).
11.2.211JJ-HSD2Substrate Binding andReaction Mechanism.
The problems of lability and inactivation ofhighly purified 11B-HSD2 necessitated a means of
tracking 11B-HSD2 when inactive. The novel affinity labelling technique developed allowed
purification to homogeneity. The work with affinity chromatography and affinity labelling
both give additional findings regarding the affinities of 11B-HSD2 for its two substrates:
dinucleotide cofactor (NAD) and glucocorticoids. This information allows conclusions to be~
drawn which may shed some light on the form of the enzyme's active site and kinetic
mechanism. The striking specificity of the photoaffinity labelling of 11B-HSD2 by
corticosterone and Cortisol, in the presence ofNAD, demonstrates that 11B-HSD2 exhibits an
unusually high, receptor-like, affinity for these glucocorticoids, which may come close to that
of GR or MR. This finding reflects the physiological role of 11B-HSD2 in binding, and
inactivating, glucocorticoids with high avidity before or in competition with GR and MR, so
regulating glucocorticoid access to these receptors. 11B-HSD2 is probably not the same as the
45k "low affinity" (K^ lOOnM) dexamethasone binding proteins identified in studies on
male rat liver[97] as it differs in localisation, hierarchical order of binding affinities and
2+
possibly Mg -dependence of binding (11B-HSD2 labelling occurs in EDTA containing
buffers). However, 11B-HSD2 does resemble another, incompletely characterised
receptor/binding protein for glucocorticoids: the type 3 corticosteroid (corticosterone) receptor.
Thus, tire rank order of affinities determined in binding studies of steroids for the 'type 3
receptor sites'[22,98] is consistent with the order of potency of the steroids used to affinity
label 1 lB-HSD2(Fig. 5.1). 'Type 3 sites' often are regarded as cytosolic, which 11B-HSD2 is
not. However, the work originally defining them (in rat kidney) largely used supernatants from
centrifugation at 30000g x 30min; which is very similar to tire 25000g x 40min fractionation
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we have used. Supernatant from such a spin will probably have 95% ofprotein from cytosol,
but the remaining 5% will be rich in protein from 'light microsomes' and contain abundant
11B-HSD2. Recent work, on isolated renal cortical collecting duct cells characterises a similar
binding site in whole cells (where endogenousNAD may facilitate binding), which may be the
renal 11B-HSD2 isoform. The characteristics ofplacental 11B-HSD2 are thus clearly similar to'
the 'type 3 sites' in these reports. In Chapter 8 this matter was addressed further by examining
affinities of recombinant 11B-HSD2. This reveals, amongst steroidal compounds, a similar
rank order ofpotency as inhibitors of 11B-HSD2 activity (Fig. 8.3) to the rank order ofbinding
affinities described for 'type 3 sites'[22,98]. However at present it is not settled whether 'type 3
sites' and 11B-HSD2 are the same entity.
The affinity chromatography data provide some clues to the reaction order and nature of the
active site of placental 11B-HSD2. It is likely that 11B-HSD2 binding to N6-5'AMP-agarose
was via an interaction at the cofactor binding site. 5'AMP is the 'half molecule' of NAD
(nicotinamide comprising the remainder) and instances of N6-5'AMP affinity matrices
interacting with the cofactor site of NAD-dependent dehydrogenases are well
documented[84]. In Chapter 3 it was mentioned that the rank order of potency in which free
cofactors elute bound human placental 11B-HSD2 activity from N6-5'AMP agarose fr
NAD>NADH>5'AMP»NADP (with 10-fold more 5'AMP required for elution than NAD).
This indicates that the site at which 11B-HSD2 binds the N6-5'AMP matrix behaves like a
NAD cofactor site, as opposed to a 5'AMP allosteric site, as it has a clear preference for
NAD(free cofactor). When cofactor is on the affinity matrix and not free, the rank order
changes to N6-5'AMP(yield over 35%)>C8-NAD(yield 2%) > (N6-NAD = C8-5'AMP =
NADP = nil). Clearly the attached spacer arms make a considerable difference, sterically
hindering NAD from binding more strongly than 5'AMP (as occurs with free cofactors). This
may be a limitation of the particular affinity matrix products used or simply be because the
larger size ofNAD makes its binding more sensitive to steric hindrance. A further possibility is
that NAD may cause a conformational change on binding (as quite frequently occurs with
dehydrogenases), whereas 5'AMP, filling only a half site, does not. Thus, steric interference by
die new conformation prevents 11B-HSD2 binding toN6-NAD, but permits limited binding to
NAD when linked at C8 (which has the spacer attachment rotated >90° relative to N6, both'
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coming from the 5'AMP half of the NAD molecule). 5'AMP, causing no such change, binds
well whenN6-linked, but not at all when C8-linked.
The 5'AMP affinity chromatography results suggest NAD can bind first to 11B-HSD2
(explaining both binding and elution with NAD). The NAD dependence of glucocorticoid
affinity labelling suggests glucocorticoid cannot gain full access to the steroid binding pocket
unless NAD has bound first. Under a range ofelution conditions affinity chromatography with
dexamethasone agarose was unsuccessful. The finding that under similar conditions 11B-
HSD2 is bound well by N6-5'AMP agarose, but not at all by dexamethasone agarose (though
dexamethasone is a substrate) may possibly also reflect a 'cofactor first' binding order. By
analogy with other dehydrogenases (e.g. lactate dehydrogenase[175]), these findings
collectively suggest a compulsory ordered ternary complex mechanism may operate for 11B-
HSD2, with NAD binding first. Further studies of these matters will assist in mapping the
active site and in design ofdrugs specifically to inhibit, or possibly constitutively activate, 11B-
HSD2.
11.3 11B-HSD2 and Control ofBlood Pressure.
It was clear from an early stage (Chapters 3 and 4, [60]) that the properties of the 11B-HSD
activity in human placenta suggested it was the same isoform as that predicted and later
characterised in distal nephron[64,65]. Comparison of 11B-HSD activity in placenta and
kidney showed the major properties were the same [180], with minor differences again leading^
us to the conclusion the same isoform (11B-HSD2), was present in both tissues. The human
placental 11B-HSD2 cDNA and the antiserum raised to human placental peptide sequence
both detected 11B-HSD2 in the expected site in kidney, confirming sequence similarity
sufficient to result in high cross-reactivity. The sequence published for 11B-HSD2 from human
kidney[70] was not identical to the human placental 11B-HSD2 cDNA described in this thesis.
The renal cDNA has 2 deletions in the 3'UTR (bases 1270 and 1495: Fig.7.2) and a base
substitution at position 442 resulting in a change in the predicted amino acid sequence,
3.1 Leu
148 .At the points of difference, the sequence reported above has been confirmed
in cDNA we have sequenced derived from a second placenta, and the Vail48 residue is
clearly present in human placental 11B-FISD2 as it is the first amino acid of the D peptide
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sequence derived from purified 11B-HSD2 tryptic digests(Chapter 6: Table.6.1).
Moreover, in other work we have partially sequenced 11B-HSD2 from the genomic DNA
of over 20 individuals and always found the sequence is as given in this thesis, in
particular amino acid 148 always being valine. This makes true microheterogeneity at this
locus seem very unlikely and if the locus is polymorphic then we have found the
Val
prevalence of the 148 allele to be 100% in the individuals tested (all Caucasian or
Hispanic origin). There is also the possibility that the variations are due to sequencing
errors in the renal clone sequence. A human genomic 11B-HSD2 sequence has been
published by Agarwal et. al.. [146], but unfortunately the Genbank sequence files and the
Val
associated paper disagree with the paper having 148 while the Genbank sequence file
Phe
has 148 . The publication also identifies a different major start site for 11B-HSD2
transcription in kidney and placenta. This is in keeping with the fact that the renal cDNA.
lacks the first 25 bases of the placental cDNA given above in Fig.7.2. However the
putative placental start site described cannot be the only one as the human placental 11B-
HSD2 cDNA described in Chapter 7 begins upstream of it. Two groups have now
determined the chromosomal locus of 11B-HSD2 as 16q22 [146,147].
From the above it can be seen that it is most likely that the 11B-HSD2 enzyme activity in
placenta and kidney are derived from the same gene, driven by different promoters, but
with the same coding region. It was clearly of great interest to determine whether this
gene was mutated in the human hypertensive syndrome SAME. Two groups reported,
approximately simultaneously, describing inactivating mutations in SAME
patients[148,199]. Other subsequent reports have found further 11B-HSD2 mutations in
SAME patients [196-198], Thus it is established, beyond doubt, that 11B-HSD2 is the
tissue specific protector of the mineralocorticoid receptor and that normal activity of this
enzyme is required to maintain normal systemic arterial blood pressure and electrolyte
balance. 11B-HSD2 thus becomes one of the few genes proven to be the cause of human
hypertensive syndromes and now stands alongside the amiloride-sensitive sodium
channel (the cause of hypertension in Liddle's syndrome[200,201]) and aldosterone-
synthase (a natural fusion mutation of which is the cause of hypertension in
glucocorticoid remediable hyperaldosteronism [202,203]) as genes which may also
contribute to the causation of essential hypertension. Thus, it is expected there will be
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studies looking for mutations in 11B-HSD2 not only to explain the dramatic loss of 11B-
HSD2 enzyme activity that occurs in SAME but also where there are more subtle
variations in 11B-HSD activity such as those indicated by the altered urinary,
glucocorticoid metabolites described in (i)subsets of patients with essential hypertension
[72] or (ii)polycystic ovary disease [66]. Moreover, as mentioned in Chapter 1 (section
1.3) deficient placental 11B-HSD2 activity has been implicated in the link between the in
utero environment and the programming of low birth weight and subsequent hypertension
in humans [77], The work of this thesis has produced important tools (cDNA, specific
antibody and 11B-HSD2 sequence) for further study of this important enzyme and these
may help shed further light on the fundamental processes underlying the control of the
level of blood pressure in humans and how these are distorted in human hypertensive
states including essential hypertension.
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ABSTRACT
Excess glucocorticoids impair fetal growth and cause teratogenesis.
Placental 11/3-hydroxysteroid dehydrogenase (11/3HSD) catalyzes the
inactivation of Cortisol to cortisone, preventing the high maternal
Cortisol levels from reaching the fetal circulation and thus preserving
the low Cortisol fetal environment. In previous work, an NADP-de-
pendent isoform of 11/3HSD has been purified from rat liver, a cDNA
isolated, and the human homolog cloned. However, much evidence
suggests tissue-specific llfiHSD activities that cannot be explained by
the liver-type isoform. Therefore, we have partially purified human
placental 11/3HSD and compared it to the enzyme in rat liver. Human
placental subcellular fractions exhibited NAD-dependent 11/3HSD ac¬
tivity, but showed little activity with NADP. The enzyme had a pH
optimum of 7-8.5 (peak, 7.7), was only sparingly soluble in detergents
(solubility with Triton X-100 was very poor), and exhibited little
latency or change in pH profile in detergent solution. By contrast, rat
liver 11/3HSD was exclusively NADP dependent and was easily solu-
bilized by a wide range of detergents (including Triton X-100), revealing
substantial latency and altered pH profile [optimum of 10, becoming
7-10 (peak, 9.5) in detergent]. These data do not merely reflect species
differences, as rat placental 11/3HSD was similiar to the human placen¬
tal isoform. AMP affinity chromatography, which was completely with¬
out affinity for rat liver 11/3HSD, achieved a 1000-fold purification of
human placental 11/3HSD. This had Km values for corticosterone (mean
± SE, 14 ± 1 nM) and Cortisol (~55 nM) that were over 100 times lower
than that for liver 11/3HSD. Sodium dodecyl sulfate-polyacrylamide gel
electrophoresis allowed identification of a band (apparent mol wt,
40,000) that correlated consistently with human placental 11/3HSD
activity (contrasting with a mol wt of 34,000 for rat liver 11/3HSD).
Thus, the NAD-dependent human placental 11/3HSD is distinct from
the previously characterized rat liver isoform and may be the product
of a separate gene. (Endocrinology 132: 2614-2621, 1993)
n/3-HYDROXYSTEROID dehydrogenase (11/3HSD)plays a crucial role in corticosteroid physiology by
regulating glucocorticoid access to both glucocorticoid and
mineralocorticoid receptors. It achieves this by catalyzing the
rapid conversion of active physiological glucocorticoids (Cor¬
tisol and corticosterone) into inactive 11-dehydro products
(cortisone and 11-dehydrocorticosterone) (1, 2). Indeed, in
the classic aldosterone target tissue, renal distal convoluted
tubule (DCT), it is 11/3HSD that ensures mineralocorticoid
receptors, which are nonselective in vitro (binding aldoste¬
rone and physiological glucocorticoids with equal affinity),
achieve aldosterone selectivity in vivo in the face of 100- to
1000-fold excess of circulating glucocorticoids (1, 2). 11/3HSD
from rat liver has been purified (3), and a cDNA isolated (4)
and recombinantly expressed (4, 5), allowing this NADP-
dependent enzyme to be characterized. However, within
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several tissues, particularly the distal nephron, there are
striking discrepancies between the presence of 11/3HSD en¬
zyme activity and the absence of the liver-type protein (by
immunohistochemistry) (1, 6) or liver-type (1.7-kilobase)
mRNA (7, 8). This and other evidence suggesting the pres¬
ence of variant tissue-specific forms of 11/3HSD (8-12) have
led to speculation about a second 11/3HSD enzyme
(11/3HSD2) (13, 14). Recent work on renal DCT has partic¬
ularly supported this view, with the finding of an apparent
NAD-dependent 11/3HSD isoform detectable by histochem-
ical activity staining (15, 16) and direct assay (14).
Placental 11/3HSD is of particular importance, as it regu¬
lates the transfer of maternal glucocorticoids to the fetus (17-
19). Excess glucocorticoids may cause deleterious effects on
the fetus, impairing fetal growth and causing teratogenesis,
and, moreover, may predispose the individual to hyperten¬
sion in adulthood (17). Despite its physiological importance,
placental 11/3HSD has been relatively poorly characterized
and has not been purified. Furthermore, there is a long¬
standing controversy as to its cofactor dependence (19-23),
with some studies finding NADP preference [in homogenates
(21, 22) and microsomes (19)], some equal preference [in
microsomes (20)], and others NAD preference [in microsomes
(23)]. Therefore, we have partially purified and characterized
11/3HSD from human placenta. We present evidence of an
abundant NAD-dependent 11/3HSD activity in human pla¬
centa that represents an isoform distinct from that previously
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characterized from rat liver microsomes (3, 24). To determine
if this is solely due to differences between species, we have
tried, where possible, to present parallel findings in the rat
placenta.
Materials and Methods
[l,2,6,7-3H]Corticosterone and [l,2,6,7-3H]cortisol (SA, 78 and 73 Ci/
mmol, respectively) were obtained from Amersham International (Ay¬
lesbury, Buckinghamshire, United Kingdom). NAD, NADP, NADH,
NADPH, AMP, AMP-agarose, dithiothreitol, EDTA, Triton X-100,
3-[(3-cholamidopropyl)dimethyIammonio]l -propanesulphonate
(CHAPS), and porcine heart mitochondrial malate dehydrogenase were
obtained from Sigma Chemical Co. (Poole, Dorset, United Kingdom).
Glycerol and Electran protein electrophoresis mol wt standards were
purchased from BDH Laborotory Supplies (Poole, Dorset United King¬
dom). Coomassie blue dye concentrate and standardized BSA were
purchased from Bio-Rad (Hemel Hempstead, United Kingdom). HPLC
grade methanol and water were purchased from Rathburn Chemicals
(Walkerburn, Scotland, United Kingdom), and Quickszint 302 HPLC
scintillant from Zinsser Analytic (Maidenhead, Berks, United Kingdom).
Buffers
Buffer systems used were as follows: buffer A, 20% glycerol, 5 ira
potassium phosphate (pH 7.0), 1 mm EDTA, and 1 mm dithiothreitol;
buffer B, 10% glycerol, 300 mm sodium chloride, 4 mm CHAPS, 1 mm
EDTA, and 0.02 m Tris-HCl (pH 7.7; buffer B2, sodium chloride omitted);
and buffer C, 10% glycerol, 300 mM sodium chloride, 1 mM EDTA, and
0.02 m Tris-HCl (pH 7.7). Where pH was varied, buffers included 10%
glycerol, 1 mm EDTA, 300 mm sodium chloride, and 0.1 m buffer: pH
5-6, potassium acetate; pH 6.5-7.5, potassium phosphate; pH 7.5-9,
Tris-HCl; pH 9.5-10, potassium carbonate; and pH 10.5-11, glycine-
NaOH. Buffers were pH adjusted at the temperature of use.
Tissues and tissue processing
Rat livers and placentae were obtained from adult male and female
(20-21 days pregnant) Wistar rats, respectively. Fasted animals were
killed by decapitation. Human term placentae (400-600 g) were obtained
at normal vaginal delivery. All tissues were rapidly placed on ice. Tissue
processing was begun within 2 h of placing on ice. Loose membranes
and umbilical cord were trimmed from placentae. Adherent membranes
and large vessels were also trimmed off human placentae. All tissues
were minced with scissors and washed in ice-cold 0.9% saline, blotted
dry, suspended in approximately 3 times their weight of buffer A, and
homogenized with a Ystral homogenizer (Scientific Instrument Centre,
Liverpool, United Kingdom) (rat tissue) or commercial blender (human
placental tissue). Human placental homogenate was filtered through
two layers of muslin. For rat placentae, to aid fractionation, the homog¬
enate was diluted 2-fold (with buffer A), rather than being filtered, so
as to minimize losses from the small tissue quantities. Homogenates
were subjected to subcellular fractionation without delay by a differential
centrifugation protocol (similiar to that described in Ref. 23): 1) 750 x g
for 10 min, 2) 25,000 x g for 40 min, and 3) 110,000 x g for 60 min.
The supernatant from each spin was subjected to the next centrifugation,
finally leaving cytosolic supernatant (discarded). The resulting pelleted
fractions of human placental or rat liver tissue were frozen and kept at
—80 C if not used immediately. Rat placental fractions were not frozen,
but placed on ice and used rapidly.
Assays of 11 (3HSD activity
C-ll dehydrogenase activity was determined by measuring the rate
of conversion of 1.12 x 10~8 m [3H]steroid substrate (corticosterone or
Cortisol) to product (11-dehydrocorticosterone or cortisone, respectively)
in the presence of 400 mm NAD or NADP (unless otherwise stated) and
calculating the percent conversion during the assay. The 250-^1 assay
consisted of 10 jd containing tritiated steroid, 50 /d containing cofactor,
and 190 m1 enzyme in 0.1 m potassium phosphate (pH 7.5) and 300 mm
sodium chloride buffer (buffer only in blank controls). Reactions were
incubated at 37 C for 10 min and terminated by adding 2 ml ice-cold
ethyl acetate and mixing. The organic layer was separated and evapo¬
rated, and the steroid was resuspended in 0.6 ml 50% methanol-50%
water. Part (0.2 ml) of this was injected into a Berthold HPLC system
(Berthold Instruments Ltd., St. Albans, Herts, United Kingdom) fitted
with a Waters Associates ^Bondpack C18 column (Waters, Milford, MA),
which was eluted with 50% methanol-50% water (vol/vol; at 1.8 ml/
min for corticosterone substrate reactions). Eluted steroids were moni¬
tored by a UV absorbance detector and a Berthold LP506 CI scintillation
counter to detect tritiated steroids. The latter was flushed with Quickszint
302 scintillant (at twice the column elution rate), and output was
calibrated against known authentic steroid standards. The percent con¬
version of steroid substrate to product was calculated as an index of
enzyme activity. Cofactor concentrations and buffer pH were varied in
experiments specifically examining these effects. The assay pH was
verified by measuring the pH of a parallel mixture containing unlabeled
steroid.
Protein was estimated by the method of Bradford (25), using Bio-Rad
protein dye (Bio-Rad) and calibration against standards of BSA. Prelim¬
inary work identified optimum assay conditions for each tissue, so that
the amount of protein added 1) was in the linear region of the curve of
protein concentration t;s. percentage substrate converted with 400 mm of
the more active cofactor (NAD or NADP), and 2) resulted in a percent
conversion of 10-40% in 10 min. All experiments had blank (no protein)
assays run in parallel to establish the background level of steroid product.
11/J-Reductase activity was measured using the same reaction condi¬
tions, except 400 mm NADH or NADPH and [3H]ll-dehydrocorticoster-
one were used as substrates. The latter was prepared from [3H]corticos-
terone by a variation of the method of Lakshmi and Monder (3), using
human placental enzyme with NAD at pH 7.5.
Kinetic parameters were calculated from the initial velocity determi¬
nations obtained from experiments performed with a wide range of
substrate concentrations. Inhibition by 0.06-2 mm CHAPS was also
studied. Enzyme concentrations giving less than 30% conversion at 10
min were used.
Detergent solubilization of llflHSD activity
All steps were carried out at 0-2 C. Tissue fractions, resuspended in
buffer C to 6 mg protein/ml, were mixed with an equal volume of
solubilization buffer (buffer C with detergent at twice the final concen¬
tration). After 30 min, the mixture was centrifuged at 110,000 x g for 1
h. Supernatant containing soluble enzyme was carefully removed. It
was found that 4 mM CHAPS was optimal for solubilization of human
placental llflHSD, and 0.06% Triton X-100 (final detergent/protein
ratio of 0.2) was optimal for solubilizing microsomal rat liver 11/3HSD
[in agreement with Lakshmi and Monder (24)].
Affinity chromatography
One or 5 ml AMP-agarose equilibrated with buffer B was used. The
CHAPS-solubilized tissue fraction containing 11/8HSD activity was
loaded onto the column, which was then washed with buffer B. 1 lflHSD
was eluted with nucleotide cofactor in buffer B, as indicated in the text.
Fractions (1.5 ml) from the column were collected, placed on ice, and
rapidly assayed for 11/3HSD enzyme activity. In some experiments, a 0-
to 3000-mm gradient of NAD, AMP, or NADP in buffer B2 was applied
to the column across a total of 10 column vol (50 ml) After completion
of the gradient, the column was washed with buffer B, and any remain¬
ing 11/3HSD was eluted with buffer B containing 3 mm NAD. This
protocol was designed to determine thresholds of elution with different
cofactors, allowing their affinities for the active site of the enzyme to be
cuinpaied (26, 27).
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE)
SDS-PAGE was performed by the method of Laemmli (28) with
12.5% resolving gels (3.3% cross-linker). Fractions with low protein
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levels were concentrated by acetone precipitation. Gels were silver
stained by the method of Wray et al. (29), with variations of the NH4+/
Na+ ratio to minimize the chances of protein being undetected.
Removal of NAD from affinity-purified llflHSD
NAD was removed from partially purified llfiHSD enzyme (eluted
as described above) by three successive filtration/dilution cycles in a
Centricon-10 concentrator (Amicon, Lexington, MA). After filtration by
centrifugation at 4600 X g for 90 min, samples were diluted in buffer B,
and the cycle was repeated. Removal of NAD was verified by measuring
A28o. During this process, samples were assayed for 11/3HSD activity to
determine dependence on added cofactor.
Statistics
Results are shown as the mean ± se. Series of paired samples were
compared by one-way analysis of variance of their differences. Kinetic
parameters were estimated by Lineweaver-Burke and Eadie-Hofstee
analyses facilitated by computer-generated linear regression.
Results
For all three tissues, [3H]corticosterone and [3H]cortisol
produced qualitatively similiar results, but [3H]corticosterone
was clearly a better substrate for 11/3HSD than [3H]cortisol
(as illustrated for human placenta in Fig. 1A). Moreover,
separation of substrate and product on HPLC was better in
assays with [3H]corticosterone. Thus, we have mostly used
corticosterone in the studies presented here.
We concentrated on ll/J-dehydrogenase in these studies,
because 11/3-reductase in the human placental tissue studied
(full term placentae) was only a very minor activity (<5% of
11/3-dehydrogenase at pH 7.5). Rat placental reductase was
even less abundant. Moreover, the activity of placental
11/3HSD reductase was unstable and underwent a progres¬
sive decline at 37 C. This attenuation of activity was detect¬
able even at 10 min.
Preliminary subcellular localization of placental llflHSD
Human placental 11/3HSD was most abundant in the
25,000 X g pellet, which contained over two thirds of the
total 11/fHSD activity, 5-fold higher than the level in the
microsomal 110,000 X g pellet. Moreover, the 25,000 X g
pellet had as high a specific activity as the 110,000 X g
microsomal pellet, and its activity was stable and more
rapidly prepared. Differential centrifugation of the resus-
pended 25,000 X g pellet (which contains mitochondria and
heavy microsomes) did not produce any useful refinement.
Accordingly, this fraction was used for further studies on
human placenta. The same fraction was used for rat placenta.
Rat liver microsomes (110,000 X g pellet) were used, as these
were the source of the purified enzyme (3) for which the
encoding gene has been cloned (30, 31). Fractions selected
for further study were assayed at protein concentrations of
2-5 pg/ml for human placenta, 20-50 /ug/ml for rat liver,
and 100-500 Mg/ml for rat placenta; these gave percent
conversions in 11/3HSD assays in the desired range, as de¬
fined in Materials and Methods. Comparing the three tissues,
rat placental 11/3HSD was found to be the least abundant
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Fig. 1. Cofactor dependence of 11/3HSD activity. 11/3HSD activity
(mean ± SE) in human placenta (A), rat liver (B), and rat placenta (C)
with corticosterone as substrate in the presence of 0-1000 /iM cofactor
(NAD or NADP). Assays used placental 25,000 x g pellets and liver
microsomes at protein concentrations of: human placenta, 2 Mg/mf rat
liver, 50 g.g/ml; and rat placenta, 500 Mg/ml- Also shown is human
placental 11/3HSD activity with Cortisol and NAD (with Cortisol and
NADP conversion remains <2%). Rat placenta, n = 4; otherwise, n =
5.
uated by freezing and thawing. Accordingly, rat placental
fractions were freshly prepared and used rapidly.
All further studies compared 11/1HSD in the 25,000 X g
pellet of placental tissues with rat liver microsomal 11/fHSD.
11 fSHSD cofactor dependence
To define and compare the cofactor preferences of
11/3HSD in the three tissues, the activity of 11/3HSD was
determined when the concentration of NAD or NADP varied
across the range 0-1000 pM (Fig. 1). Both human and rat
placental 11/3HSD preferred NAD (P < 0.001 for both tissues,
by analysis of variance), while the rat liver enzyme preferred
NADP (P < 0.001). Activities with 100-1000 pM cofactor
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were comparable in the three tissues (30-45% conversion),
whereas with no cofactor, the activity was 22% conversion
for rat liver and only 2% and 5% for human and rat placenta,
respectively. Although there appeared to be no NAD-de-
pendent 11/3HSD activity in liver microsomes, the high activ¬
ity without the addition of exogenous cofactor [which has
been noted previously in liver (20)] made this difficult to
assess. Minor NADP-associated 11/3HSD activity was seen
in human and rat placental fractions. Eadie-Hofstee analysis
(not shown) of the data for human placental 11/3HSD show
rectilinear plots with NAD (apparent Km for NAD, 13 ^m;,
maximum velocity, 180 pmol/mg protein • min), but curved
plots with NADP, suggesting the possibility that two distinct
enzymes (with low and high Km values for NADP) contribute
to the minor NADP-associated activity.
pH dependence of llfiHSD activity
The variation in 11/3HSD activity in the three tissues over
the pH range 5-11 is shown in Fig. 2. The similiarity between
human and rat placental 11/THSD activities with either NAD
or NADP is striking, as is their difference from 11/3HSD
activity in rat liver microsomes. Placental 11/3HSD has a
broad pH optimum of 7-8.5 with NAD (peak, 7.5-8 in
human placenta). With NADP as cofactor, the optimum is
more alkaline (pH 8-9). Above pH 9, placental 11/3HSD
activity falls off sharply (especially NAD-associated activity).
In contrast, pH 9-10 is the optimum for rat liver lldHSD.
The activity of liver 11/3HSD is largely or wholly independent
of added NAD (Fig. IB). The liver 11/1HSD activity with
added NAD may be due to a relatively high level of endog¬
enous cofactor (32). Reductase activities for all three tissues
were optimal at more acidic pH: pH 5 for rat liver 11/3-
reductase with NADPH and pH 5-6 for human placental
reductase (data not shown). Solubilized 11/3HSD pIT profiles
are discussed below.
Detergent solubilization
Detergents were used to solubilize 11/1HSD, which was
membrane associated in all three tissues. CHAPS (4 mm) was
found to be optimal for solubilizing human placental
ll^HSD. This is a lower concentration than that used in
other studies on 11/3HSD (24, 33). Triton X-100 has been
shown to be a good detergent for solubilization of rat liver
(24) and renal (33) 11/3HSD. Triton X-100 (0.06%) was
optimal for solubilizing rat liver microsomal 11/1HSD activity.
This corresponds to a detergent/protein ratio of 0.2, the
optimum found by Lakshmi and Monder (24).
To compare detergent solubilities, all three tissues were
treated with 1) 0.06% Triton X-100, 2) 4 mM CHAPS, or 3)
buffer only. For each detergent, the proportion of total pro¬
tein solubilized was similiar for all three tissues (~65% with
Triton X-100 and 45% with CHAPS). 11/3HSD assays were
performed on samples taken 1) before centrifugation and
from the detergent-solubilized fraction (110,000 X g super¬
natant) at 2) 1 h and 3) 24 h after centrifugation. The results
for samples 1 and 2 are shown in Fig. 3. Solubilization of rat







































Fig. 2. pH dependence of 11/3HSD activity. 11/3HSD activity (mean ±
SE) in human placenta (A), rat liver (B), and rat placenta (C) with
corticosterone and 400 ixM NAD or NADP across pH range 5-11.
Assays used placental 25,000 X g pellets and liver microsomes at protein
concentrations of: human placenta, 2 jug/ml; rat liver, 20 Mg/mk and
rat placenta, 100 Mg/ml. The dotted line shows the pH profile of
solubilized enzyme (with 0.06% Triton X-100 or 4 mm CHAPS for rat
liver and 4 mm CHAPS for human placenta). These are superimposed
(to allow comparison of shape) to intersect the corresponding graph
without detergent at its pH optimum (human placenta: NAD, pH 7.7;
NADP, pH 8.5; rat liver: NADP, pH 10). Rat placenta, n = 4; human
placenta and rat liver, n = 5.
11/3HSD. The addition of either Triton X-100 or CHAPS
increased rat liver ll/JHSD activity (before centrifugation),
demonstrating considerable latency. After centrifugation, a
large proportion of the activity was soluble (between 90-
100% of that before detergent, compared to <2% when no
detergent was added).
In contrast, human placental 11/3HSD showed minimal
latency and was sparingly soluble (9%) in CHAPS, whereas
the use of Triton X-100 did not significantly increase solu¬
bilized 11/3HSD activity (1 ± 0.08% compared to 0.84 ±
0.02% without detergent). Rat placental 110HSD behaved
similiarly to human placental 11/3HSD (compare Fig. 3, A
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Fig. 3. Behavior in detergent of 11/3HSD activity (mean ± Se) in
human placenta (A), rat liver (B), or rat placenta (C) with corticoster-
one and 400 gM NAD or NADP. Tissue fractions (placental 25,000 x
g pellets and liver microsomes) were each suspended at 3 mg/ml in
buffer C only (NIL), buffer C and 0.06% Triton X-100 (TX100), or
buffer C and 4 mm CHAPS and assayed first before centrifugation and
then in supernatant after centrifugation at 110,000 X g for 60 min.
Results are expressed as a percentage of the activity with preferred
cofactor, without detergent and before centrifugation, with protein
concentrations as follows: human placental, 2 gg/m\\ rat liver, 20 gg/
ml; and rat placenta, 300 Mg/ml. Rat placenta, n = 4; otherwise, n =
10.
with C); however, analysis of rat placental 11/3HSD was
hindered by the lability of the enzyme. The soluble 11/3HSD
activities in both human placenta and rat liver extracts were
stable, with more than 80% remaining after 24 h at 0-2 C.
Solubilization changed the pH profile of rat liver 11/3HSD,
whereas very little change occurred when the human placen¬
tal enzyme was solubilized. The altered liver 11/3HSD pH
profile remained very different from those of the placental
enzymes in the pH 8.5-10 range (Fig. 2).
Thus, using the same detergent and protein concentrations,
the liver and placental 11/3HSD enzyme activities behaved
very differently. Although human placental llflHSD was
difficult to solubilize, with reextraction of the initially insol¬
uble 110,000 X g pellet, approximately 20% of the enzyme
activity (from the 25,000 X g pellet) could be solubilized in
a stable active form with 4 mM CHAPS, allowing further
analysis.
Affinity chromatography
Human placental and rat liver CHAPS-solubilized extracts
(containing solubilized llflHSD) were subjected to AMP
affinity chromatography. Sequential elution was performed
with 1 mM NAD, NADP, and AMP (for human placenta;
Fig. 4A), with NADPH following this for rat liver. A large
proportion of the human placental 11/3HSD activity eluted
specifically with NAD (Fig. 4A). By contrast, liver 11/3HSD
had no affinity for the same column (no 11/3HSD activity
eluted with any of the pyridine nucleotides; data not shown).
Human placental llflHSD fractions that eluted from the
column were analyzed by SDS-PAGE (Fig. 4C). A protein of
40,000 mol wt coeluted with llflHSD activity (Fig. 4C). In
multiple fractions over many chromatography experiments
(under a variety of conditions), the 40K protein band, and
no other, repeatedly segregated with 1 l/'IHSD activity (as
shown in Fig. 4, C and D). This contrasts with the rat liver
11/fHSD isoform that has a mol wt of 34,000 (3). The quantity
of protein in the fractions with llflHSD activity was esti¬
mated by comparison with known quantities of protein
standards run in parallel. The purification achieved was in
excess of 1000-fold (Fig. 4C).
When gradients of nucleotide cofactors were used to elute
bound human placental llfiHSD from the AMP affinity
column, the llflHSD activity began to elute at thresholds of
30 /xm NAD and 300 mm AMP, but did not elute at all during
a 0- to 3000-mm NADP gradient (Fig. 4B). After the AMP
gradient, a small amount of enzyme eluted with 3 mM NAD.
After the NADP gradient, a large amount of llflHSD activity
eluted with NAD (Fig. 4B).
Substrate and cofactor preference of partially purified human
placental llfiHSD
CHAPS produced competitive inhibition of human placen¬
tal llfiHSD, reaching 50% (Kj) at 0.37 mm. Estimates of
kinetic parameters for the partially purified enzyme eluted
both with and without CHAPS were in good agreement
when corrected for this competitive inhibition. Thus, the Km
of the partially purified human placental llflHSD was 14 ±
1 nM (mean ± se) for corticosterone and 54 ± 14 nM for
Cortisol, with a maximum velocity of approximately 25 nM/
mg protein-min with either steroid. The cofactor preference
of placental llflHSD was examined by removal of NAD by
repeated filtration in a Centricon-10 apparatus. At a residual
NAD concentration below 2 mm, the addition of 400 mm
NADP promoted an increase in llfiHSD activity. When
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Fig. 4. AMP affinity chromatography of solubilized human placental 11/3HSD. A and B, 11/3HSD activity of fractions assayed with corticosteronf
and 400 /iM NAD added. Spectrophotometric A28o demonstrates the falling protein concentration and shows cofactor addition. A: Fraction S
Detergent-solubilized tissue extract loaded; fractions 1 and 2, flow-through/wash; fractions 3-5, wash; fractions 6-20, alternating cofactor elutions
(as indicated) and brief washes. B: NADP gradient. Fractions 1-5, Flow-through/wash; fractions 6-15, wash; fractions 16-48, increasing NAD!
gradient (0-3000 ^m); fractions 48-50, wash; fractions 51-60, 3 mM NAD elution. In the equivalent scheme for NAD and AMP gradients, lldHSE
eluted beginning at fractions 29 (30 \iM) and 38 (300 ^m), respectively (not shown). C and D, 12.5% SDS-PAGE gels (silver stained). C, Gel of the
experiment shown in A. Proteins from 25 /d fraction S and 500 id fractions 4-9 were loaded onto respective lanes. Corresponding 11/3FISD activitj
(shown above gel) was assayed with corticosterone and 400 mm NAD and used 15 ,ul of each fraction. ND, Not detectable. PS, Protein standards
which included the addition of 100 ng malate dehydrogenase [35K mol wt (Mr)]. The protein that repeatedly segregated with 11/3HSD activitj
migrated at the position indicated by the arrow (40K mol wt). The factors of purification of 11/3HSD in lanes 4, 6, 7, and 8 compared to that o:
fraction S were 40-50, greater than 1000, greater than 1000, and greater than 600, respectively. D, Gel showing proteins and 11/3HSD activity thai
eluted with NAD (beginning at lane 24) after a long wash. The 40K putative 11)3HSD is the only protein consistently segregating with 11/3HSE
activity.
residual NAD was above 2 pM, the addition of 400 p.M NADP
was without effect. Thus, a more than 200-fold excess of
NADP over NAD was required to demonstrate an effect on
the enzyme.
Discussion
We have compared human placental, rat placental, and
rat liver 11/THSD and found that the placental enzymes differ
markedly from the rat liver isoform [the only isoform for
which a cDNA has been isolated (4) and the gene cloned
(30, 31)]. Placental 11/3HSD differs from liver 11/3HSD in
cofactor preference, pH profile and optimum, latency release,
and ease of solubilization in detergents. Moreover, we have
achieved in excess of 1000-fold purification of human pla¬
cental 11/3HSD with AMP affinity chromatography (whicl
was completely without affinity for rat liver 11/3HSD). This
is the first reported substantial purification of this enzyme
Binding of human placental 11/3HSD activity to the columr
has the properties expected for the active site of an NAD
dependent enzyme. Mosbach and Brodelius (26, 27) havf
shown a linear correlation between thresholds for elution ir
affinity chromatography and the dissociation constants (Kd
for the corresponding binary enzyme-nucleotide complexes
Accordingly, the Kd and Km of placental 11/3HSD are pre¬
dicted to be an order of magnitude or more higher for NAD!
than for NAD. This is strongly supported by the NAT
preference of the enzyme both before solubilization and afte:
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affinity chromatography (when 400 /xm NADP is without
affect in the presence of NAD concentrations in excess of 2
xm). Human placental 11/3HSD activity consistently segre¬
gates with a protein of apparent 40K mol wt, which we
relieve to be the strongest candidate to be the human pla-
zental 11/fHSD enzyme [in contrast to an apparent mol wt
z>f 34K determined by Lakshmi and Monder (3) on gels of
dentical composition for the purified rat liver isoform]. Al-
:hough there are copurifying contaminating proteins, these
/ary and do not consistently segregate with 11/3HSD activity.
Human placental 11/3HSD has a very high affinity for glu-
:ocorticoids, with a Km of 54 nM for Cortisol and 14 nM for
:orticosterone. Apparent Km values, for the same substrates,
af the unpurified enzyme (in the 25,000 X g pellet) were also
estimated and found to be even lower. Liver 11/3HSD has a
much lower affinity for glucocorticoids, with a Km over 100-
rold higher for both corticosterone and Cortisol (3, 5).
Rat placental 11/IHSD seemed less abundant and more
abile than its human counterpart, being easily inactivated
ay freeze/thaw or detergent action. However, despite this,
:he characteristics of 11/?HSD in rat and human placentae
seem qualitatively similiar; both have NAD preference, pH
aptimum between 7-8.5, poor solubility in active form in
ietergents, and relatively little activity with no added cofac-
:or. The lability and poor solubility of rat placental 11/3HSD
precluded affinity chromatography.
Placental and rat liver 11/3HSD seem to differ in some
rurther characteristics. Firstly, the level of 11/3HSD reductase
ictivity in human term placenta is small compared to that of
lldHSD dehydrogenase activity, which is in contrast with
:he abundant rat liver 11/3HSD reductase activity (5, 34).
secondly, the subcellular localization of 11/IHSD appears
different. Rat liver 11/3HSD is localized to microsomal and
auclear fractions (34), and NADP-dependent rat kidney
11/dHSD appeared to be similiarly distributed, with no activ-
ty in mitochondrial fractions (35). By contrast, our prelimi-
aary work suggests a different and more widespread subcel-
ular localization of placental 11/fHSD; further differential
:entrifugation produced mitochondria-enriched and micro-
some-enriched subtractions with similiar 11/3HSD activities,
rhirdly, rat liver microsomes were found to have substantial
11/3HSD activity in the absence of added cofactor, being
ncreased less than 2-fold by 400 /xm NADP. In contrast,
placental 25,000 X g membrane pellets had little 11/3HSD
ictivity in the absence of added cofactor, but this was in-
zreased 10-fold by 400 /xm NAD. The cause of this difference
s unclear, although the higher pyridine nucleotide cofactor
zoncentrations in liver (32) and the relatively low Km of liver
11/3HSD for NADP (0.196 /xm) (3) would cause any NADP
sequestered in the microsomes to have a potent influence.
Fhe apparent Km of human placental 11/3HSD for NAD is
zonsiderably higher (13 /xm), making the enzyme less sensi-
:ive to trace amounts of endogenous cofactors and causing it
:o show a clearer cofactor preference. In intact cells, NAD is
rtore abundant (32), so both enzymes are suited to respond
:o physiological cofactor levels. Fourthly, our preliminary
lata suggest that their immunoreactivities to antiliver-type
mtiserum is very different. In conditions that cause minor
immunoneutralization and major immunoprecipitation of
solubilized liver microsomal 11/3HSD, the solubilized placen¬
tal 11|8HSD showed absolutely no immunoneutralization or
immunoprecipitation of 11/3HSD activity with either 56-125
or 56-126 antiserum (10) (gift of Dr Carl Monder, Population
Council, New York, NY).
Blasco et al. (19) calculated that an average human placenta
approaching term is exposed to approximately 70 nmol ma¬
ternal free cortisol/min. We estimate placental capacity to
convert Cortisol to cortisone to be at least 4 times higher than
this. Moreover, the especially high affinity of placental
11 /'iHSD for glucocorticoids would ensure their effective
clearance, preventing access to the fetal circulation. Liver-
type 11/3HSD, although present in great abundance, would
be relatively poorly suited to providing such a protective
barrier, as its affinity for glucocorticoids is approximately
100-fold lower (Km, 17 /xm for Cortisol and 1.8 /xm for corti¬
costerone).
The existence of a second enzyme (11/1HSD2) has been
the subject of much speculation (13), largely based on evi¬
dence of the presence of 11/3HSD activity in the absence of
liver-type 11/3HSD protein or mRNA. In addition, variant
mRNAs that hybridize to rat liver 11/3HSD cDNA have been
identified in kidney (8) and colon (9, 11). Further experimen¬
tation, however, has shown these renal mRNA variants to
be derived from differential promoter usage of the charac¬
terized liver 11/1HSD gene (31) and may encode proteins
with no demonstrable 11/3HSD activity (36). This has impli¬
cations for in situ hybridization results on renal cortex (37,
38) as hybridization to liver-type 11/fHSD probes in kidney
may be detecting variant mRNA species without the potential
for translation to active 11/3HSD enzyme. Antibodies to liver-
type 1 1/1HSD also detect what appear to be additional tissue-
specific proteins (e.g. 26K in brain, 40K in kidney, and 47K
in testis) with strong antigenic similarities to liver-type
11/3HSD (10). Indeed, when attempts have been made to
separate such proteins (26K species) from the 34K liver-type
11/3HSD protein, the variant protein had no demonstrable
activity (12). Thus, it is possible that 11/3HSD2 is the product
of a separate gene and is not, therefore, readily detectable
by antibodies or nucleic acid probes specific for liver-type
11/3HSD. Both the NAD-dependent isoform in renal DCT
(14-16) and the placental isoform described here may rep¬
resent 11/lHSD enzymes distinct from rat liver 11/3HSD. It
may be more than coincidence that both renal DCT and
placental 11/3HSD 1) are NAD dependent, 2) have a Km for
physiological glucocorticoids 2 orders of magnitude lower
than that of liver 11/JHSD (14), and 3) appear not to be
immunoreactive to liver-type antiserum (6), and 4) that rat
renal DCT activity is markedly inactivated by freeze/thaw
(39), as we find for rat placental ll/lHSD. If the rat renal
DCT enzyme behaves like rat placental 11/3HSD in deter¬
gents, it might explain why Triton X-100-solublized rat renal
11/3HSD appeared to consist of the liver-type 11/3HSD only
(33). Moreover, a recent study of the 11/1HSD cofactor pref¬
erence in a range of tissues suggests that NAD-using 11/1HSD
activity is distributed more widely, being present in colon
and lung as well as placenta and renal cortex (40).
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In summary, we found strong evidence for an NAD-
dependent 11/3HSD isoform in both human and rat placental
tissue that is distinct from the previously characterized en¬
zyme in rat liver and may be encoded by a separate gene.
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11 -Beta-hydroxysteroid dehydrogenase:
on several roads to hypertension
Jonathan R. Seckl and Roger W. Brown
Journal of Hypertension 1994, 12:105-112
Keywords: Glucocorticoids, mineralocorticoids, receptors, Cortisol, 11 (3-reductase, fetal programming.
Introduction
Elevated levels of adrenocorticosteroids (glucocorti¬
coids or mineralocorticoids), due to Cushing's dis¬
ease, Conn's syndrome or pharmacotherapy, are
well-recognized causes of (secondary) hyperten¬
sion. In essential hypertension blood steroid con¬
centrations are usually normal, suggesting that ex¬
cessive corticosteroid secretion is not causative in
essential hypertension. It has recently become ap¬
parent that the effects of glucocorticoids at the tissue
level are regulated by the presence of 1 ip-hydro-
xysteroid dehydrogenase (11(3-HSD), which is cru¬
cial in determining glucocorticoid access to intra¬
cellular receptors. Thus, a novel level of control of
corticosteroid action has been revealed, prompting
a re-evaluation of the effective intracellular gluco¬
corticoid concentration in particular tissues in
various physiological and disease states (for reviews
[1-6]). The present paper reviews the biology of 11(3-
HSD and its possible relevance to hypertensive dis¬
orders.
Syndrome of apparent mineralocorticoid
excess and liquorice hypertension
11P-HSD catalyses the oxidation (ostensibly re¬
versible) of the physiological glucocorticoids Cortisol
and corticosterone to their inactive 11-keto products
(cortisone and 11-dehydrocorticosterone) [7]. Until
recently the functions of this widespread enzymatic
activity were obscure. However, deficiency of 11(3-
HSD had been noted in a rare type of hypertension
known as the syndrome of apparent mineralocorti¬
coid excess [8]. This disorder presents in childhood
with sodium retention, severe hypertension and hy¬
pokalemia. Plasma renin activity is undetectable
but plasma levels of aldosterone and other mineralo¬
corticoids are suppressed. In 1985 the investigation
of a unique adult patient showed that the disorder
was due to novel renal mineralocorticoid actions of
Cortisol [91. Thus, the apparent renal mineralocorti¬
coid excess and hypertension could be reversed by
suppressing endogenous Cortisol with dexametha-
sone, and recreated by concurrent infusion of phys¬
iological doses of Cortisol. How could Cortisol act as
a potent mineralocorticoid?
Purified or recombinant mineralocorticoid receptors
(type I corticosteroid receptors) are non-selective
in vitro, and bind corticosterone, Cortisol and al¬
dosterone with similarly high affinities [10-12], By
contrast, mineralocorticoid receptors in the distal
nephron are selectively activated by aldosterone in
vivo, despite a 1000-fold molar excess of circulating
glucocorticoid. Combining these paradoxical affini¬
ties and the findings in the syndrome of apparent
mineralocorticoid excess led to the suggestion that
in the distal nephron in vivo 11(3-HSD eradicates Cor¬
tisol, thus allowing selective access of aldosterone
to mineralocorticoid receptors [9]. In the syndrome
of apparent mineralocorticoid excess 11(3-HSD defi¬
ciency leads to illicit binding of mineralocorticoid re¬
ceptors by Cortisol and, thus, apparent mineralocor¬
ticoid excess (Cushing's disease of the kidney [13]).
It must be emphasized that circulating levels of Cor¬
tisol are normal in the syndrome; it is the ability of
the glucocorticoid to gain access to intracellular min¬
eralocorticoid receptors in the distal nephron that
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is increased dramatically. Obviously, renal 11|3-HSD
must be very active; indeed, more than 99% of corti-
costerone is inactivated during its passage through a
monolayer of cultured renal cortical collecting duct
cells [14].
Supporting evidence for this hypothesis came from
the imaginative recognition of the similarities be¬
tween the syndrome of apparent mineralocorticoid
excess and the hypertension observed with liquorice
abuse [151. Liquorice hypertension is the same type
of hypertension as mineralocorticoid excess but re¬
quires intact adrenal glands and is reversed by dex-
amethasone. Moreover, liquorice, its active com¬
ponent glycyrrhetinic acid and the hemisuccinate
derivative carbenoxolone are all very potent in¬
hibitors of 11|3-HSD in vitro and in vivo (their
half-maximal inhibitory concentrations being in the
nanomolar range) [15,16]. Indeed, administration of
liquorice derivatives to rats and humans allows no¬
vel access of glucocorticoids to renal mineralocor¬
ticoid receptors in vivo, with consequent sodium
retention, hypertension and hypokalemia [15-191.
Although glycyrrhetinic acid and carbenoxolone in¬
hibit a variety of other enzymes in vitro (including
some which might lead to sodium retention [20-23],
these actions require levels of the inhibitor that are
unlikely to be achieved in vivo [24]. Moreover, the
overwhelming metabolism of glucocorticoids in the
distal nephron to their 11-keto products, rather than
to other compounds [14], indicates that the apparent
mineralocorticoid action of these inhibitors in man is
predominantly due to inhibition of 11J3-HSD.
Other actions of 11(3-HSD
In addition to protecting mineralocorticoid receptors
from exposure to Cortisol in the distal nephron, pla¬
cental 11J3-HSD protects the foetus from the dele¬
terious effects of maternal glucocorticoids ([25,26]
and see below), 11(3-HSD activity is also found in
a wide variety of non-aldosterone-selective tissues,
in which it might modulate functions mediated via
type II glucocorticoid receptors [27,28]. Thus, top¬
ical hydrocortisone-mediated cutaneous vasocon¬
striction is potentiated by co-application of gly¬
cyrrhetinic acid [29] and, in the colon, control of
Na,K-ATPase expression, mediated by type II glu¬
cocorticoid receptors, is potentiated by carbenox¬
olone [30]. Similar actions of llp-HSD underlie the
altered sensitivity to glucocorticoids during prena¬
tal lung maturation [31] and in the pubescent testis
[32]. Of course, the action of 11(3-HSD is potentially
reversible and the enzyme acts as a reductase
(activating cortisone) in some tissues, such as
adult liver [33-35], thereby recycling inert gluco¬
corticoids [2].
Biochemistry and molecular biology of
11(3-hydroxysteroid dehydrogenase
11[3-HSD has been purified from rat liver and anti-
sera have been raised against it [7,36]. The en¬
zyme is reversible (acting either as a dehydrogen¬
ase, inactivating Cortisol, or as a reductase, activat¬
ing cortisone), nicotinamide adenine dinucleotide
phosphate-dependent, predominantly located in mi¬
crosomes and has an apparent molecular weight of
34 000 [7]. The purified enzyme has a Michaelis-
Menten constant for Cortisol of approximately 17
pmol/1 and of 2jimol/l for corticosterone [7,37,38].
Isolation and cloning of a complementary DNA
(cDNA) species from a rat liver cDNA library [39]
(and of its human homologue [40]) allowed expres¬
sion of a single protein catalysing both dehydro-
genation and reduction, the predominant direction
being influenced, at least in cell culture, by cellular
redox conditions and glycosylation status of the en¬
zyme [41].
However, several lines of evidence suggest that 11(3-
HSD derived from the liver (hereafter ll(3-HSDi) is
not sufficient to explain the many biological func¬
tions attributed to 11(3-HSD. First, mineralocorticoid
receptors and high 11(3-HSD activity are found in the
distal nephron [14,42-45], which is devoid of 11(3-
HSD] immunoreactivity [17,46]. Secondly, the micro-
molecular affinity of liP-HSDj for Cortisol and cor¬
ticosterone [7] suggest that this enzyme would not
exclude low (nanomolar) levels of circulating free
glucocorticoids efficiently from renal mineralocorti¬
coid receptors. Thirdly, the expression of 11(3-HSD]
cDNA in amphibian cells with a mineralocorticoid
phenotype encodes an enzyme that acts predomi¬
nantly as a reductase; far from inactivating corticos¬
terone, it activates inert glucocorticoids [47]. A mon¬
key 11(3-HSD] homologue also acts as a reductase
[48]. Fourthly, specific hormonal manipulations or
developmental stages are associated with high re¬
nal 11J3-HSD activity but low or undetectable 11(3-
HSDj messenger RNA expression [49-51]- Fifthly,
syndrome of apparent mineralocorticoid excess pa¬
tients have isolated dehydrogenase [9], but not re¬
ductase, deficiency and have no apparent mutations
of the 11P-HSD] gene [52], A distinct feature (hir¬
sutism) is found in patients with the rare condi¬
tion of isolated cortisone reductase deficiency [531-
Thus, the existence of several species of 11|3-HSD
has been postulated [1,6].
A family of 11 (3-hydroxysteroid
dehydrogenases?
A shorter messenger RNA species (liP-HSDpj) has
been found [54,55], predominantly in kidney, which
is the product of transcriptional initiation within
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the first intron of the liP-HSDj gene. However, al¬
though the putative protein product of this messen¬
ger RNA includes the potential active sites of 11(3-
HSD}, there is little evidence that the messenger
RNA for liP-HSDjh is translated in vivo and, when
its cDNA is expressed in vitro, the recombinant
protein is devoid of llp-HSD activity, at least in the
cells in which this was studied [56,57]. Why tissue-
specific alternative transcripts without apparent
biological function should be produced remains
unexplained, although this might prevent any re¬
ductase activity of the almost ubiquitously expressed
liP-HSDj from jeopardizing the cortisol-free envir¬
onment of mineralocorticoid receptors in the distal
nephron.
More-convincing evidence for the existence of other
11(3-HSD species followed the observation that Cn-
dehydrogenation of some steroids was dependent
on nicotinamide adenine dinucleotide, not on nicoti¬
namide adenine dinucleotide phosphate, specifi¬
cally in the distal nephron [58] and the placenta [591-
Recent data [60-62] have extended these observa¬
tions and provide compelling evidence for a distinct
nicotinamide adenine dinucleotide-dependent 11(3-
HSD (11(3-HSD2) in human placenta [60], rat kidney
[61] and rabbit cortical collecting duct [62].
Placental 11|3-HSD2 differs from liP-HSDj in pH
optima, detergent solubility and lability, subcellu¬
lar localization and immunoreactivity [60], Substan¬
tial purification of this enzyme has been achieved,
using affinity columns which do not retain 11(3-
HSDj, revealing a protein of molecular weight ap¬
proximately 40 000. Most importantly, placental 11 (3-
HSD2 has a much higher affinity for Cortisol and
corticosterone (with Michaelis-Menten constants in
the low nanomolar range) and exhibits little or
no reductase activity [60]. The nicotinamide adeni-
nine dinucleotide-dependent 11(3-HSD in the dis¬
tal nephron also has high affinity for glucocorti¬
coids [62], although it is not clear whether this
species of 11(3-HSD is identical to placental 11(3-
HSD2. Whether further enzymes possess 11(3-HSD-
like activity is not known but, intriguingly, no ge¬
netic defect of the ll^-HSDj gene was found in a
patient with isolated reductase deficiency [52], im¬
plying the existence of a third gene encoding an
11(3-HSD species which acts predominantly as a re¬
ductase.
From the above it is apparent that current under¬
standing of the molecular biology and biochem¬
istry of the important 11(3-HSD enzyme family is far
from complete. Nevertheless, many studies of en¬
zyme function have been undertaken, and evidence
for the possible roles of different 11(3-HSD species
in the pathogenesis of hypertension is reviewed
below.
11 (3-Hydroxysteroid dehydrogenase and
renal (mineralocorticoid) hypertension
Deficient activity of 11(3-HSD might be expected
to cause exclusively mineralocorticoid hypertension,
but many other blood pressure-related actions of
11(3-HSD have been postulated. In addition to the
rare examples of syndrome of apparent mineralo¬
corticoid excess and liquorice abuse, attenuation of
ll(3-HSD-mediated protection of renal mineralocor¬
ticoid receptors could also account for the hyperten¬
sion and hypokalaemia seen in the ectopic adreno-
corticotrophic hormone syndrome, which is likely to
reflect 11J3-HSD inhibition, rather than saturation of
the enzyme by Cortisol excess [63]- Whether adreno-
corticotrophic hormone affects renal 11(3-HSD di¬
rectly, or indirectly inhibits the enzyme via induc¬
tion of alternative substrates [51, is not clear. In renal
failure 11(3-HSD activity is attenuated, as determined
by reduced Cortisol metabolism at the 11a position
[31, but so is expression and responsiveness of renal
mineralocorticoid receptors, thus complicating inter¬
pretation.
A proportion of essential hypertensive patients (per¬
haps one-third) have a prolonged plasma half-life
of lla-[3H]-cortisol, suggesting 11(3-HSD deficiency
[64,651- These individuals show no signs of miner¬
alocorticoid excess and, intriguingly, may also show
attenuated ll(3-reductase activity [64], suggesting the
involvement of lip-HSDi since reductase activity
is, at most, a minor feature of 11(3-HSD2 cataly¬
sis [60,62], but is a prominent activity of ll^-HSDj
[7,41,47].
11 (3-Hydroxysteroid dehydrogenase and
vascular effects of glucocorticoids
liP-HSDj is found in resistance vessels, conducting
vessels and the heart [66-68] in which tissues the en¬
zyme might modulate glucocorticoid-mediated vas¬
cular responses [64], including potentiation of vaso¬
constriction to noradrenaline [69l- Indeed, in con¬
genital and liquorice-induced 11(3-HSD deficiency
the vasoconstrictive potency of Cortisol is increased
[70]. Increased dermal vascular sensitivity to gluco¬
corticoids is observed in essential hypertension, sug¬
gesting that endogenous Cortisol might have eas¬
ier access to mineralocorticoid receptors in hyper¬
tension [71]. However, the increased sensitivity to
cortisol-induced vasoconstriction is found both in
patients with a prolonged and in those with a nor¬
mal half-life of lla-[3H]-Cortisol [64], Furthermore,
in essential hypertension, but not in congenital or
acquired 11(3-HSD deficiency, dermal vascular sensi¬
tivity to a synthetic glucocorticoid (beclomethasone;
thought to be a poor substrate for 11(3-HSD) is also
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increased [71]. The molecular basis and importance
of this increased vasoconstrictor response to gluco¬
corticoids in essential hypertension remains to be
investigated. However, unless the vascular activity
(due to llfl-HSDj [68]) can metabolize beclometha-
sone. vascular deficiency of 11(3-HSD is unlikely to
be involved in essential hypertension.
Central hypertensive effects of
corticosteroids and 11 ^-hydroxysteroid
dehydrogenase in the brain
Corticosteroids exert specific central effects on
blood pressure in the rat. Thus, intracerebroventric-
ular administration of aldosterone in small (nano¬
gram) doses, which are ineffective when given pe¬
ripherally, increases blood pressure [72], Intracere-
broventricular corticosterone antagonizes the aldos¬
terone effect [73], whereas intracerebroventricular
glycyrrhetinic acid also elevates blood pressure, sug¬
gesting that a population of central aldosterone-
selective mineralocorticoid receptors protected by
11(3-HSD might mediate the central hypertensive ef¬
fects of aldosterone and glycyrrhetinic acid. Indeed,
some brain subregions bind aldosterone selectively
in vivo[74,75]. llp-HSDj-like bioactivity and expres¬
sion of the messenger RNA is widespread in the rat
brain [28,76—79], predominantly in neurons [28,80],
11P-HSD2 may also be present in the hypothala¬
mus [81], which is a likely site for aldosterone-selec-
tive central actions on blood pressure [82]. Further¬
more, glycyrrhetinic acid administration increases
neuronal activity selectively in the anterior hypo¬
thalamus, reinforcing the notion that important llfb
HSD-related effects occur at this site [83]. Although
these data suggest that protection by IIP-HSD2 of
mineralocorticoid receptors in the brain from glu¬
cocorticoids is important in blood pressure regula¬
tion. it is possible that much of the liP-HSD] in
the brain functions predominantly as reductase [81].
This raises the possibility that inhibition of 11J3-HSD
might cause regional reductions in glucocorticoid
supply to corticosteroid receptors in the brain, in¬
cluding those glucocorticoid receptors which nor¬
mally antagonize mineralocorticoid receptor-medi¬
ated hypertensive effects. Clearly, further studies are
required to define the anatomy and physiology of
these potentially important functions of 11(3-HSD.
Placental 11 p-hydroxysteroid
dehydrogenase and the programming of
hypertension
Extensive epidemiological data [84,85] have recently
implicated prenatal events as potent determinants
of subsequent blood pressure level (and the risk of
death related to cardiovascular disease). In particu¬
lar, low (non-premature) birth weight (and, perhaps,
a large placenta) strongly predicts higher blood pres¬
sure in childhood, adolescence and adulthood, this
correlation being apparently independent of adult
risk factors, such as smoking, alcohol consumption,
weight or socio-economic status [84,85]. Several pos¬
sible explanations for these findings have been pro¬
posed, concentrating largely on the deleterious ef¬
fects of abnormal maternal nutrition [84,85]. How¬
ever. glucocorticoid administration to the pregnant
mother also reduces birth weight in animals and in
man, and glucocorticoids increase blood pressure
both in fetal and in adult animals [86,87]. The un¬
usual combination of low birth weight and increased
placental weight is also found in pregnant rats with
streptozotocin-induced diabetes; the fetal and pla¬
cental abnormalities are only partly reversed by in¬
sulin treatment producing normoglycaemia [88], and
such rats also have markedly elevated glucocorticoid
levels at term [89]- Although exogenous glucocorti¬
coid treatment usually reduces placental weight, this
does not always occur with low doses of physiologi¬
cal glucocorticoids [90]. Furthermore, higher adult
blood pressures are also observed in some humans
with low birth weight and small placentae [84,85].
What effect does intra-uterine glucocorticoid expo¬
sure have on the blood pressure of the offspring? Ad¬
ministration of dexamethasone (which crosses the
placenta freely [91]) to pregnant rats, in a mod¬
est dose which reduces birth weight by only 14%,
leads to substantially higher blood pressures in the
offspring when they reach maturity, more than 5
months after the last exposure to exogenous gluco¬
corticoid [92]. The elevation of blood pressure per¬
sists and is seen in old rats (Lindsay R, Noble J, Ed¬
wards C, Seckl J: unpublished observations, 1993).
Whether there is a particular developmental 'win¬
dow of sensitivity' to glucocorticoid programming
of elevated blood pressure in the rat is not clear,
although this may occur in fetal sheep during the
second trimester [87].
The mechanism of hypertension in rats exposed to
dexamethasone in utero is unknown, but is likely
to reflect permanent programming of blood pres¬
sure which may then track with age [93]. Secondary
changes may then amplify the phenotype. Rela¬
tively minor stresses in the neonatal period pro¬
gramme expression of corticosteroid receptors in
limbic areas of the brain throughout the lifespan of
a rat [94]; preliminary data suggest that exposure to
dexamethasone in ntero has similar effects in cer¬
tain brain regions in the rat (Holmes M, Lindsay R,
Seckl J: unpublished observations, 1993) [95]. Many
other actions of prenatal exposure to glucocorticoids
can also be envisaged, including alterations in mi¬
crovascular development; potentiated cardiovascu¬
lar responses to pressor substances, especially cate-
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cholamines (as seen after low-dose dexamethasone
treatment of fetal rats in late gestation [96]) or angio¬
tensin II (observed with infusion of Cortisol in fetal
sheep [87]); altered development of sympathetic in¬
nervations or expression of adrenergic receptors in
target organs (seen in the fetal lung [97] or neona¬
tal liver [98] after dexamethasone administration to
pregnant rats); and changes in the synthesis, trans¬
port or action of growth factors on fetal organs or
the placenta, or both [99]. Finally, indirect actions of
dexamethasone on maternal cardiovascular dynam¬
ics or ability to support fetal and placental growth
could be involved, although maternal electrolyte im¬
balance and plasma volume expansion do not ap¬
pear to occur at the dose of glucocorticoid used
(Lindsay R. Seckl J; unpublished observations, 1993).
Normally, of course, placental 11(3-HSD2 excludes
maternal glucocorticoids from the fetal circulation, at
least later in gestation [26.100]. Intriguingly, placen¬
tal 11(3-HSD activity at term in the rat is lowest, and
hence fetal exposure to glucocorticoids is greatest,
in the smallest foetuses with the largest placentae
[92], that is. those expected, on the basis of stud¬
ies in humans, to exhibit the highest blood pres¬
sures in adulthood [101]. Placental 11(3-HSD defi¬
ciency may thus allow maternal glucocorticoids ac¬
cess to the foetus, retarding its growth and program¬
ming or imprinting patterns of responses which lead
to subsequent hypertension [95]. It will be important
to determine whether prolonged administration of
synthetic glucorticoids to pregnant women affects
the blood pressure of their offspring, since gluco¬
corticoids that are poor substrates for 11|3-HSD (e.g.
dexamethasone) currently are more widely used in
the prenatal therapy of 21-hydroxylase deficiency
and other congenital adrenal hyperplasia syndromes
(prednisolone is subject to substantial metaboliza-
tion by placental 11|3-HSD [91])- Also, there may be
distinct windows for glucocorticoid actions on the
foetus, since at mid-gestation, at least in primates
and humans, reductase activity appears to dominate
in the placenta [34,59], suggesting that liP-HSDj ex¬
pression precedes that of llfl-HSDo. The implica¬
tions of excessive or deficient activation of cortisone
by placental reductase at mid-gestation have not yet
been studied.
11 p-Hydroxysteroid dehydrogenase and
other hypertensive mechanisms
Other glucocorticoid target organs may employ 11 (3-
HSD-mediated mechanisms relevant to blood pres¬
sure control. Prominent among these may be the
liver, which has both high 11(3-HSD activity and
high glucocorticoid receptor density. Indeed, in the
Bianchi-Milan rat model of hypertension it is hep¬
atic, rather than renal, 11|3-HSD activity that is al¬
tered (reduced) [102]. Intriguingly, changes are seen
in young prehvpertensive rats, suggesting a possible
pathogenetic importance of 11[3-HSD in hyperten¬
sion. However, no clear functions of hepatic 11(3-
HSD have been defined; although modulation of
glucocorticoid effects on insulin sensitivity, insulin¬
like growth factor synthesis or angiotensinogen pro¬
duction are potential functions, they await study.
The predominant direction of the reaction catalysed
by 11(3-HSD within hepatic subregions has also not
been determined, although reduction (activation of
cortisone) appears to be predominant in the liver
overall [19,33—351. Indeed, the grossly elevated (to¬
tal) plasma corticosterone levels in Bianchi hyper¬
tensive rats may, at least partly, reflect the lack of in¬
trahepatic activation of glucocorticoids by 11J3-HSD
and the consequent increase in corticosteroid-bind-
ing globulin synthesis, itself negatively regulated by
glucocorticoids in adult rats [1031-
The pituitary gland and hypothalamus also ex¬
press 11|3-HSD [78], and might modulate activity of
the hypothalamic-pituitarv-adrenal axis [104] or of
growth hormone release, affecting tissue growth and
blood pressure regulation. Finally, adipose tissue
also exhibits 11(3-HSD activity [105], and glucocor¬
ticoids exert well-documented actions on fat distri¬
bution and metabolism. The centripetal obesity of
Cushing's syndrome and syndrome X. both associ¬
ated with hypertension, might be modulated by vari¬
ations in adipocyte 11(3-HSD. Indeed, syndrome X is
very accurately predicted by low birth weight [106],
providing a possible link between deficient placen¬
tal 11(3-HSD and disorders other than hypertension.
In summary, different species of 11|3-HSD are likely
to regulate many biological processes mediated by
glucocorticoids. Tissue-specific defects in 11(3-HSD
expression are clearly associated with rare congen¬
ital and acquired hypertensive syndromes. In the
more common condition of essential hypertension,
the importance of these enzymes requires clarifica¬
tion; particularly lacking is a clear understanding of
the direction of enzyme activity in specific target
tissues in vivo. Dysfunction of placental llfbHSDo
may provide a crucial link between retardation of
intra-uterine growth and the attendant substantial
risk of common cardiovascular and metabolic dis¬
orders, particularly hypertension, in later life.
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Purification of 11/7-hydroxysteroid dehydrogenase type 2 from human
placenta utilizing a novel affinity labelling technique
Roger W. BROWN*, Karen E. CHAPMAN, Parvez MURAD, Christopher R. W. EDWARDS and Jonathan R. SECKL
University Department of Medicine, Western General Hospital, Edinburgh EH4 2XU, Scotland, U.K.
1 l/?-Hydroxysteroid dehydrogenase type 2 (11/7-HSD2) effic¬
iently inactivates potent glucocorticoid hormones (Cortisol and
corticosterone), leaving aldosterone unmetabolized. Abundant
ll/?-HSD2 activity in human placenta plays a central role in
controlling fetal glucocorticoid exposure, which if excessive is
harmful and may predispose to low birth weight and hypertension
in adulthood. Similar 11/AHSD2 activity in the distal nephron
protects mineralocorticoid receptors from glucocorticoids and
appears to be important in normal blood pressure control.
We have purified human placental 11/AHSD2 16000-fold, to
homogeneity, and determined over 100 residues of the internal
amino acid sequence. Purification was assisted by a novel
technique allowing highly specific (single spot on two-
dimensional electrophoresis) photoaffinity labelling of active
11/J-HSD2 in crude tissue extracts by its glucocorticoid sub¬
strates. This work reveals that 11/J-HSD2 is a member of the
short-chain alcohol dehydrogenase superfamily (apparent mon¬
omer Mr ~ 40000). It is a very basic (apparent pi = 9.1)
intrinsic membrane protein, requiring as yet undefined membrane
constituents for full stability. Affinity chromatography and
affinity labelling studies suggest that 11/7-HSD2 has a compulsory
ordered mechanism, with NAD+ binding first, followed by a
conformational change allowing glucocorticoid binding with
high affinity.
INTRODUCTION
1 l/?-Hydroxysteroid dehydrogenase (11/AHSD) catalyses the
rapid metabolism of physiological glucocorticoids (Cortisol and
corticosterone) to inactive 11 -dehydro products (cortisone and
11-dehydrocorticosterone respectively). In any tissue the activity
of 11/I-HSD will affect the amount of circulating glucocorticoids
reaching their intracellular receptors [glucocorticoid receptors
(GR) and mineralocorticoid receptors (MR)]. Moreover, as the
mineralocorticoid aldosterone is not metabolized by 1 1/7-HSD, it
can gain selective access to the MR in the face of 100-1000-fold
higher levels of circulating glucocorticoids, providing that 1 \ji-
HSD activity is sufficient to eradicate the glucocorticoid. It is
now widely believed that just such a selective barrier to gluco¬
corticoid is present in aldosterone target tissues [1,2] (e.g. the
distal nephron in kidney) and enables potent effects on fluid and
electrolyte balance and blood pressure to be exerted by aldo¬
sterone acting through MR (which in vitro bind aldosterone and
physiological glucocorticoids with equal affinity [3]). Deficiency
of 11/7-HSD due either to the congenital syndrome of apparent
mineralocorticoid excess (SAME) [4,5] or to the ingestion of 11/?-
HSD inhibitors [6] (liquorice constituents or carbenoxolone)
leads to the normally protected tissues being accessed by gluco¬
corticoids, which occupy MR and cause mineralocorticoid
hypertension.
There is also abundant 1 1/7-HSD activity in the placenta which
has a major influence on the glucocorticoid exposure of the
developing fetus [7-10]. Glucocorticoids are important in normal
development, facilitating the maturation of tissues (e.g. lung [11])
and influencing the set point of aspects of fetal physiology, a
number of which then become fixed for life (fetal programming)
[12-15], If the fetus is exposed to excessive glucocorticoids, birth
weight is reduced [9,16] and, in animal models, the offspring are
hypertensive in adulthood [9], Inhibition of placental 11/AHSD
similarly reduces birth weight and results in hypertensive off¬
spring (R. S. Lindsay, R. M. Lindsay, C. R. W. Edwards and
J. R. Seckl, unpublished work). Human epidemiology also reveals
that those babies with the lowest birth weight have the greatest
risk of adult hypertension [17]. Furthermore, in rats [9] and
humans [10], birth weight correlates with placental 11/THSD
activity.
The previously identified isoform of 11/AHSD (11/J-HSD1) is
not responsible for the renal and placental barriers to gluco¬
corticoids. It has been purified from rat liver [18], and cor¬
responding rat [19], human [20], squirrel monkey [21], sheep [22]
and mouse [23,24] cDNA clones have been isolated. 11/AHSDl
is a reversible, NADP(H)-dependent enzyme, with high ex¬
pression in some tissues (e.g. liver), but not in the distal nephron
or placenta, and it has relatively low affinity for glucocorticoids
{Km in the low micomolar region) [18]. Moreover, no mutations
of the 11/J-HSD1 gene have been identified in SAME patients
[25]. A distinct NAD+-dependent, exclusively dehydrogenase,
11/J-HSD activity with high affinity for glucocorticoids has been
identified in biochemical studies in rabbit kidney cortical collec¬
ting duct cells [26] and human placenta [27]. Similar activity has
now been described in renal tissue of other species [28] and
several human fetal tissues [29], These activities are due to a
distinct isoform, 11/AHSD2 (or possibly several closely related
ones), and seem likely to be responsible for the important
barriers to glucocorticoid access described above. Further study
of 11/THSD2 has been hampered by the lack of specific 'mole¬
cular tools' to investigate it at the protein and nucleic acid levels.
In this paper we present the first purification of 11/AHSD2 to
homogeneity and an extensive amino acid sequence derived
directly therefrom. We also describe a novel affinity labelling
procedure allowing 11/THSD2 to be specifically labelled by its
natural substrates. Aspects of this work should facilitate study of
the mechanism of action of 11/5-HSD2 and the mapping of its
Abbreviations used: 11 /?-HSD(2), 11/?-hydroxysteroid dehydrogenase (type 2); GR, glucocorticoid receptors; MR, mineralocorticoid receptors; SAME,
syndrome of apparent mineralocorticoid excess; CAPS, 3-(cyclohexylamino)-Tpropanesulphonic acid; 2-D, two-dimensional; CMC, critical micelle
concentration; IEF, isoelectric focusing; NEPHGE, non-equilibrium pH-gradient gel electrophoresis; TFA, trifluoroacetic acid; SCAD, short-chain
alcohol dehydrogenase; PVDF, poly(vinylidene difluoride).
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active site. Such study will be valuable in the efficient design ofnew
drugs influencing corticosteroid physiology (e.g. by selectively
inhibiting, bypassing or being metabolized effectively by this key
enzyme). In an accompanying paper we report use of the 11/?-
HSD2 amino acid sequence to isolate and characterize a full-
length human placental ll/?-HSD2 cDNA clone and to raise




dexamethasone and [l,2,6,7-3H]aldosterone (specific radio¬
activity 78, 73, 84 and 80 Ci/mmol respectively) were obtained
from Amersham International (Little Chalfont, Bucks., U.K.).
Autodigestion-resistant modified trypsin and Staphylococcus
aureus V8 protease were obtained from Promega (Southampton,
U.K.), and hydrogenated Triton X-100 (RTX-100; protein grade)
was from Calbiochem (Nottingham, U.K.). Glycerol and protein
standards for SDS/PAGE (#44264L), electrophoresis-grade SDS
and urea were purchased from BDH Laboratory Supplies (Poole,
Dorset, U.K.). Coomassie Blue dye concentrate, standardized
BSA and protein standards for two-dimensional (2-D) electro¬
phoresis (#1610320) were purchased from Bio-Rad (Hemel
Hempstead, U.K.). HPLC-grade methanol and water were
purchased from Rathburn Chemicals (Walkerburn, Scotland,
U.K.) and Quickszint 302 HPLC scintillant was from Zinsser
Analytic (Maidenhead, U.K.). Entensify fluoroautoradiography
solutions were obtained from du Pont/NEN (Stevenage, U.K.).
Poly(vinylidene difluoride) (PVDF; Problott) membranes were
obtained from Applied Biosystems (Warrington, U.K.). Affinity
chromatography matrices, Pharmalytes, detergents and other
chemicals were obtained from Sigma Chemical Co. (Poole,
Dorset, U.K.).
Buffers
Chromatography buffer systems used were as follows. Buffer A:
20% glycerol, 5 mM potassium phosphate, pH 7.0, 1 mM
EDTA, 1 mM dithiothreitol. Buffer B: 10% glycerol, 300 mM
NaCl, 4 mM CHAPS, 1 mM EDTA, 0.02M Tris/HCl, pH 7.7.
Buffer C: 10% glycerol, 300 mM NaCl, 1 mM EDTA, 0.02 M
Tris/HCl, pH 7.7. Where the buffer varies from that above, the
variation is appended in [brackets].
Subcellular fractionation of placental tissue
Human term placentae (400-600 g; normal vaginal delivery)
were rapidly placed on ice, and tissue was processed within 2 h.
Adherent membranes, umbilical cord and large vessels were
removed. Placental tissues were rapidly minced with scissors,
washed in ice-cold 0.9% NaCl, blotted dry, suspended in
approximately 3 times their weight of buffer A and homogenized
with a commercial blender. Homogenate was filtered through
two layers of muslin and the filtrate fractionated rapidly by
differential centrifugation: (i) lOmin at 750/*, (ii) 40 min at
25000 g and (iii) 60 min at 110000 g. The supernatant from each
centrifugation was subjected to the next centrifugation, finally
leaving a cytosolic supernatant. Resulting fractions were frozen
at — 80 °C or used immediately.
Assays of 11/?-HSD activity
1 l/?-HSD2 activity was determined by measuring the percentage
conversion of 1.12 x 10~8 M3H-labelled steroid substrate (cortico-
sterone unless otherwise stated) to product (11-dehydrocortico-
sterone) in the presence of NAD+ (400 /tM unless otherwise
stated). The 250 /d assay consisted of 10 /d containing tritiated
steroid, 50 p\ containing cofactor and 190 /tl of enzyme in buffer
C. Reactions were incubated at 37 °C for 10 min and terminated
by adding 2 ml of ethyl acetate. The steroids (in the organic
layer) were assayed by HPLC as previously described [27], and
the percentage conversion of steroid substrate to product was
calculated as an index of enzyme activity. Protein was estimated
by the method of Bradford [31]. 1 l/?-HSD assay conditions were
such that the amount of protein added was in the linear region
of the curve of protein concentration versus percentage substrate
converted with 400 /tM NAD+, and resulted in conversion of
10^10% in 10 min. All experiments had blank (no protein)
assays run in parallel. Kinetic parameters were calculated from
initial-velocity determinations in assays giving less than 30%
conversion.
Detergent solubilization
All solubilization was carried out at 0-2 °C. Tissue fractions,
resuspended in buffer C to 6 mg of protein/ml, were mixed with
an equal volume of solubilization buffer (in buffer C with
detergent at twice the final concentration). After 30 min the
mixture was centrifuged at 110000/* for 1 h. Supernatant con¬
taining soluble enzyme was carefully removed. A screen was
performed using 13 detergents of diverse classes [32] (Triton
DF18 [18], CHAPS, taurodeoxycholic acid, polyoxyethylene-10-
lauryl ether, digitonin, n-octyl glucoside, Tween 20, Tween 80,
SDS, n-lauryl sarcosine, Triton X-100, Zwittergent 3-10 and
Bigchap). Following this screen, conditions were refined for the
most promising detergent (CHAPS).
Affinity chromatography
Affinity chromatography matrices were hydrated, loaded into
simple columns and equilibrated in buffer B. For the preparative
5'-AMP-agarose chromatography, six 5 ml columns were run in
parallel, having a common outflow; 5 ml fractions were collected.
A CHAPS-solubilized placental 25000/* pellet fraction (180 ml)
was loaded (2.4ml/min) on to the columns, which were then
washed with 205 ml of buffer B and 45 ml of buffer B[0.25 M
NaCl], and ll/?-HSD was eluted with 170 ml of buffer B[0.2 M
NaCl+ 1 mM NAD+], all at 3.5 ml/min. Fractions were placed
on ice and rapidly assayed for ll/?-HSD enzyme activity.
Fractions with abundant ll/?-HSD2 were pooled and con¬
centrated (Amicon stirred cells; Centricon 10 concentrators;
acetone precipitation).
Analytical work used 1 ml columns run manually (1.0-1.5 ml
fractions). To obtain the highest purity of eluted 1 l/?-HSD an N-
6-5'-AMP-agarose column was washed with buffer B (15 ml),
buffer B[0.02 M NaCl + 0.4mM NADH] (10 ml) and buffer B
(15ml), and then eluted with buffer B[0.125M NaCl+1 mM
NAD+]. The flow rate was 420 /tl/min, decreasing to
200-300 /d/min on elution. The increased purity was at the cost
of lower yield and reproducibility than with the preparative
protocol (above).
UV photoaffinify labelling and fluoroautoradiography
A portion of 467 /d of tissue sample diluted in buffer C was
added to wells of24-well plates (diameter 15 mm) and maintained
at 37 °C for 3 min. Addition of 60 /tl of 250 mM dithiothreitol,
48 /tl of 5 mM NAD+ (both in buffer C) and finally [3H]steroid
(in 25/tl of 10% ethanol/buffer C) completed the reaction,
giving approx. 50 nM [3H]steroid in 600 /tl, unless otherwise
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stated. In the experiments presented here (to minimize UV
damage to protein), reactions were placed in UV light (312 nm
transilluminator at a distance of 50 mm above plate; lid off) for
15min at 37 °C. The procedure was easily scaled up. Similar
labelling occurs at 254 nm and is even stronger at 0 °C or with
longer UV exposure. However, all three of these variations also
induce formation of minor bands below Mr 40000, and protein
damage with prolonged 254 nm UV exposure will be more
extensive.
Labelled samples were acetone-precipitated and resolved by
SDS/PAGE [33] or 2-D electrophoresis. Finished gels, stained
with Coomassie Blue to allow detection of major proteins and
Mr standards, were processed for fluoroautoradiography in
Entensify solutions and vacuum-dried before exposure to film.
2-D electrophoresis
2-D electrophoresis work involved running duplicate gels in
parallel; usually one was silver stained (to visualize all the
proteins), and the other stained with Coomassie Blue (to allow
alignment between gels and to visualize SDS/PAGE protein
standards) and processed for autoradiography. A set of 2-D
electrophoresis protein standards was run under identical con¬
ditions on a third gel when new running parameters were used.
Conventional 2-D PAGE, i.e. isoelectric focusing (IEF) plus
SDS/PAGE, used a variation of the method of O'Farrell [34].
2-D non-equilibrium pH-gradient gel electrophoresis (NEPHGE)
conditions were based on the methods of O'Farrell [35] and
Witzmann [36], with variations of sample buffer and rod gel
composition. Rod gels (170 mm x 2.5 mm; length x internal
diameter) were cast from 9M urea, 2% Nonidet P40, 4%
acrylamide/bisacrylamide (19:1, w/w) and 3% Pharmalytes
(1.2% pH 6-8 and 1.8% pH 3-10), and polymerized with 32 /d
of 10% ammonium persulphate and 21 /A of NNN'N'-tetrd-
methylethylenediamine (TEMED) per 20 ml of rod gel mixture.
Optimal results (higher yield, better resolution), especially for
basic hydrophobic proteins, were obtained with a dodecyl
maltoside-based NEPHGE sample buffer: 5.71 gof urea, 154 mg
of dithiothreitol, 4 ml of 10% dodecyl maltoside, 750 #1 of
Pharmalytes (300 /d of pH 6-8; 450 /A of pH 3-10) and 2.25 ml
of HPLC-grade water, and adjusting the pH to 4.2 (by adding
approx. 90 /d of 5 M HC1 and 160 /d of HPLC-grade water).
This buffer, which was a great improvement, is close to solidifying
at room temperature and is melted, by warming to 30 °C, to
adjust pH on preparation and on use. NEPHGE gels were run at
500 V for 2250 V-h. After NEPHGE, rods were extruded into
10 ml of equilibration buffer for 7 min and either frozen or
loaded directly on to second-dimension SDS/PAGE gels. Equi¬
libration buffer (150 ml) consisted of 15 ml of /Tmercaptoethanol,
9 g of SDS, 90 ml of HPLC-grade water, 5.6 ml of 0.075%
Bromophenol Blue and 37.5 ml of 4 x Laemmli stacking buffer
(0.4% SDS, 0.5 M Tris/HCl, pH 6.8). For both IEF and
NEPHGE the second dimension was run according to the
resolving gel system of Laemmli [33] using 12.5% gels (3.3%
cross-linker). Silver staining was by the method of Wray [37].
Concentrated protein from preparative AMP affinity chroma¬
tography runs was divided among several 1.5mm-thick pre¬
parative 2-D gels. Precautions were taken to minimize protein
N-terminal modifications: the second-dimension gel was pre-run
in a Laemmli running buffer containing 0.5 % (v/v) freshly made
100 mM glutathione and then changed to running buffer with
0.1% (v/v) 100 mM sodium thioglycholate [38], These pre¬
cautions were successful in allowing N-terminal sequence to be
obtained for other proteins in our laboratory.
Protein blotting for sequencing
This was based on the CAPS [3-(cyclohexylamino)-l-
propanesulphonic acid] buffer method of Matsudaira [39] and
was performed from SDS/PAGE or second-dimension gels on to
PVDF (Problott) membranes using a Bio-Rad Mini Trans-Blot
apparatus. Sections of gels to be blotted were washed for exactly
30 s in CAPS transfer buffer (to allow shrinkage and removal of
excess surface SDS). Electroblotting was for 75 min at 250 mA
(90-110 V). After transfer, the PVDF sheets were stained (Amido
Black), destained (water) and air dried, and desired bands/spots
were cut out and stored at —70 °C.
Proteolytic digests of PVDF-blotted protein
These were based on the method of Fernandez et al. [40]. Mem¬
branes were cut into small pieces, blocked [0.2 % polyvinyl¬
pyrrolidone (average Mr 40000) in methanol for 45 min] and
extensively washed in deionized HPLC-grade water.
Autodigestion-resistant trypsin was added in AHT buffer (20 %
acetonitrile, 1% hydrogenated Triton X-100 in 100 mM Tris,
pH 8) to a concentration of 1:20 (w/w) (trypsin/blotted protein),
and digestion was continued for 24 h at 37 °C. Fragments were
eluted using vigorous sonication and washes [AHT buffer, then
0.1% (w/v) trifluoroacetic acid (TFA)] [40]. Eluted peptides
were concentrated, removing the acetonitrile, and loaded as a
100/tl sample on to an Applied Biosystems microbore HPLC
system fitted with a C8 RP300 column (1 mm x 250 mm; 7 /tm
particle size) equilibrated in solvent A (0.1 % TFA/water). This
was developed with a linear gradient of 0-100% solvent B
(0.08% TFA in 80% acetonitrile/water) over 45 min at
200 /A/min. The spectrophotometric absorbance at 220 nm (A220)
of eluate allowed collection of peptide peaks. Control digests
(trypsin with polyvinylpyrrolidone-blocked blank PVDF slices)
were run in parallel to ensure identification of all peaks not due
to the blotted protein substrate. A large peptide peak yielding no
sequence which was thought to be the blocked N-terminal
peptide was sub-digested in solution (50 mM sodium phosphate,
pH 7.8) with S. aureus V8 protease at an estimated concentration
of 20:1 (w/w, peptide/protease). Products were resolved on
HPLC, as were those from a control (protease only) digest.
Amino acid sequencing
Peptide peaks selected for sequencing were pyridyl-ethylated
[41], to allow detection of cysteine residues, and loaded into an




Human placental ll/THSD activity was well preserved during
subcellular fractionation. Placental 11/7-HSD was clearly a
membrane-associated protein (as < 2 % of activity remained in
the cytosolic supernatant) and was most abundant in the 25000 #
pellet, which contained over two-thirds of the total enzyme
activity in under one-sixth of the total protein. Differential
centrifugation of the 25000# pellet did not produce any useful
refinement. This fraction was used for further purification, and
has been found to be very stable on storage at —70 °C, with no
decline in activity in over 2 years.
Solubilization
Solubilization (i.e. remaining in supernatant after 1 h at
110000#) of placental 11/7-HSD (from resuspended 25000#
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Figure 2 Native photoaffinity labelling of 11/1-HSD2
The bottom panels are autoradiographs of labelled protein samples run on the SDS/12.5%-
PAGE gels shown in the top panels (stained with Coomassie Blue). 10-3 x Apparent M,
of protein standards (PS) are indicated on the left side of the gels, (a) Triplicate samples of rat
liver microsomes (' Liver'), AMP-chromatography-purified human placental 11 /?-HSD (' Purified';
similar to fraction 32 in Figure 1) and three human placental subcellular fractions (Cytosol,
25000 g and Nuclear). All samples were photoaffinity labelled simultaneously with [3H]corti-
costerone in the presence of 400 /iM NAD+ (lanes d), 400 /M NADP+ (lanes p), both
cofactors at 400 /M (lanes dp) or both cofactors plus 50 gU carbenoxolone (lanes c(). A single
protein band at 40000-fty is labelled in an NAD+-dependent, carbenoxolone-blockable fashion,
(a) samples of human placental 25000 g pellet (mitochondria+heavy microsomes)
photoaffinity labelled simultaneously in the presence of 400 /M NAD+ and [3H]cortisol (F),
[3H]corticosterone (B) or [3H]dexamethasone (Dx). Protein loading was < 0.5 ytg for 'Purified'
lanes; otherwise it was ~ 30 ^g/lane.
Figure 1 5 -AMP affinity chromatography
(a) SDS/12.5%-PAGE gels (silver stained) from 5'-AMP-agarose chromatography. 11/J-
HSD2 activity (percentage conversion of 12 nM [3H]corticosterone in 10 min) is indicated above
the lanes; ND, not detected. The positions of 11/J-HSD2 protein (starred arrow) and of markers
(10~3 x A4r) are shown between the panels. Left panel, preliminary analytical study showing
samples before, during and after harsh elution with NAD+ (fractions 31-34); right panel,
samples from two particularly clean analytical runs (A1 and A2) and pooled high-activity
fractions from two typical preparative runs (P1 and P2), as described in the Experimental
section. For analytical runs 190 g\ samples of fractions were used in standard 11 ^-HSD assays
and 1 ml samples (acetone precipitated) were used for SDS/PAGE; in preparative runs 50 g\
(assays) and 250 g\ (SDS/PAGE) samples were used, (b) Chromatographic profile of
preparative-scale run showing 11 /J-HSD2 activity (bars) in relation to A2m (protein concentration
or NAD+ on elution) of fractions (5 ml) from the common outflow of six 5 ml AMP-agarose
columns run in parallel. Fractions 1-36, loading; 37-86, washes; 87-120, elution with 1 mM
NAD+. The most active of these fractions are equivalent to samples P1 and P2 described above.
pellet) was attempted using 0-2.4 M NaCl. The ionic strength
clearly affected ll/?-HSD activity before centrifugation (activity
was highest with 0.3 M NaCl: 160% of that with no NaCl). As
~ 99 % remained insoluble, solubilization was attempted with
an extensive screen of detergents. Placental 11//-HSD activity
was inactivated by concentrations of detergents required to
transform membrane proteins fully into micelles [detergent
concentration>critical micelle concentration (CMC)]; however,
limited though useful solubilization was achieved with gentle
conditions (detergent concentration < CMC), being best with
zwitterionic detergents with bile acid- or steroid-like head groups.
CHAPS (4 mM) in combination with buffer C (which contains
0.3 M NaCl) was found to be optimal, solubilizing 40—45 % of
the 25 000 g pellet protein and 9.5 % of its 1 l/?-HSD activity. On
repeated re-extraction of the initially insoluble protein with
4 mM CHAPS, 13-20% of the original 1 l/?-HSD activity could
be solubilized. Thus placental 11/THSD2 appears to be an
integral membrane protein that requires factor(s) present in
membrane subfractions of the placenta which are not satis¬
factorily substituted by a wide range of detergents.
Affinity chromatography
Since 11/J-HSD uses NAD+ and glucocorticoids as substrates,
columns with ligands that mimic these factors were screened. It
was found that one matrix, N-6-linked 5'-AMP-agarose (Sigma;
cat. no. A3019), bound substantial 11/J-HSD activity that could
be eluted with cofactor (NAD+ > NADH > 5'-AMP >
NADP+). Two other kinds of 5'-AMP-agarose [ribose hydroxyl-
(Sigma A8895) and C-8-linked (Sigma A1271)] and two types of
NAD+-agarose were ineffective, with a small percentage (2%)
binding to the third type of NAD+-agarose available (linked at
C-8; Sigma N1008), eluting specifically with NAD+. 11/J-HSD
activity did not bind to NADP+-agarose, cAMP-agarose or
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dexamethasone-agarose (Sigma D4657; 0.5-1.0 /rmol/ml dexa-
methasone immobilized at C-17).
Preliminary studies with this N-6-linked 5'-AMP-agarose
revealed it to be very useful for ll/?-HSD2 purification. Over a
large number of running conditions, a band migrating at approx.
Mr 40000 on SDS/PAGE was seen to co-segregate with the 11/?-
HSD2 activity of the fractions (e.g. Figure la). Chromatography
for highest purity (e.g. lanes A1 and A2, Figure la) suffered from
a low yield of active ll/?-HSD.
The large-scale preparative conditions adopted (see the Ex¬
perimental section and Figure lb) reproducibly gave a 20-fold
higher yield (35%) at somewhat decreased, though still 1000-
fold, purification (Figure la, lanes PI and P2). The 40000-Mr
band (starred) was the most prominent, but contamination
persisted at various Mr values, notably several narrow bands
very close to (especially above) 40000. These closely flanking
bands indicated contaminating proteins that were likely to defeat
further purification steps based solely on resolution by size (e.g.
gel filtration). Accordingly it was decided to separate by size and
charge using 2-D electrophoresis. As this would inevitably result
in inactivation of ll/?-HSD2 activity, an alternative method of
detecting the enzyme was required. This was provided by a novel
affinity labelling method.
Affinity labelling
Kinetic studies of 1l/?-HSD2 purified by AMP-agarose chroma¬
tography revealed a very low Km for corticosterone (14+1 nM)
[27], and therefore affinity labelling with this steroid was attem¬
pted. As Figure 2 shows, a protein with all the expected
characteristics of ll/?-HSD was uniquely photoaffinity labelled.
This protein was Mr 40000 in size, and was present in the
subcellular fractions along with 1l/?-HSD activity [25000 g pellet
750 g pellet (nuclear/debris)« 110000 g pellet (light microsomes;
not shown)], but absent from cytosol. The labelling was NAD+-
dependent, independent of NADP+ and blocked by carben-
oxolone. Labelling of fractions after AMP-agarose chromato¬
graphy showed the labelled protein exactly corresponded to 11/?-
HSD activity, being present when ll/?-HSD was eluted with
NAD4 (e.g. Figure lb, fractions 87-120) and in the flow-through
(fractions 1-30), but absent from the inactive wash fractions.
Moreover, the same protein could be affinity labelled with
Cortisol and dexamethasone (corticosterone Cortisol dexa-
methasone; Figure 2b), but there was no labelling with aldo¬
sterone. This novel technique appears to result in completely
selective labelling of placental 1 l/?-HSD by glucocorticoids, with
a potency which parallels their affinities as substrates for the
enzyme. Using this technique it was possible to track the 11/?-
HSD2 protein after activity had been lost, so allowing final
purification by 2-D electrophoresis.
The affinity labelling technique developed here is unusually
straightforward and specific for ll/?-HSD2. Photoaffinity label¬
ling is more commonly described for receptors and binding
proteins, and a few such procedures report labelling by un¬
modified steroid compounds acting as the ligand (e.g. GR by
dexamethasone), but even in such cases these 'common' ligands
lack the desired specificity and are replaced by compounds
developed to allow high specificity (e.g. RU26988 and RU28362
for exchange assays/photoaffinity labelling specific for the GR
[42,43]). Affinity labelling of enzymes is much less common by
photoactivation, and is more often achieved using a specifically
designed activatable compound containing a reactive functional
group (usually electrophilic, e.g. bromoacetate) which is attacked
by an activating substituent (usually a nucleophilic side chain of
an amino acid) in the enzyme's active site {e.g. 3-methoxyoestriol
16-(bromo[2-14C]acetate) labelling of homogeneous placental
17/?-HSD type 1 at two histidines in its active site [44]}. Less
commonly, enzymes can be photoaffinity labelled by precisely
chosen synthetic compounds which, when photoactivated, de¬
velop short-lived, highly reactive substituents which label the
target enzyme if a suitable amino acid residue is nearby (e.g. UV-
induced labelling by 19-nortestosterone acetate of purified A5-3-
ketosteroid isomerase from Pseudomonas testosteroni [45]). What
makes the labelling technique described here particularly unusual
is that it can use a physiological substrate in a crude tissue extract
containing thousands of different proteins (in contrast to the two
examples given above, which used pure enzyme), and labels the
enzyme for that substrate with such specificity that analysis
reveals only a single spot on 2-D electrophoresis. To our
knowledge, the only other study describing photoaffinity labelling
of a steroid-metabolizing enzyme by what may be a natural
substrate is the labelling of Pseudomonal A5-3-ketosteroid iso¬
merase with testosterone [45]. This, however, is a less avid label
than synthetic 19-nortestosterone acetate. Though the parallels
are intriguing, that study [45] utilized pure enzyme and ~ 500-
fold higher steroid concentrations than were employed here for
I l/?-HSD2 labelling.
Several findings suggest that the affinity labelling procedure
described above occurs within the steroid binding pocket of the
active site. Firstly, the affinity labelling is NAD+-dependent, as is
II /?-HSD2 activity. There are a few reports ofcofactor-dependent
affinity labelling of other dehydrogenases. NAD+-dependent
lactate dehydrogenase is affinity labelled, in the presence of
NAD+, by bromopyruvate on the major catalytic residue
(histidine-195) [46]. Secondly, carbenoxolone, an ll/?-HSD2
inhibitor, blocks labelling, as does a 1000-fold excess of unlabelled
corticosterone. Thirdly, the rank order of potency for gluco¬
corticoid labelling correlates with the substrate affinities ofhuman
placental 11/5-HSD2.
Finally, the glucocorticoid groups most likely to participate in
covalent photoaffinity labelling of ll/?-HSD2 are the carbonyl
group at C-3 and the C-l 1 position itself. Labelling via the C-20
carbonyl appears less likely as it is expected to be less photo-
excitable, and covalent attachment of the C-20-C-21 grouping
(following the common C-17-C-20 cleavage) would not attach
any radioactivity, as the steroids are tritiated at C-l, -2, -6 and
-7 only. The C-3 carbonyl would be highly photoactivated to
produce both alkoxy radicals and reactive ketenes; both of these
would react relatively indiscriminately [47], potentially with
almost any closely approximated amino acid, but especially with
reactive cysteine, lysine, histidine or tyrosine residues. The
photoreactive state ofC-l 1 is harder to anticipate, but is likely to
be greatly heightened in the active site where it will make the
transition to a C-l 1 carbonyl, a photoexcitable group in its own
right.
2-D electrophoresis
Fractions containing enzyme eluted from AMP-agarose were
affinity labelled with [:!H]corticosterone and then subjected to
conventional 2-D electrophoresis (IEF plus SDS/PAGE). After
prolonged exposure, gel autoradiography remained negative.
Accordingly, NEPHGE gels were run. A strong signal, indicating
the presence of a single, affinity-labelled, protein spot of basic pi
(~ 9.1) and apparent Mv 40000, was seen on autoradiography
(Figures 3a and 3b). It was notable that this was accompanied by
other proteins close to 40000-M,, which were not affinity labelled.
NEPHGE conditions were optimized (Figure 3) to allow
preparative-scale gels with substantially increased yield and
reduced smearing of the affinity-labelled protein, which was
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Figure 3 Identification and preparative 2-D electrophoresis of homogeneous 11//-HSD2
Panels (a), (c) and (d) show silver-stained second-dimension gels of NEPHGE 2-D electrophoresis (running to basic pH as indicated). 11/?-HSD2 (starred arrow) and two protein contaminants
(upward-pointing arrows) are indicated to assist orientation. Panel (b) shows an autoradiograph of a gel run in parallel, identical to the one in (a), but stained with Coomassie Blue and processed
for autoradiography, (a) and (b) NEPHGE analysis, with an even pH gradient (3-10; see the Experimental section) showing that the protein band(s) at 40000-M, resolve into multiple protein spots,
of which 11/?-HSD2 (clearly identified by autoradiography; b) is one of the most abundant and basic in pi. (c) NEPHGE analysis with the pH gradient expanded at pH 6.5-8.0 to allow better
horizontal separation of 11/?-HSD2 from nearby proteins at M: 4000CM3000. (d) Optimized preparative-scale 2-D electrophoresis for 11/?-HSD2 with dodecyl-maltoside-based buffer (greatly
reducing streaking) and running the second dimension further to increase the vertical resolution. Note that the 10 mm scales refer to actual gels.
otherwise a major problem. The optimized procedure allowed
preparation of over 40 /ig of homogeneous 11//-HSD2 protein,
which was blotted on to PVDF (Problott) membranes.
Several findings suggest that the ll/?-HSD2 membrane en¬
vironment has polar aspects. Thus moderate ionic strength
stimulates activity, the most hydrophobic lipid-like detergents
(e.g. Tween 20) are not the most useful for preserving 11/J-HSD2
activity, and the 1l/?-HSD2 protein has a very high pi (> 9). The
very basic pi (9.1) is surprising. Proteins this basic are unusual,
often being ribosomal or associated with nucleic acid (chromatin
or RNA). Rarely are they intrinsic membrane proteins, and this
combination suggests interactions of 1 l/?-HSD2 beyond NAD+
and steroids, perhaps with other membrane proteins or charged
lipid. Thus it may well be that interactions of this nature
(especially with phospholipid head groups) may be involved in
stabilizing the enzyme, as occurs with the related NAD*-
dependent short-chain alcohol dehydrogenase (SCAD) enzyme
3-hydroxybutyrate dehydrogenase [48], We have not investigated
this further, as development of the affinity labelling technique
allowed purification of 1 l/?-HSD2 to homogeneity, when activity
was not maintained.
Amino acid sequence
PVDF blots were stained with Amido Black and the 40000-M,.
target protein accurately excised. Sequencing of PVDF pieces
revealed that homogeneous 11 /?-HSD2 was N-terminally
blocked. This is unlikely to be an artifact of the purification as,
on sequencing, an amino acid signal was completely absent
(rather than just low), and we have obtained high-yield N-
terminal sequence from other proteins blotted from gels in the
same fashion. In situ tryptic digestion of approx. 30 /ig of
11 /?-HSD2 protein produced multiple peptides and several of
these were sequenced, yielding in total over 100 residues of amino
acid sequence (Figure 4 and Table 1). Peptide G was blocked.
This was sub-digested with S. aureus V8 protease, yielding a
sequencable daughter peptide.
All peptide sequence obtained was unique, confirming 11/?-
HSD2 as a novel protein. This is the first directly determined
11/J-F1SD2 peptide sequence from any source. Direct amino acid
sequencing provides information about amino acid order and
post-translational modification, and avoids some pitfalls of
cDNA-predicted amino acid sequencing, such as the use of rare
codons (e.g. selenocysteine). There is one potential N-linked
glycosylation site (7VLS; peptide B) which in the native protein,
at least in human placenta, appears to be largely free of
glycosylation, as the amino acid sequence yield did not drop
across this asparagine residue. Peptide C contains a classical
SCAD motif (boxed in Table 1) indicating that ll/?-HSD2
belongs to this enzyme superfamily. There was one clear 'blank'
cycle in the middle of peptide C (cycle 15); it is possible that a
modified amino acid naturally occurs here. Further discussion of
the sequence is presented in the accompanying paper [30].
Overall purification procedure
Table 2 summarizes the steps in the purification procedure
described that allowed isolation of homogeneous 11//-HSD2
Purification of human placental 11/?-hydroxysteroid dehydrogenase type 2 1003
Figure 4 Microbore HPLC profile of 11/?-HSD2 tryptic digest
The solid line indicates the elution of peptide peaks (detected by A2X\ highest peaks
corresponding to ~ 500 pmol). The elution positions of trypsin and peaks from which the
peptide sequence was obtained (G obtained by V8 sub-digest) are indicated. The digest was
loaded on to the HPLC RP300 column equilibrated in solvent A (0.1% TFA in water) and
developed with a linear gradient (broken line) of 0-100% solvent B (0.08% TFA and 80%
acetonitrile in water) over 45 min at 200 ytl/min.
protein from human placenta (> 16000-fold purification) and
direct determination of over 100 residues of its internal amino
acid sequence. In an accompanying paper [30], the amino acid
sequence derived has been used to clone a full-length 1 1/THSD2
cDNA from a human placental library which, on transfection
into mammalian cells, expresses 11^-^02 activity and an
approx. 40000-A/,. protein which can be affinity labelled by the
method described above.
11/7-HSD2 substrate binding and reaction mechanism
The primary objective of this work was to accomplish 1 1/THSD2
purification. We feel that it also allows conclusions to be drawn
which may shed some light on the form of the enzyme's active
site and kinetic mechanism. The striking specificity of the
photoaffinity labelling of 11/THSD2 by corticosterone and
Cortisol, in the presence ofNAD+, demonstrates that 1 l/i-HSD2
exhibits an unusually high, receptor-like, affinity for these
glucocorticoids, which may come close to that of GR or MR.
This finding underlies the physiological role of ll/?-HSD2 in
binding, and inactivating, glucocorticoids with high avidity
before or in competition with GR and MR, so regulating
glucocorticoid access to receptors. 1 l/?-HSD2 is probably not the
same as the ~ 45000-Mr Tow-affinity' (Kd ~ 100 nM) dexa-
methasone binding proteins identified in studies on male rat liver
[49], as it differs in localization, hierarchical order of binding
affinities and possibly Mg2+-dependence of binding (11/THSD2
labelling occurs in EDTA-containing buffers). However, 11/?-
HSD2 does resemble another, incompletely characterized,
receptor/binding protein for glucocorticoids: the type 3 corti¬
costeroid (corticosterone) receptor [50,51]. Thus the rank order of
affinities determined in binding studies of these 'type 3 sites'
CYCLE. SEQUENCED PEPTIDES [Residues, Y i e 1 d ( p m o 1) ]•
A A2 B B2 B3 C D E F G
1 N 445 L 190 A 180 412 L 315 V 126 I 55 V 411 ? ? ? ? V 45
2 V 426 P 163 L 96 405 L 330 s 119 V 36 L 364 L 406 L 16 N 29
3 G 383 V 182 Q 83 354 Q 318 I 117 T 16 E 231 L 307 D 9 F 27
4 Q 311 A 180 p 76 339 M 316 I 117 V 19 F 333 Q 238 S 75 F 15
5 w >60 T 112 G 66 281 D 170 Q 85 G 15 T 74 L 214 ML ? G 10
6 E 195 R 31 Q 57 271 L 243 p 46 SI ? K 37 L 221 G 5 A 9
7 K 97 P 71 243 T 134 G 40 P 15 R 21 F 6 L 7.5
8 G 62 197 K 135 C 40 A 16 TO 7 E 2.5
9 T 39 135 P 170 F 41 G 14 V 8
10 T 40 116 G 175 K 8 D 12 L 53
11 P 40 121 D 120 M 13 A 3.8
12 P 33 92 I 167 P 11 T 3
13 Q 30 82 S 60 Y 10 VP 7
14 D 18 43 R 28 P 10
15 A 23 62 - 0
16 A 25 71 L 8.4
17 Q 15 43 G 7.4
18 D 11 16 A 8.1
19 P 10 21 Y 3.5
20 N 10 17 G 2.5
21 L 13 T 1.8
22 S 6 S 2





Table 111 b-HSD2 peptide sequence
The amino acid and yield (in pmol) obtained on sequencing 11 b-HSD2 peptides A-G are given by cycle number. Peptide B was sequenced twice (using a second sample from tryptic digestion of
purified 11 b-HSD2). Cycle C(15) produced no residue signal. Cycles F(5), F(8), F(13) and C(6) produced two residues with similar yield, making assignment difficult. Cycle A(5) is definitely W, but
the yield imprecise. Note that the boxed sequence in peptide C is a classical SCAD motif, indicating the likely active site.
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Table 2 Summary of purification of 11/?-HSD2
Purification using 10 placentas yielded ~ 43 /vg of ~ 16000-fold-purified 11/?-HSD2. Affinity labelling of tracer amounts ot 11//-HSD2 after AMP-agarose chromatography allowed a means
of assessing yields beyond this stage. 11/7HSD2 peptide recovery (following in situ tryptic digestion, elution from PVDF and microbore HPLC) was generally lower with increasing peptide
hydrophobicity (see Figure 4). Activity was measured as nmol/min per mg of protein.
Yield (%) Purification (fold)
Activity Recovery of
Purification step Protein Step Cumulative Step Cumulative (nmol/min per mg) radioac
Homogenate 46.8 g _ 100 _ 0.025 _
Subcellular fractionation 5.22 g 67 67 6 • 0.150 -
Solubilization 1.85 g 13 8.7 0.367 2.2 0.055 -
AMP-agarose 640 fig 36 3.15 1040 2290 57.3 -
2-D gel 43 fig 47 1.47 > 7 >16000 - 100
Blot 30 fig 70 (1.05) - - - 70.2
Eluted peptides ~ 520 pmol (~ 21 /iQ) 70* (0.75) - - - 49.8
Initial sequencing yield 445 pmol* 85 - - - - -
* Best yield.
[50,51] is consistent with the order of potency of the four steroids
used to affinity label ll/?-HSD2 (Figure 2). 'Type 3 sites' are
often regarded as cytosolic, which ll/?-HSD2 is not. However,
the work originally defining them (in rat kidney) largely used
supernatants from centrifugation at 30000 g for 30 min, which is
very similar to the 25000^/40 min fractionation that we have
used. Supernatant from such a spin will probably have approx.
95 % of protein from the cytosol, but the remaining 5 % will be
rich in protein from light microsomes and contain abundant 11/?-
HSD2. Recent work on isolated renal cortical collecting duct
cells characterizes a similar binding site in whole cells (where
endogenous NAD+ may facilitate binding), which may be the
renal ll/?-HSD2 isoform [51], The characteristics of placental
11/J-HSD2 are thus clearly similar to the 'type 3 sites' in these
reports. In the accompanying paper [30] this matter is addressed
further by examining the affinities of recombinant ll/?-HSD2.
However, at present it is not settled whether 'type 3 sites' and
ll/?-HSD2 are the same entity.
The affinity chromatography data provide some clues to the
reaction order and nature of the active site of placental 11/?-
HSD2. It is likely that ll/?-HSD2 binding to N-6-5'-
AMP-agarose was via an interaction at the cofactor binding site.
5'-AMP is a 'half molecule' ofNAD4 (nicotinamide comprising
the remainder), and instances of N-6-5'-AMP affinity matrices
interacting with the cofactor site of NAD'-dependent dehydro¬
genases are well documented [52]. We have shown the rank order
of potency by which free cofactors elute bound human placental
ll/5-HSD2 activity from N-6-5'-AMP-agarose to be NAD+ >
NADH > 5'-AMP > NADP4 (with 10-fold more 5'-AMP than
NAD+ required for elution) [27]. Thus for free cofactor the
binding site prefers NAD+, so appearing like a NAD4 cofactor
site as opposed to a 5'-AMP allosteric site. When the cofactor is
on the affinity matrix and not free, however, the rank order
changes to N-6-5'-AMP (yield over 35 %) > C-8-NAD+(yield
~ 2%) > N-6-NAD4" = C-8-5 -AMP = NADP+ (yield = 0).
Clearly the attached spacer arms make a considerable difference,
sterically hindering NAD+ from binding more strongly than 5'-
AMP (as occurs with free cofactors). This may be a limitation of
the particular affinity matrix products used or simply be because
the larger size of NAD4 makes its binding more sensitive to steric
hindrance. A further possibility is that NAD+ may cause a
conformational change on binding (this quite frequently occurs
with dehydrogenases), whereas 5'-AMP, filling only a half site,
does not. Thus steric interference by the new conformation
prevents ll/?-HSD2 binding to N-6-NAD+, but some limited
binding is then possible with C-8-NAD+ (which has the spacer
attachment rotated > 90° relative to N-6, both coming from the
5'-AMP halfofNAD^). 5'-AMP, causing no such conformational
change, binds well when N-6-linked, but not at all when C-8-
linked. The 5'-AMP affinity chromatography results suggest that
NAD+ can bind first to 1 l/?-HSD2 (explaining both binding and
elution with NAD4). The NAD'-dependence of glucocorticoid
affinity labelling suggests that glucocorticoid cannot gain full
access to the steroid binding pocket unless NAD+ has bound
first. Affinity chromatography with dexamethasone-agarose was
unsuccessful under a range of elution conditions. The finding
that under similar conditions 1 l/?-HSD2 is bound well by N-6-5'-
AMP agarose, but not at all by dexamethasone-agarose (though
dexamethasone is a substrate), may possibly also reflect a
'cofactor first' binding order. By analogy with other de¬
hydrogenases (e.g. lactate dehydrogenase [46]), these findings
collectively suggest that a compulsorily ordered ternary complex
mechanism may operate for ll/?-HSD2, with NAD" binding
first. Further studies of these matters will assist in mapping the
active site and in the design of drugs specifically to inhibit, or
possibly constitutively activate, ll/?-HSD2.
This work was supported by an MRC Training Fellowship (R.W.B.; grant no.
G84/2857), and grants from The Wellcome Trust (J.R.S.) and The Scottish Hospital
Endowments Research Trust. We thank Douglas Lamont for sequencing the 11/?-
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Cloning and production of antisera to human placental 11/Miydroxysteroid
dehydrogenase type 2
Roger W. BROWN*§, Karen E. CHAPMAN*, Yuri KOTELEVTSEV*}, Joyce L. W. YAU*, Robbie S. LINDSAY*, Lawrence BRETTf,
Caroline LECKIE*, Parvez MURAD*, Val LYONS*, John J. MULLINSJ, Christopher R. W. EDWARDS* and Jonathan R. SECKL*
University Departments of 'Medicine and fPathology, Western General Hospital, Edinburgh EH4 2XU, and JThe Centre for Genome Research, Edinburgh, Scotland, U.K.
By inactivating potent glucocorticoid hormones (Cortisol and
corticosterone), l l/?-hydroxysteroid dehydrogenase type 2(11 /?-
HSD2) plays an important role in the placenta by controlling
fetal exposure to maternal glucocorticoids, and in aldosterone
target tissues by controlling ligand access to co-localized gluco¬
corticoid and mineralocorticoid receptors. Amino acid sequence
from homogeneous human placental 11/AHSD2 was used to
isolate a 1897 bp cDNA encoding this enzyme (predicted Mr
44126; predicted pi 9.9). Transfection into mammalian (CHO)
cells produces 11/7-HSD2 activity which is NAD+-dependent, is
without reductase activity, avidly metabolizes glucocorticoids
(Km values for corticosterone, Cortisol and dexamethasone of
12.4+1.5, 43.9 + 8.5 and 119+15nM respectively) and is inhi¬
bited by glycyrrhetinic acid and carbenoxolone (IC50 values
10-20 nM). Rabbit antisera recognizing 11/J-HSD2 have been
raised to an 1 l/?-HSD2-(370-383)-peptide-carrier conjugate.
Recombinant ll/?-HSD2, like native human placental 11/?-
HSD2, is detectable with affinity labelling and anti-1 l/?-HSD2
antisera, and appears to require little post-translational proces¬
sing for activity. ll/?-HSD2 mRNA (~ 1.9 kb transcript) is
expressed in placenta, aldosterone target tissues (kidney, parotid,
colon and skin) and pancreas. In situ hybridization and immuno-
histochemistry localize abundant ll/?-HSD2 expression to the
distal nephron in human adult kidney and to the trophoblast in
the placenta. 1 l/?-HSD2 transcripts are expressed in fetal kidney
(but not lung, liver or brain) at 21-26 weeks, suggesting that an
1l/?-HSD2 distribution resembling that in the adult is established
by this stage in human development.
INTRODUCTION
Placental 1 l/?-hydroxysteroid dehydrogenase (ll/?-HSD) meta¬
bolizes the potent glucocorticoids Cortisol and corticosterone to
inert 11-dehydro products (cortisone and 11-
dehydrocorticosterone respectively) and thus protects the fetus
from the deleterious effects of the higher glucocorticoid levels in
the maternal circulation [1,2]. This protective placental enzyme
barrier is very efficient so that almost all maternal Cortisol is
inactivated [3], ensuring that in late gestation the majority of
Cortisol reaching fetal tissues is derived from the fetal adrenals
[4], A relative deficiency of this enzyme in both rats and humans
correlates with low birth weight [5,6]. Moreover, administration
of the 1 l/?-HSD inhibitor carbenoxolone to pregnant rats results
in offspring with reduced birth weight and hypertension in
adulthood (R. S. Lindsay, R. M. Lindsay, C. R. W. Edwards
and J. R. Seckl, unpublished work). These effects parallel the
well documented human epidemiological association between
low birth weight and hypertension in adult life [7].
The 11/i-HSD activity in placenta (ll/?-HSD2) is due to an
isoform distinct from the previously characterized bi-directional
NADP(H)-dependent enzyme (11 /7-HSD1) originally purified
from liver [8]. Thus placental 1 l/?-HSD2 has a higher affinity for
glucocorticoid, is NAD+-dependent and acts as an exclusive 11/?-
dehydrogenase (always inactivating glucocorticoids) [9], Closely
related or identical ll/?-HSD2 enzyme activities have been
described in rabbit renal cortical collecting duct cells [10], renal
tissue from other species [11], and several human fetal tissues
[12], This enzyme activity in the distal nephron excludes gluco¬
corticoids from otherwise non-selective mineralocorticoid recep¬
tors, so producing aldosterone selectivity in the face of a 1000-
fold molar excess of circulating Cortisol [13,14], In the accom¬
panying paper [15] we report the purification to homogeneity of
human placental ll/?-HSD2. Here we describe the isolation of a
cDNA clone encoding human placental ll/?-HSD2, the tissue
distribution of the corresponding mRNA and studies examining
the characteristics of the expressed protein and enzyme activity.
In addition, we have raised antisera allowing the detailed
localization of the ll/?-HSD2 protein.
EXPERIMENTAL
Materials
3H-, 35S- and 32P-labelled compounds, Hybond N and Hybond
enhanced chemiluminescence (ECL) membranes, Hyperfilm
Bmax , Sequenase v2 and the ECL Western blotting systems were
purchased from Amersham International (Little Chalfont,
Bucks., U.K.). Ascl was obtained from New England Biolabs
(Hitchin, U.K.). PGEM-1 lzf( + )plasmids, micrococcal nuclease-
treated canine pancreatic microsomes (cat. no. Y4041) and other
restriction enzymes were obtained from Promega (Southampton,
U.K.). Synthetic oligonucleotides were synthesized by Oswel
DNA Service (Edinburgh, Scotland, U.K.). DNA size markers
(1 kb ladder), Lipofectin, media and reagents for tissue culture
were purchased from Gibco-BRL (Paisley, Scotland, U.K.).
Abbreviations used: 11 /?-HSD(2), 11/?-hydroxysteroid dehydrogenase (type 2); SAME, syndrome of apparent mineralocorticoid excess; ECL,
enhanced chemiluminescence; RT-PCR, reverse transcription-PCR; UTR, untranslated region; TBS, Tris-buffered saline; DHEA(S), dehydro-
epiandrosterone sulphate; SCAD, short-chain alcohol dehydrogenase.
§ To whom correspondence should be addressed.
The nucleotide sequence data reported have been submitted to the Genbank/EMBL/DDBJ Nucleotide Sequence Databases under accession no.
U26726.
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Vectastain Elite ABC and DAB reagent system for immuno-
histochemistry was purchased from Vector Laboratories
(Peterborough, U.K.). Reagents and molecular biology grade
chemicals were purchased from Sigma Chemical Co. (Poole,
Dorset, U.K.).
Degenerate primer PCR and cloning of 11/FHSD2 fragment
Tissue was snap-frozen and RNA was extracted as described
[16]. RNA was treated with DNase I, re-extracted to remove any
contaminating genomic DNA and reverse transcribed using the
Promega Reverse Transcription system (cat. no. A3500) ac¬
cording to the manufacturer's instructions. Inosine-containing
degenerate primers were designed based on the amino acid
sequence of five 11/J-HSD2 tryptic peptides: A. B, B2, C and D
(t = top strand, b = bottom strand) [15]. The primers from
peptides B and C generated the most useful results and had the




3'; Cb, 5'-AGCICCIA(A/G)IIlIGG(A/G)TAIGGCAT-3'. In¬
itial screening used the following protocol. A 5 jA sample of
human placental cDNA was heated, under mineral oil, at 96 °C
for 10 min and placed on ice. The reaction mixture was then
added in a volume of 45 /tl to give a final reaction mix containing
70 pmol of each degenerate primer, 50 //mol of dNTP and 2 units
of Taq polymerase in 1 xPCR buffer (Promega, Southampton,
U.K.). Reactions were placed into a thermal cycler (HB-TR1;
Hybaid, Teddington, U.K.) with the block held at 90 °C and the
programme commenced: 5 cycles of 60 s at 95 °C, 45 s at 43 °C,
43 -> 55 °C at 1 °C/3 s and 90 s at 72 °C, followed by 35 cycles of
60 s at 95 °C, 60 s at 50 °C and 90 s at 72 °C, and finally 10 min
at 72 °C. Subsequently a specific DNA product (of 531 bp) was
efficiently amplified using the Ct/Bb primer pair and the following
programme: five cycles of 60 s at 95 °C, 60 s at 47 °C, 47 —> 50 °C
at 1 °C/5 s, 50 -► 55 °C at 1 °C/2 s and 150 s at 72 °C, followed
by 40 cycles of 60 s at 95 °C, 60 s at 50 °C, 50 -> 55 °C at 1 °C/s
and 150 s at 72 °C, and finally 10 min at 72 °C. This allowed
the 531 bp product to be directly cloned into pCRII (TA
Cloning system v2; Invitrogen, San Diego, CA, U.S.A.: cat. no.
K2000-01) to yield clone pCRIICtBb.
PCR screening of a pcDNAI human placental cDNA library
Specific PCR primers nested within this 531 bp fragment were
designed [top primer (SCt), 5'-ATCCGTGCTTGGGGGCCTA-
TGGAACCT-3'; bottom primer (SBb), 5'-CTGCAGTGCTCG-
AGGCAGACAGTGACT-3']. These produced a strong band of
the expected size (455 bp) as the only product amplified by
reverse transcription (RT)-PCR of human placental RNA. A
human placental cDNA library in pcDNAI (Invitrogen; A900-
11) was then screened by increasing dilutions using this 455 bp
product to detect positive pools and adapting the PCR screening
method of [17] for use with plasmid libraries. Other specific
primers were used to cross-check positives. PCR with one primer
to the pcDNAI vector arm and the other to the insert was used
to estimate clone insert size. A partial 11/7-HSD2 clone was
isolated. On re-screening only one clone (>1.9 kb) long enough
to be full length [with coding region (40000-Mr protein) plus 3'
untranslated region (UTR) being 5: 1.7 kb] was found, but this
produced no 11/7-HSD activity on expression in CHO cells.
Screening of a 7.DR2 cDNA library
A ADR2 human placental cDNA library (Clontech, Palo Alto,
CA, U.S.A.; HL1144x), with a higher proportion of longer
cDNA inserts, was screened by conventional means using the
incomplete 11/5-HSD2 sequence isolated from the pcDNAI
library. Briefly, 700000 plaques were plated and duplicate filter
lifts were made, denatured, fixed, rinsed, dried and UV cross-
linked before hybridization in SSC/formamide buffer (6 x SSC,
50 % formamide, 5 x Denhardt's solution, 0.5 % SDS, 100 /tg/ml
salmon sperm DNA) with random primed [32P]dCTP-labelled
probe from the incomplete 11^-14802 sequence. Washes were
SSC/SDS-based, finishing with one 15 min wash at 65 °C in
0.2 x SSC/0.1 %SDS. Positives from the primary screen were
purified by a secondary screen at low density. Secondary positives
were converted from phage (ADR2) to plasmid (pDR2) clones by
means of the endogenous CRE/LOX recombinase of the host
bacterial strain (Escherichia coli AMI) [18] and were tested for
11/THSD2 enzyme activity by transfection into CHO cells, as
described below. Nucleotide sequences were determined fol¬
lowing sequencing of both strands by the dideoxy termination
method using Sequenase v2 (Amersham/USB).
Nucleic acid and protein sequence analysis
The 11 /J-HSD2 cDNA sequence and predicted 11 /J-HSD2 protein
sequence were analysed using the computing facilities at the
HGMP Resource Centre (Cambridge, U.K.) [19], specifically
PredictProtein [20] and the GCG package [21]. Protein secondary
structure was predicted by three methods, according to (1)
Chou-Fasman as amended for overall structure probability
[22,23], (2) Garnier-Osguthorpe-Robson [24], (3) and Rost-
Sander [20], The features described are for regions where there
was no disagreement in predictions, while Figure 2 (middle panel)
also extends illustration to areas (grey regions) with complete
concordance between two predictions and where the third
'dissenting' prediction is not in complete agreement. Assessment
of hydrophobicity was based on the Kyte-Doolittle index [25],
while prediction of flexible and exposed/buried regions was
according to the methods of Karplus-Schulz [26] and Emini et al.
[27] respectively. Estimates of percentage identity in nucleic acid
and protein alignments used the GAP algorithm [21] with
standard settings of gap weight = 3 and length weight = 0.1 for
protein alignment.
In vitro translation
The 11/THSD2 cDNA was subcloned into pGEM-llzf oriented
so that the 5' end of the cDNA was adjacent to the vector T7
promoter. In vitro translation was performed with a T7 poly¬
merase driven, rabbit reticulocyte-based, coupled transcription/
translation system (TNT lysates; Promega; L4610), to which a
methionine-deficient amino acid mixture and [35S]methionine
were added. In a standard volume of 25 /A, 0.5 /ig of subcloned
11/THSD2 plasmid DNA was added. Microsomal co-
translational processing was examined by including 0-4.5 /tl of
micrococcal nuclease-treated canine pancreatic microsomes in
the standard 25 /tl incubation at 30 °C for 90 min. Control
reactions to verify signal peptide cleavage (0.1 /tg of E. coli /?-
lactamase mRNA) and glycosylation (0.1 fig of Saccharomyces
cerevisiae a-factor mRNA) activities of the microsomes were
carried out in parallel. For autoradiography, 0.05-5 /tl of each
reaction was run per lane on SDS/PAGE, stained with
Coomassie Blue, processed in Entensify fluoroautoradiography
solutions (NEN/DuPont, Stevenage, U.K.), dried and exposed
to Kodak X-OMAT AR film.
CHO cell transfection
CHO cells were maintained in Dulbecco's modified Eagle's
Cloning of human placental 11/?-hydroxysteroid dehydrogenase type 2 1009
medium supplemented with 15% fetal calf serum, 100 units/ml
penicillin, 100/fg/ml streptomycin and 200 mM glutamine. At
24 h prior to transfection cells were seeded on to dishes at a
density of 2 x 106 cells/100 mm plate. For transfection, 5 fig of
DNA (in 800 /tl of Optimem) was mixed with 42 //l of Lipofectin
(in 800 fd of Optimem) and incubated for 15min at room
temperature. Optimem was added to 10 ml and the mixture was
gently overlaid on to cells which had been washed in Optimem.
After 24 h the Optimem/DNA mix was removed and replaced
with normal medium. Cells were harvested 24 h later. The human
placental 11/J-HSD2 cDNA was transfected into cells using the
clone (in pDR2) isolated from library screening and there were
appropriate controls for transfection efficiency. Assays of 11/J-
HSD activity were either with intact cells ([3H]steroid added to
the medium within the last 24 h, as described [28]) or using
homogenates of scraped cells (as below).
Kinetic and inhibitor studies
CHO cells were scraped, homogenized [2 x 106 cells/0.5 ml of
Buffer C (0.02 M Tris, pH 7.7, 10% glycerol, 1 mM EDTA,
300 mM NaCl)], centrifuged briefly (15000 g, 15 s to pellet heavy
debris, and the supernatant assayed for protein concentration
and 11 /?-HSD2 activity essentially as described [15]. 11/7-HSD2
assays contained 400 /;M NAD/ unless otherwise stated, and
were analysed by HPLC when the [:iH]steroid concentration was
> 2.5 nM; TLC-based analysis was also used at [;iH]steroid
concentrations < 5 nM. Reaction products were identified
(HPLC and TLC) by comparison with steroid standards run in
parallel. Incubations were for 60 min (120 min for dexametha-
sone). Kinetic parameters were calculated from the initial-
velocity determinations, obtained with experiments performed
with a wide range of substrate concentrations (0.3, 0.4, 0.8, 1.5,
2, 3, 4, 8, 15, 20, 40, 80 and 150nM [3H]steroid, with 80 and
150 nM omitted for corticosterone). Enzyme concentrations
giving less than 30% conversion were used. Control ('vector-
only' transfected cells) and blank assays were carried out in
parallel.
11/?-HSD2 photoaffinity labelling
This was carried out as described in the accompanying paper
[15], with the labelling performed at 0 °C. Transfected cells were
homogenized, briefly centrifuged (1000 rev./min x 15 s) to pellet
lumpy debris, and the supernatant labelled at 0.25 mg of
protein/ml. Labelling reactions of the placental 25000 # pellet
(at ~0.15mg of protein/ml) were run in parallel. The post-
labelling samples were acetone-precipitated and analysed by
electrophoresis (SDS/PAGE) and fluoroautoradiography.
Northern hybridization
Adult human tissue samples were obtained at surgery, frozen
within 10 min and stored at —80 °C. Most samples were normal
tissue removed adjacent to a tumour on resection; this was the
case for kidney (with adjacent adrenal), parotid, colon (splenic
flexure), breast (with adjacent skin and dermis) and stomach
(with distal oesophagus). Normal ovary (pre-menopausal) was
obtained at hysterectomy. Pancreas was an unaffected area in a
pancreatic tail resected for chronic pancreatitis. Liver was from
a partial hepatectomy in a young woman to remove a hepatic
cyst (benign). Placenta was from a normal delivery. Regions of
a normal human brain obtained post mortem (36 h) were also
dissected. RNA was extracted as described [16], separated on
denaturing agarose/formaldehyde gels (~ 10 //g/lane) and blot¬
ted on to Hybond N membrane (Amersham). A human multiple
tissue Northern blot was purchased from Clontech (7756-1).
Highly purified poly(A) RNA (2 /<g) from fetal tissues [brain,
lung, liver (female) and kidney] recovered following spontaneous
abortions (at least two specimens pooled for each organ) were
run in each lane and blotted. The exact age ranges were: fetal
brain, 21-26 weeks; fetal lung, 22-23 weeks; fetal liver, 22-26
weeks; fetal kidney, 19-23 weeks. Blots were hybridized with a
randomly primed 32P-labelled p 11 /?2 Ascl-Dral fragment (bases
217-1737; see Figure 2) at 55 °C overnight in hybridization
buffer (0.2 M sodium dihydrogen phosphate, 0.6 M disodium
hydrogen phosphate, 5 mM EDTA, 6% SDS and 100/tg/ml
denatured herring testis DNA). Washes were SDS/SSC-based,
finishing with 0.1 x SSC/0.1 % SDS at 65 °C followed by auto¬
radiography ( — 70 °C; 3-8 days).
In situ hybridization
Cryostat sections (10/rm) were cut from frozen samples of
human kidney (normal tissue from the opposite pole to a discrete
renal cell carcinoma) obtained at surgery and normal placenta.
Sections were mounted on to gelatin- and poly(L-lysine)-coated
slides, and stored at — 80 °C. Slides were post-fixed in 4%
paraformaldehyde, washed in 2 x SSC and incubated with pre-
hybridization buffer for 3 h at 50 °C, as previously described [29],
before hybridization with SP6-transcribed [35S]UTP-labelled anti-
sense cRNA probes from A&al-linearized pCRIICtBb (531 bp of
pi l/?2; bases 654-1184; dashed box in Figure 2, top panel).
Sense controls used T7-transcribed cRNA primed from Hindlll-
linearized pCRIICtBb. RNA probes were denatured, added at a
final concentration of 10 x 106 c.p.m./ml in hybridization buffer,
applied to slides as described [29] and incubated overnight at
50 °C. Following hybridization, sections were rinsed twice in
2 x SSC, treated with RNase A (30 /fg/ml, 60 min, 37 °C), and
washed to a maximum stringency of 0.1 x SSC at 60 °C for
60 min. After dehydration in increasing concentrations of ethan-
ol, slides were exposed to autoradiographic film (Hyperfilm
Bmax). Slides were dipped in photographic emulsion (NTB-2;
Kodak) and exposed in a light-tight box (D19; llford) for 5
weeks, before being developed and counterstained with 1 %
pyronin.
Raising of antisera and immunohistochemistry
Solid-phase synthesis of an 11/7-HSD2 peptide
HCLPRALQPGQPGT (residues 370-383; see Figure 2) with
high predicted antigenicity was carried out. The peptide was N-
terminally coupled to keyhole limpet haemocyanin and rabbits
were inoculated with the conjugate in Freund's adjuvant, boost¬
ing monthly. Antisera highly specific for 1 1/LHSD2 and reacting
to the peptide were obtained after the fourth boost. Western
blots were performed with the 11/LHSD2 antisera, at 1:10000
dilution (as primary antibody), using the Amersham ECL system
and methods recommended by the manufacturer.
Immunohistochemistry including pre-absorption with excess 11/7-
HSD2-(370-383)-peptide antigen
Sections of human tissue, stored at —80 °C, were thawed into
neutral formalin fixative (for 8 h), paraffin-processed and 4 /tm
sections cut. After drying, sections were dewaxed, hydrated and
treated in 3 % H20, (20 min) and blocked with 20 % sheep serum
in TBS (Tris-buffered saline, pH 7.6, with 1 % BSA and 0.1 %
sodium azide). This diluent was also used for primary and
secondary antibodies. Immunostaining, using an avidin-biotin
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complex (ABC) method at room temperature, was as follows:
primary antibody (1:2000), 30 min; TBS wash; secondary anti¬
body [1:400 biotinylated sheep anti-rabbit F(Ab)2 fragments;
Boehringer Mannheim, Lewes, W. Sussex, U.K.], 30 min; TBS
wash; Vectastain ABC Elite reagent, 30 min; diaminobenzidine
substrate/chromagen reagent, 5 min. Sections were counter-
stained in Mayer's haematoxylin, dehydrated, cleared and
mounted. Primary antibody preparations used were (a) 11/?-
HSD2 antisera, (b) preimmune serum from the same rabbit and
(c) 11/7-HSD2 antisera pre-absorbed for 16 h with 11/7-HSD2-
(370-383)-peptide at 50 fig per ml of diluted antibody. Both (b)
and (c) were used as controls for (a).
RESULTS AND DISCUSSION
Cloning of 11/7-HSD2 from human placenta
Degenerate primers (based on five 11/7-HSD2 tryptic peptide
sequences, both strands) were used in all pairwise combinations
in an initial RT-PCR screen carried out on human placental
mRNA. Combinations involving primer Bb resulted in the
amplification of several particularly prominent DNA products,
the majority of which appeared to be independent of the top
primer used (Figure 1, lanes 1-4), and indeed PCR with Bb alone
reproduced many of these bands. A clear exception was the PCR
product arrowed in Figure 1 (lane 2); this was specific to the
CtBb primer pair and became the major product (Figure 1, lane
5) using more stringent PCR conditions. This CtBb fragment
was directly cloned and sequenced, revealing a single open
reading frame spanning its length (531 bp) and with a predicted
amino acid sequence encompassing four ll/?-HSD2 peptides (C,
B, A and B3), including a short-chain alcohol dehydrogenase
(SCAD) motif (YXXXK; see below). This CtBb fragment was
used (a) to design a synthetic peptide to raise antisera (see below)
and (b) to isolate a complete ll/?-HSD2 cDNA.
A human placental cDNA library in pcDNAl was initially
screened by a PCR-based approach and a 1177 bp partial clone
isolated (Figure 1, lane 7) which contained the CtBb fragment,
45 bp further 5' and 603 bp further 3' [reaching to the 3' end of
the cDNA with a 22 bp poly(A) tail]. Conventional screening of
700000 plaques from a human placental DR2 library (Clontech),
using the incomplete ll/?-HSD2 sequence as a probe, allowed
isolation of a single clone which, when converted to a pDR2
plasmid form (see the Experimental section), produced very
abundant, NAD+-dependent, ll/?-HSD2 activity in transfected
CFIO cells. This clone was designated pi 1/72.
Characteristics of the cDNA clone and predicted 11/FHSD2
protein sequence
General features of the 11/J-HSD2 cDNA clone
This active 1 l/?-HSD2 clone, pi l/?2, contained a 1897 bp cDNA
with 22 bp poly(A) tail (1919 bp total), and has a G +C-rich
composition (63.25%). The 5' end of the cDNA (first ~ 385
bases) is extremely G +C-rich (79.2%) and contains a 'CpG
island' [30] with 56 occurrences (in 385 bases) of this usually
scarce dinucleotide. The G + C and CpG content falls abruptly
beyond this region (to 55 % G + C; CpG frequency falls 4-fold).
These features, which extend to the start of the 11/MTSD2
cDNA, are suggestive of a 5' transcription regulatory region. The
best candidate for initiation of translation is the ATG codon
beginning 134 bases from the 5' end of the cDNA (set to +1 in
Figure 2, top panel); this is in a good context for initiation of
translation, with 9/10 matches to the putative ideal ribosome
binding site (GCCGCCATGG) [31], and is within the longest
open reading frame ( — 63 -> +1215; Figure 2), defining a pre¬
dicted coding region of 1215 bp (+!—*• +1215), flanked by a 5'
UTR of 133 bp (-133 - — 1) and a long 3' UTR of 549 bp
(+1216 -> + 1764). The predicted coding region encodes a 405-
amino-acid protein (calculated Mr 44126) encompassing all the
1 l/?-HSD2 peptide sequence derived from digests of the purified
protein [15] (boxed in Figure 2). The most abundant amino acids
are leucine (68 residues in ll/?-HSD2), alanine (46) and glycine
(32), which are all highly represented in proteins in general,
followed by proline (32) and arginine (30). The high arginine
content seems responsible for the very basic nature of the 11/7-
HSD2 protein, so clear during purification, as basic residues
(Arg = 30, Lys = 12, His = 7) markedly outnumber acidic ones
(Asp = 15, Glu = 15), giving a predicted net positive charge
(+19) and a very basic predicted isoelectric point of 9.92 for the
ll/?-HSD2 polypeptide. Nine cysteine residues are present, one
of which occupies the position at which a blank cycle resulted on
sequencing of an 11/7-HSD2 peptide (cycle 15, peptide C) [15],
suggesting that this residue may be particularly reactive or
modified in the native protein.
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Figure 1 PCR to amplify 11/7-HSD2 sequences
Ethidium bromide-stained agarose gels showing analysis of PCR amplifications. Lanes 1-5, RT-
PCR on human placental mRNA using degenerate primers based on 11 /7-HSD2 peptide
sequences A-D. Primers used (Xt = top; Xb = bottom; X = peptide) are indicated above the
corresponding lane. Lanes 1-4, initial PCR conditions used; lane 5, more stringent amplification
used, yielding only the CtBb specific product (531 bp) identified initially (arrowed, lane 2). Lanes
6 and 7, PCR (using vector-specific primers flanking the cloning sites) of 11/7-HSD2 inserts
of a 1179 bp partial pcDNAl library clone [1157 bp+ 22 bp poly(A); lane 7] and the 1919 bp
[1897 bp+ 22 bp poly(A)] pDR2 clone containing the full coding region (lane 6). Lanes L, 1 kb
ladder (Gibco—BRL.)
Detailed analysis of the predicted structure of the 11/?-HSD2 protein
Analysis of the primary structure (Figure 2, top panel) and the
predicted secondary structure (Figure 2, middle panel) of the
11/7-HSD2 protein suggests four distinct regions. The most N-
terminal region (region I) begins with an exposed loop (Met-
l-Gly-9) followed by a very leucine/alanine-rich area (60% of
residues 11-73). This has some incomplete repeats
(AALALLAAL; residues 36-44; close variants beginning at
residues 16 and 56) and appears likely to have secondary structure
broken by helix-breaking residues (Gly-31 and Pro-33; Pro-
53-Pro-54-Pro-55) into three buried, predicted a-helical, seg¬
ments centring on residues 16-22, 35-41 and 63-69 respectively.
The region has imperfect heptad symmetry, and in such a
secondary structure is likely to form a particularly hydrophobic
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face along which leucines align, there being two such potential
axes: (1) L14-L21-L28-L35-A42. stretching around to the nearby
helical face L13-L20-D27-L34-L41. and (2) reaching further
C-terminal in the region L23-L30-A37-L44-L51-L58-G65-L72.
On the helical aspect opposite to these axes all seven positively
charged residues in the area line-up: R18-R25-R32—R74 and
R29-R50-R71. Such a structure is suggestive of a domain with
a leucine-zipper-like tendency to form protein-protein inter¬
actions (often dimerization) along the hydrophobic axes.
The second region (region II), which unlike the rest of the
protein has predicted secondary structure rich in //-sheets,
contains three motifs characteristic of members of the SCAD
superfamily. Firstly, the putative cofactor-binding site motif
(V/I)TGXXXGXG is present (ITGCDSGFG; residues 87-95)
in an area with secondary structure predicted to incorporate
buried /?-sheet (residues 84—88), buried loop (89-92) and an
exposed helix (96-102). Secondly a 'substrate positioning' motif,
noted in previous alignments of SCAD enzymes [32], which is of
the form [LFVM][VI][NL][N][AVH(F)][GI], is present
(LVNNAG; residues 164—169). The major predicted features of
this substrate positioning area are an exposed loop (residues
156—160)/buried /J-sheet (161-166 + ) being preceded by an a-
helix (centred on residues 145-152) and exposed flexible region
likely to loop around Pro-142-Gly-143. Thirdly, the putative
catalytic motif YXXXKX(SAG) is present (YGTSKAA;
residues 232-238). This motif, which is predicted to form a small
loop around Gly-233, is in the centre of a stretch predicted to
have flanking areas consisting of loop -> buried /5-sheet -> loop
structures (at 211-223 and 252-264). A long hydrophobic a-helix
(residues 236-250) bridges the motif-loop/sheet/loop stretch to
the C-terminal side; however, the secondary structure is unclear
for the region (residues 224-231) bridging between the motif and
the loop/sheet/loop on the N-terminal side. The equivalent of
this 'upstream bridging region' in the related SCAD enzyme
3a,20/?-HSD was shown to be part of the steroid substrate
(cortisone) binding pocket in X-ray crystallographic studies [33],
Region III (residues 275-370) has three positively charged
segments, EKRKQ, ARPRRRY and LRRRF (residues 277-281,
332-338 and 358-362 respectively). Such segments may form
charge interactions with negatively charged molecules or exert
electrostatic influence on a substrate. In the context of a
membrane protein, interactions with phospholipids helping to
stabilize or anchor the protein are particularly likely and often
occur adjacent to helical transmembrane domains (e.g. glyco-
phorin [34]). Indeed most of the region between the charged
segments has predicted helical secondary structure, especially
residues 274-294, 298-312 and 324-331.
Finally region IV, the C-terminal region, is proline/glycine-
rich (36 % of residues 373—405) and is predicted to form a flexible
area with several exposed loops. It contains the only potential N-
glycosylation site in 1l/?-HSD2. The potential for glycosylation
at this motif is weakened as it is flanked by prolines. Moreover,
amino acid sequencing yields across the B peptide (Figure 2)
suggested that Asn-394 was largely unglycosylated in the native
protein from human placenta [15].
Although much of the secondary structure can be predicted
with some certainty, there are important aspects of the higher-
order structure of 11//-HSD2 that are unclear. As ll/?-HSD2 is
an intrinsic membrane protein from a family ofenzymes (SCADs)
thought usually to be tetrameric in the native form, it probably
contains both transmembrane segments and dimerization inter¬
faces. The N-terminal leucine/alanine-rich region (residues
11-73) may potentially fulfil either role, whereas the helical/
charge cluster region (residues 275-370) contains predicted
hydrophobic helical segments which are good candidates as
possible transmembrane regions. Dimerizing elements outside
the N-terminal region seem likely, as a number of other SCADs
which lack such a region have been demonstrated to form
tetramers. Figure 2 (middle panel) also illustrates the secondary
structure of the related SCAD enzyme 3a,20/?-HSD as de¬
termined from X-ray crystallography studies. There is a very
striking similarity within region II (the SCAD region), with
almost all the major structural features from /?A-/?F of 3a,20/?-
HSD being represented clearly in the predicted 11 /T-HSD2
structure [the only exception being that /?B corresponds to a
segment of 11//-HSD2 (residues 104-109) with uncertain sec¬
ondary structure]. Studies on 3a,20/?-HSD have identified areas
involved in steroid and cofactor binding and in dimerization;
some of the corresponding regions in lI/?-HSD2 may have
similar functions The dimerization interfaces of 3a,20/?-HSD
include the the region between the LVNNAG and YXXXK
SCAD motifs (aE-/?E-aF) and the most C-terminal /?-sheet
element (/iG) [33],
Sequence similarities to human placental 11/7-HSD2
A search of sequence databases shows that the most clearly
related proteins are SCAD members (Figure 2, bottom panel),
the closest being microsomal NAD+-dependent human 17/?-HSD
type 2 [35] (38.9 % amino acid identity), retinal pigment epi¬
thelium NAD'-dependent bovine 1 l-c«-retinol dehydrogenase
(35.5% identity) and mitochondrial human NAD'-dependent
enzyme 3-hydroxybutyrate dehydrogenase [36] (32.6 % identity).
There is 28.3% identity to human 11//-HSD type 1 [37] (micro¬
somal; NADP'-dependent). Similarities of the four 1I/7-HSD2
regions (I IV) are shown in Figure 2 for these enzymes and
others with some functional similarity that are related to 11/?-
HSD2. The three SCAD motifs referred to above are highly
conserved, although the middle motif is atypical in 11/?-HSDl
and is shifted in relative position or absent in 3//-HSD2. This
latter enzyme appears to have the other two SCAD motifs in the
same orientation and with spacing typical of SCADs. This
highlights the fact that members of the bifunctional 3/i-HSD
family (which share high sequence identity and also have
ketosteroid isomerase activity) fit somewhat uncomfortably into
the SCAD superfamily, and it is unclear whether they should be
considered as SCADs or as a separate family. NAD'-dependent
11/7-HSD enzymes have been expression-cloned from kidney in
sheep [38] and human [39], The sheep kidney ll/?-HSD2 has
78.5% identity at the protein level (82.6% at the nucleic acid
level). Similarity is non-uniform across regions I-IV at both the
protein (Figure 2) and nucleic acid levels; thus sheep 1l/?-HSD2
has 94.2%, 88%, 80% and 65% identity with human 11/?-
HSD2 at the cDNA level in regions I-IV respectively. The 5'
UTR and most of the 3' UTR have ~ 70% identity; however,
this rises sharply again between bases 1536 and 1624 (Figure 2,
top panel) (91 % identity; reason unclear) and for sequences
adjacent to the polyadenylation motif aaataa (92%; bases
1731-1764; Figure 2). The human renal clone is similar, but not
identical, to the cDNA from placenta reported here. The renal
clone lacks the first 25 bases (— 133 —► — 109), has two deletions
in the 3' UTR (bases 1270 and 1495; Figure 2) and a base
substitution at 442 resulting in a change in the predicted amino
acid sequence of Val-148 -> Leu. At the points of difference, the
sequence reported above has been confirmed in cDNA that we
have sequenced derived from a second placenta, and the Val-148
residue is clearly present in human placental 1 l/?-HSD2 as it is
the first amino acid of the D peptide sequence derived from
purified 1 l/?-HSD2 tryptic digests. Although it is most likely that
these differences arise from polymorphisms, there may be isoform
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-90 acc ccc gca etc cgc gee ccg gee tag aag
1 M E R W P W P S G G
1 atq gag cgc tgg cct tgg ccg teg ggc ggc
31 G R P L L A A L A L
91 ggc cgc ccg ctg ctg gcg gcg ctg gcg ctg
61 L A A A G W I A L S
181 ctg gee gee gee ggc tgg ate gcg ttg tee
91 D S G F G K E T A K |_
271 gac tct ggt ttt ggc aag gag acg gee aag
121 A I E L R T C C S P
361 gee ate gag ctg cgt acc tgc tgc tee cct
151 F T K 1 A H T T S T G
451 ttc acc aag gee cac acc acc age acc ggc
181 P V A T F R S C M E |
541 cca gtg gee act ttc cgt age tgc atg
211 R G R I V T V G 1 s p
631_ agg ggc cgc ate act age cca
241 L L M D T F S c E L
721 eta etc atg gac aca ttc age tgt gaa etc
271 R 1 N V <? <? w E R 1 R K
811 aga aac gtg ggt cag tgg gaa aag cgc aag
301 E H L H G Q F L H S
901 gag cac ttg cat ggg cag ttc ctg cac teg
331 A A R P R R R Y Y P
991 gca get egg ccc cgc cgc cgc tat tac ccc
361 R F L Q A F F I S H
1081 cgc ttc ctg cag gee ttc ttc ate agt cac
feet etc ccc get
g acg aga gaa age gag tgt ccc tct cgc
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G D M P Y P CO L G A Y G T S K1 A A V A 240
ggg gac atg cca tat ccg tgc ttg ggg gee tat 22* acc tee aaa gcg gee gtg gcg 720
p W G V K 1 V S I I 2 P G C F K| T E S V 270
ccc tgg ggg gtc aag gtc age ate ate cag cct ggc tgc ttc aag aca gag tea gtg 810
L L L A N L P Q E L L Q A Y G K D Y I 300
ttg ctg ctg gee aac ctg cct caa gag ctg ctg cag gee tac ggc aag gac tac ate 900
R L A M S D L T P V V D A I T D A L L 330
cgc ctg gee atg tee gac etc acc cca gtt gta gat gee ate aca gat gcg ctg ctg 990
Q G L G L M Y F I H Y Y L P E G L R R 360
cag ggc ctg ggg etc atg tac ttc ate cac tac tac ctg cct gaa ggc ctg egg cgc 1080
L P Rl A L Q" P G Q P G T T P P Q D A A 390
ctg cct cga gca ctg cag cct ggc cag cct ggc act acc cca cca cag gac gca gee 1170
A V A R 405
gca gtg get egg tga gee atg tgc acc tat ggc cca gee act gca gca cag gag get 1260
age att acg ate ccc caa gtg tee tgg acc ctg gee taa aga ate cca ccc cca ctt 1350
tga ggc caa ggt ttc cca gtg age etc tgc gee tct cca ctg ttt cat gag ccc aaa 1440
tgg aga act ccg ctg gat ggg Gag tct cat gca aga ctt cac tgc age ctt tea cag 1530
gtg act agg tgg gtt ggg gac ccc etc agg att gtt tct egg cac cag tgc etc agt 1620
tga ctg get caa gaa tta ggg ccc caa eta cac acc ccc aag cca cag gga age atg 1710
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Figure 3 Labelling of native, expressed and in vitro translated 11/I-HSD2
protein
Lanes 1-3 and 9-11: affinity labelling with [3H]corticosterone of native human placental 11/?-
HSD2 from placental membrane fractions [PM; lanes 3 and 9; 20 and 80 yzg of protein loaded
respectively, from 25000# pellet (heavy microsomal and mitochondrial fraction)] and from
homogenates of CH0 cells (160 mg of protein/lane) transfected with 11/f-HSD2 cDNA (lanes
2 and 10) or with vector only (lanes 1 and 11). Lanes 4-8, products of coupled in vitro
transcription/translation of 11/7HSD2 cDNA (subcloned into pGEM11zf) in rabbit reticulocyte
lysates labelled with [35S]methionine in the presence of various amounts of microsomes
[indicated above lane: 0; + = 1.5/<l; + + = 3/4; + + + = 4.5/4 (excess)]. The
lysate volume loaded in lanes 4-8 was 0.5,1,1,1 and 0.1 yd respectively. The volume loaded
was varied to facilitate size comparison of the translated products and was needed to counter
the decrease in translation in the presence of higher microsome concentrations. The positions
of protein standards (10~3 x M) are indicated.
microheterogeneity similar to that observed with other steroid-
metabolizing enzymes, notably 3a-HSD (98.8 % identity) [40,41]
and 3/J-HSD (rat 3/?-HSD2 being 99.2% and > 93% identical
to 3/?-HSD2 male liver variant [42] and 3/J-HSD1 [43] re¬
spectively). The finding of polymorphisms that affect the 11/?-
HSD2 protein sequence is clearly of considerable interest, es¬
pecially if they are associated with a difference in steroid
metabolism. Placental ll/?-HSD2 has a Km for corticosterone
(see below; Table 1) virtually identical to that of the 1000-fold
purified native 1 l/?-HSD2 from placenta [9], The Km reported for
the renal clone is 3-fold lower (~ 4.4 nM), and it could be that
amino acid substitutions at residue 148 cause subtle alterations in
steroid-metabolizing activity by affecting the predicted a-helical
region of which it is part.
Expression studies with human placental 11/FHSD2 cDNA
Expression of 11/?-HSD2 protein
Expression of pll/?2 in CHO cells produced abundant 11/?-
HSD2 enzyme activity (see below), accompanied by the ex¬
pression of an ~ 40000-Mr protein which could be affinity-
labelled with corticosterone (Figure 3, lanes 2 cf. 1 and 10 cf. 11),
in a similar manner to the affinity labelling of 1 l/?-FISD2 from
crude placental subcellular fractions (Figure 3, lanes 3 and 9).
Coupled in vitro transcription/translation of 1 l/?-F!SD2 in rabbit
reticulocyte lysates (without microsomal processing) also pro¬
duced a protein (Figure 3, lanes 4 and 8) of similar size to 11/?-
HSD2 in placenta or expressed in CHO cells. Thus activity in
these tissues appears not to require major cleavages or large
covalent attachments. Addition of canine pancreatic microsomes
resulted in a small size increase and broadening of the protein
band, suggesting that co-translational processing, possibly in¬
volving glycosylation, was occurring (Figure 3, lanes 4-8).
Addition of increasing amounts of microsomes also resulted in a
reduced efficiency of translation (a standard finding with TNT
lysates); accordingly more sample was loaded (to facilitate size
comparison), and a minor band at ~ 31000-AF,. became visible.
It is unclear if this is a different, minor, translation product or the
result of ll/?-HSD2 proteolytic cleavage (processing or degra-
dative) occurring at a low level in the presence of these micro¬
somes. Clearly a range of processed states of ll/?-HSD2 is
demonstrated and may indicate the possibility of tissue-specific
co-translational processing depending on the activities within
host tissue microsomes. If cleavage to an ~ 31000-A/r form
occurs, this is likely to affect enzyme structure/function and
possibly its subcellular localization. Finally, although native
placental 1 l/?-HSD2 is most likely to be located in microsomes,
this is not confirmed by the presence of a classical C-terminal
microsomal retention motif [44,45], in contrast to the closely
related human 17/J-HSD2 [35],
Characteristics of expressed enzyme activity
Expression of the ll/?-HSD2 cDNA in CHO cells produced
high-affinity ll/?-HSD activity which had the expected charac¬
teristics of ll/?-HSD2 activity in placenta. This v#as exclusively
NAD*-dependent in cell homogenates (12 nM corticosterone
and 0.15 mg of protein/ml), showing 49% conversion with
400 /<M NAD+, whereas 400 /rM NADP+ produced no increase
over assay with no added cofactor (1.8%). No 11/?-reductase
activity was detected in homogenates of 1 l/?-HSD2-transfected
CHO cells, or in the medium of the intact cells (which metabolized
99 % of 25 nM [3H]corticosterone in 24 h). 11 -Dehydro products
were the only metabolites detected by HPLC. Thus after a 1 h
incubation of [3H]steroid (12 nM) with recombinant ll/?-HSD2
Figure 2 cDNA and predicted amino acid sequence of human placental 11/?-HSD2
Top panel: the cDNA numbering ( — 133 to +1764; shown on the left of the DNA sequence) sets +1 at the start of the predicted coding region (note that the 'no base zero' convention is
followed). The ATG initiation codon and polyadenylation motif are double-underlined. The broken line encloses the 531 bp CtBb fragment identified by RT-PCR (Figure 1, lane 5). Boxed sections
of predicted amino acid sequence are those of the 10 peptides sequenced from tryptic digests of purified human placental 11/J-HSD2; peptide nomenclature (small boxes) and numbering of the
amino acid sequence are to the side of the sequence (amino acid sequence numbers are underlined). Circled residues are Cys-227 (unidentifiable residue on amino acid sequencing of peptide
C) and Asn-394 (the only potential N-glycosylation site in 11/?-HSD2, probably unused in placenta). Middle panel: predicted secondary structure of human placental 11/?-HSD2 and that derived
from X-ray crystallography for 3a,20/?-HSD from Streptomyces hydrogenans [33], Segments represented as white (a-helix, above line; /?-sheet, below line) and black (loops; close to line) are
of the greatest certainty; grey segments are of moderate certainty and segments represented by a flat line cannot be predicted with even moderate certainty. Bottom panel: alignment of 12 enzymes
with sequence and functional similarity to human 11/?-HSD2. On the left, percentage amino acid identity with regions I—IV of human 11/?-HSD2 is indicated by larger-type numbers (small type
indicates amino acid residue numbers at the start of regions). On the right, alignment of three motifs highly conserved in SCADs, with (X)„ indicating that n amino acids separate the first residues
of the adjacent motifs (inclusive). Enzymes are: h11/?2 and s11/?2, human and sheep 11/?-HSD type 2 respectively; h17/?1/2/3, human 17/?-HSD types 1, 2 and 3; p17/?4, pig 17/7-HSD type
4; b11 retdh, bovine 11 -c/s-retinol dehydrogenase; h3hbdh, human 3-hydroxybutyrate dehydrogenase; hi 1 /?1, human 11 /J-HSD type 1; C.s7ahsd, 7a-HSD from Clostridium sordellii; 3a20/?hsd,
3a,20/?-HSD from Streptomyces hydrogenans-, pCarbred, pig carbonyl reductase; h3/?2, human 3/?-HSD type 2 (the adrenal/ovarian isoform).
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Table 1 Kinetic parameters of 11>9-HSD2 activity in cells transfected with
11/7-HSD2 cDNA
All values are based on at least 10 steroid concentrations; n = 5 at each concentration for
corticosterone and n = 2 for Cortisol and dexamethasone. Aldosterone was not metabolized.
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Figure 4 Studies on inhibition of 11/AHSD2
The extent to which a range of compounds inhibit the conversion of 12 nM [3H]corticosterone
by recombinant 11/?-HSD2 is shown. GA, glycyrrhetinic acid; CBX, carbenoxolone; A, 11-
dehydrocorticosterone; P, progesterone; E, cortisone; E2, oestradiol; DHEAS, DHEA sulphate.
Reactions were in the presence of 400 /zM NAD+, using homogenates (0.15 mg of protein/ml)
of cells transfected with 11/J-HSD2 cDNA. Values are means of four determinations, with
S.E.M.s < 4%.
(0.5 mg of homogenate protein/ml), > 95% of corticosterone,
63 % of Cortisol and 17 % of dexamethasone were metabolized,
whereas aldosterone was unaltered. There was no evidence of 5a-
or 5/7-reductase activity encoded by pll/?2.
Recombinant human placental 11/J-HSD2 has a high affinity
for glucocorticoid substrates, especially corticosterone (Table 1).
At corticosterone concentrations higher than 80 nM there ap¬
peared to be a degree of product/substrate inhibition. Exam¬
ination of 11/7-HSD2 inhibition (IC50 values) by a range of
steroids showed potent inhibition by glycyrrhetinic acid (11 nM)
and carbenoxolone (18 nM), with significant inhibition by 11-
dehydrocorticosterone (45 nM), progesterone (0.8 /zM) and cor¬
tisone (1 /zM), whereas there was little effect (> 30/zM) with
dehydroepiandrosterone (DHEA), DHEA sulphate, testosterone
and oestradiol (Figure 4). Affinity labelling studies (results not
shown) on transfected CHO cells indicated the same rank order
of potency in labelling [corticosterone P Cortisol P dexame¬
thasone (aldosterone = 0)] as indicated by their Km values
(Table 1) as 11/THSD2 substrates. A rank order of affinity as
substrate/inhibitor is thus suggested for placental 11/7-HSD2
of: glycyrrhetinic acid « carbenoxolone « corticosterone >11-
dehydrocorticosterone « Cortisol > dexamethasone > pro¬
gesterone x cortisone DHEA sulphates; testosterone « oestra¬
diol x DHEA x aldosterone. This rank order is very similar to
that determined for the type III corticosterone receptor sites
[46,47] and suggests that these sites are related to 11/7-HSD2, but
whether they are actually due to the 11/7-HSD2 protein remains
unclear. In late human gestation progesterone levels often rise to
0.3-0.5 /zM in the mother and > 1 /zM in the fetus [48]. Thus the
IC50 of progesterone for 11/THSD2 (0.8/zM) may signify a
potential influence of progesterone on corticosteroid action
during late pregnancy.
Distribution of 11/7-HSD2 mRNA and protein in tissues
11/7-HSD2 mRNA distribution
Northern analysis revealed a hybridizing ~ 1.9 kb transcript in
the placenta, aldosterone target tissues (kidney, colon, parotid.
Figure 5 Northern hybridization of 11/J-HSD2 cDNA in human tissues
Hybridization of RNA from a range of human adult (total RNA) and fetal [F.; highly purified poly(A) RNA] tissues with a random-primed human placental 11/J-HSD2 cDNA probe (bases 217-1737;
see Figure 2). Positions of fetal RNA markers and of 18 S and 28 S markers are indicated. Check-marks on left of the fetal-tissue blot correspond to the two mRNA species hybridizing, at ~
1.9 and — 4 kb. .
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Figure 6 11/7-HSD2 in situ hybridization in human kidney
In situ hybridization of sections of human kidney to human placental 11/7-HSD2 cRNA probes (sense and antisense to CtBb fragment; dashed box in Figure 2). The middle panel shows a light
field (silver grains = dark), whereas the other panels are dark field (silver grains = white). The left and middle panels are of the same section, the latter at a slightly higher magnification, whereas
the right-hand panel is of a neighbouring section from the same kidney slice (at higher magnification). The following are labelled: G, glomerulus; D, distal convoluted tubule; P, area with many
proximal convoluted tubules. Clearly 11/7-HSD2 mRNA is abundant in the distal nephron.
skin), pancreas and fetal kidney (Figure 5). There was also
hybridization to mRNA of a larger size (~ 4 kb) in fetal kidney.
Under these conditions there was no detectable hybridization to
RNA from liver, oesophagus, stomach, ovary, prostate, breast,
fetal lung, fetal liver or fetal brain, or from adult human brain
sub-regions (frontal cortex, cerebellum, hippocampus, hypo¬
thalamus, pons and medulla; results not shown). In situ hybrid¬
ization with 11/7-HSD2 cDNA on normal human adult kidney
(Figure 6) showed abundant 11/7-HSD2 mRNA expression
restricted to the distal nephron (distal convoluted tubule, cortical
collecting duct and medullary collecting ducts), with no specific
hybridization in other regions (glomerulus, proximal tubule,
etc.). Expression in the distal convoluted tubule extended to
loops participating in juxtaglomerular complexes. There was no
hybridization in sense controls. There was also abundant ex¬
pression of 11 /?-HSD2 mRNA in human placental trophoblast
(results not shown).
The nature of the — 4 kb 1 l/7-HSD2-hybridizing transcript in
fetal kidney is unclear. Interestingly, flanking duplications in¬
volving the genes encoding human steroid-metabolizing enzymes
are common (e.g. 17/J-HSD type 1, the 3/7-HSD family, 5a-
reductase type 1, 21-hydroxylase and 17/7-HSD type 4), and
duplicates are often transcribed, either as separate transcripts or,
in the case of 17/7-HSD4, as a large transcript traversing the
apparent gene duplication.
Immunohistochemistry
Antisera raised to a synthetic 11/7-HSD2 peptide (residues
370-383) coupled to keyhole limpet haemocyanin identified a
single strong protein band at ~ 40000-Mr in Western blots of
human placenta and kidney tissue extracts (Figure 7a). This was
also detected in CHO cells transfected with 11/7-HSD2 cDNA,
but not in untransfected controls. This band was not observed
when the antisera were preabsorbed with 1 l/?-HSD2-(370-
383)-peptide. An additional, much weaker, band was seen at
~ 70000-Mr in some kidney extracts. Immunohistochemistry on
human placenta revealed dense immunostaining of the tropho¬
blast (in the syncytiotrophoblast layer), but not the decidua
(Figure 7b). Very dense immunostaining in adult human kidney
(Figure 7c) was seen localized to the distal nephron (distal
convoluted tubule including juxtaglomerular loops, cortical and
medullary collecting ducts). In both tissues the immunostaining
was abolished by preabsorption with 1 l/7-HSD2-(370-383)-
peptide (Figures 7b and 7c). Neither tissue showed any immuno¬
staining using preimmune serum (results not shown).
In situ hybridization and immunohistochemistry demonstrated
abundant 11/7-HSD2 mRNA and protein in kidney in the location
expected (distal nephron) for 11/7-HSD2 to confer aldosterone
selectivity on mineralocorticoid receptors. 11/7-HSD2 expression
in the distal convoluted tubule extends into loops participating in
juxtaglomerular complexes. In placenta 11/7-HSD2 expression
was abundant in the syncytiotrophoblast lining the placental
villi, thus being at the very interface between the fetal tissue and
maternal blood, which flows in the intervillus spaces. This is
exactly the location which would allow 11/7-HSD2 the greatest
influence over the passage of maternal glucocorticoid to the
fetus.
Developmental expression
Two studies, using tissue slices from fetuses at 10-20 weeks
gestation [49] or adding NAD+ to tissue homogenates from
16-19-week fetuses [12], have found substantial levels of 11/7-
dehydrogenase activity in almost all human fetal tissues (in¬
cluding kidney, lung and brain). Fetal liver was found to have net
11/7-reductase in the first study and an NAD^-dependent 11/7-
dehydrogenase in the second. We found no 11/7-HSD2 hybrid¬
ization in fetal lung, liver or brain. As 11/7-HSD1 mRNA is
reported absent at least from fetal lung and liver [12], it is
possible that a third 11/7-HSD isoform is expressed in the fetus.
However, as our samples were from fetuses slightly later in
gestation it is possible that 11/7-HSD2 expression, while present
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Figure 7 Studies with antisera to human placental 11/?-HSD2-(370-383)-peptide
(a) Western blot using anti-11 /7-HSD2 antisera and blotted tissue subtractions (25000 g pellet; mainly heavy microsomes and mitochondria) from: CHO cells transfected with (lane 1) and without
(lane 4) 11/7-HSD2 cDNA, human placenta (lane 2) and human adult kidney (lane 3). Positions of protein standards are indicated, (b) and (c) Immunohistochemistry on (b) human placenta and
(c) human adult kidney with haematoxylin counterstaining (stains nuclei). Lower panels, antisera to human placental 11/?-HSD2-(370-383)-peptide; upper panels, control with antisera preabsorbed
with the 11 /?-HSD2-(370—383)-peptide. Panel (b) shows a high-power view of placental villi cut cross-sectionally. Fetal blood circulates in fetal capillaries (two are marked F) within the villi, maternal
blood occupies the intervillus space (marked M), and abundant 11 /7-HSD2 expression is localized in the syncytiotrophoblast layer (T) which intervenes between the fetal and maternal circulations.
Panel (c) shows a medium-power view of human kidney cortex. The following are labelled: G, glomerulus; D, distal convoluted tubule; P, area with proximal tubules; C, cortical collecting duct.
Clearly the 11/J-HSD2 protein is abundant in the distal nephron.
during early gestation, is switched off in many fetal tissues (the
kidney being a clear exception) at mid-gestation (specifically
before 22-23 weeks in lung, 22-26 weeks in liver and 21-26 weeks
in brain). Indeed, our preliminary studies on mouse development
support this pattern of expression (R. W. Brown, R. Diaz and J.
R. Seckl, unpublished work). The mechanism of such devel¬
opmental control is unknown but, interestingly, it seems that a
CpG island may be associated with 5' regulatory regions of the
11/J-HSD2 gene, since: (1) the CpG island extends to the very
start of the 1l/?-HSD2 clone, (2) from the 1l/?-HSD2 transcript
size on Northern blots it appears that the pi 1/52 clone must be
approximately full length (although we have not precisely map¬
ped the start site) and (3) CpG islands are large (typically > 1 kb)
and often include the most 5' exon as well as upstream sequences
[30]. This is intriguing because CpG islands are often methylated
in tissues where the gene is not expressed. Silencing of the
expression of genes with 5' CpG islands may be associated with
methylation of the CpG island. Whether a regulatory influence
of this kind occurs in the 11//-HSD2 gene remains to be
elucidated. Work on baboon pregnancy suggests that the 11/?-
HSD barrier to maternal glucocorticoids only becomes firmly
established after mid-gestation [48,50]; prior to this fetal tissues
may express ll/?-HSD2 and 'protect themselves' from high
maternal glucocorticoid levels. As the placenta takes over the
protective role, fetal tissues adopt a much more 'adult' 11/?-
HSD2 expression pattern and fetal adrenal activity may begin to
dictate their glucocorticoid exposure.
Conclusion
The human placental cDNA that we have isolated encodes an
enzyme with the expected characteristics of 1 l/?-HSD2 activity in
placenta. The location of ll/?-HSD2 mRNA and protein in
human tissues supports its proposed key roles as a modulator of
glucocorticoid action and mineralocorticoid receptor specificity
and as a major determinant of the glucocorticoid exposure of the
developing fetus.
It is unlikely that a direct X-ray-crystallography-derived struc¬
ture will be available in the near future for 1 l/?-HSD2 (which is
an intrinsic membrane protein). We have presented its predicted
secondary structure in some detail. This will be of particular
relevance, as mutations are sought in the protein which may
explain: (i) the dramatic loss of 1 l/?-HSD2 enzyme activity that
appears to occur in the syndrome of apparent mineralocorticoid
excess (SAME), (ii) the more subtle variations in 11/7-HSD
activity indicated by the altered urinary glucocorticoid metab¬
olites described in subsets of patients with essential hypertension
[51] or polycystic ovary disease [52], or (iii) the impaired placental
11//-HSD2 activity which correlates with reduced birth weight in
humans [6].
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Finally, two further points remain unexplained. First, why
does ll/?-HSD2, which metabolizes a hydrophobic substrate
using a positively charged cofactor (NAD+), possess such a
positively charged structure? Secondly, if mutations in 11/?-
HSD2 cause SAME, how do the associated alterations in 5a/5/?-
reductase activity [53,54] come about, as 1 l/?-HSD2 appears to
have neither activity? Clearly further studies of this key enzyme,
1 l/?-HSD2, will not only shed light on such matters but are likely
to contribute to a better understanding of the role of cortico¬
steroid physiology in development and the aetiology of hy¬
pertension in humans.
Note added in proof, (received 13 November 1995)
After completion of this work the first crystal structure for 17/?-
HSD1 has been reported [55], showing an N-terminal SCAD
region followed by a-helices and a flexible C-terminal region.
This is intriguingly similar to the structure predicted above for
ll/?-HSD2.
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